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Food toxicology 
Toxicology is one of the oldest practical sciences [1]. From the very beginning, animals 
including humans needed to recognize and avoid eating the various toxic plants and 
animals in their environment to survive. Evaluation of potential risks and benefits of food, 
such as berries, nuts and water sources, was of critical importance. The assessment of any 
potential risk of particular foods was carried out by trial and error. Foods were selected or 
rejected based on observation (if foods were avoided by other animals) in combination 
with trial and error (if eating a particular food component made people sick or not). 
Nutritional toxicology is essential for health and well-being since the dawn of man.  
Nutrition and Medicines 
In the past, nutrition was also used in treating diseases and staying healthy. There was no 
fundamental difference between nutrition and medicine. Already in 500 BC, Hippocrates 
stated: ‘Let food be your medicine and let medicine be your food’[2]. The ancient Greek 
considered food as one of the three categories of medicines. Also in other traditional 
medicinal systems, such as Ayurveda and Traditional Chinese Medicines, food is used in 
healthcare [3, 4].  
In contrast to these traditional medicinal systems, in which nutrition and medicines 
overlap, the two fields of nutrition and pharmacology developed separately in the Western 
world [2, 5]. Nutrition developed as a ‘tool’ to provide sufficient energy, proteins and 
(micro)nutrients and to prevent deficiencies [6].  Pharmacology had developed into a field 
in which medicines were primarily used to cure diseases by repairing or improving body 
functions. This was based on the one disease-one target concept; a single natural or 
synthetically compound had to act on a specific target. During the last decades, the gap 
between the two fields of nutrition and medicines is narrowing again. The use of nutrition 
in optimizing a good health became more important and it became clear that diseases 
could not always be treated by using a single drug for only one target. It was again realized 
that nutrition and medicine overlap and that nutrition and pharmacology can benefit from 
each other.  
Nutrition is not only important for providing energy and nutrients, it can also be used to 
improve health and treat diseases.  This has resulted in the development of new bioactive 
compounds that can influence health or a diseased status. Different nutritional product 
categories have evolved which have a specific health claim beyond providing sufficient 
nutrients. The most prominent examples are food supplements. Currently, countless of 
food supplements are available on the market, all of which claim to be healthy or to 
improve health. The use of food supplements has enormously increased over the past 
years. People take food supplements often assuming that this only has benefits and is 
without risks.  This is of course a fallacy as any compound, including water can be toxic. 
The importance of accurately assessing the risks can be exemplified by the herbal 
supplement containing Kava Kava, an herb derived from the roots of the plant Piper 
methysticum. Kava Kava has been used for many years as a recreational and ceremonial 
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drink in Oceania. More recently it is used in concentrated forms in herbal supplements to 
treat anxiety and insomnia[7, 8]. However, in assessing the safety of these kava products, it 
appeared that in the applied dose Kava Kava may induce liver injury that even can be lethal 
[9-11]. For this reason, the use of Kava Kava has been banned or restricted in many 
countries of the world such as the Netherlands, Germany, Switzerland, France, Canada, and 
Great Britain. Apparently, food toxicology is still mandatory in order to protect consumers, 
as it was during the dawn of man. 
Ageing population 
The world population is rapidly ageing [12]. In the first five decades of the 21st century, the 
world population over 60 years is estimated to be doubled to 22% of all people [13]. The 
absolute number of elderly is expected to increase to 2 billion. Also in the Netherlands, the 
population is rapidly ageing [14]. This is attributable to a decreased birth rate, but more 
importantly to an increased life expectancy. The average life expectancy of a 65-year old 
person in 2010 was 17.6 years for males and 20.8 years for females [15]. In 2050 this 
expectancy will increase to 21.1 years for males and to 23.6 years for females. 
Approximately 75% of all deaths among men and 85% of all deaths among women take 
place after the age of 65 [15]. This is mainly due to improved hygiene, the progress in 
health care and the increase in economic welfare. Consequently, the age composition of 
the Dutch population has changed over the years, as shown in figure 1. In 2000, 24.000 
men and 42.000 women had an age of 80 years. The prognosis is that these numbers will 
increase to 94.000 men and 99.000 women in 2050. The total number of people over the 
age of 65 in 2050 will be approximately 4.5 million, which will be 25% of the total Dutch 
population. Other European countries even have higher percentages of elderly people. In 
2010, the percentage of elderly people in Germany and Italy were already approximately 
20%. A main consequence of an ageing population is that the need for medical and social 
care increases.  
Free radical theory of ageing 
‘Ageing’ can be defined as ‘processes in an organism that increase the mortality risk as a 
function of time’[16]. In the early 90s, it was proposed that the longevity of an organism 
was inversely correlated to its metabolic rate: increasing an organism’s metabolic rate 
would decrease longevity. However, it was observed that birds, which have a much higher 
metabolic rate than mammals, lived much longer. Despite their high rate of oxygen 
consumption, birds appeared to have a much lower rate of reactive oxygen species (ROS) 
production. It was concluded that the rate of ROS production was more important than the 
metabolic rate regarding longevity. The mechanistic basis of ageing was then proposed in 
the ‘free radical theory of ageing’[17]. Ageing and ageing-related diseases are assumed to 
be the consequence of free radical-induced damage to cellular molecules and the failure to 
counterbalance these effects by endogenous antioxidant systems [18]. Free radicals are 
molecules which possess an unpaired electron, and are therefore highly reactive and can 
react with and damage other molecules such as proteins [19]. In aerobic life forms, many 
free radicals are oxygen radicals, and the term ROS is often used in combination with the 
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term free radical, although they do not completely overlap. For example, the ROS hydrogen 
peroxide is not a radical, but it can give rise to radical formation via the Fenton reaction. 
Besides hydrogen peroxide, superoxide radical and hydroxyl radical are the most well-
known ROS [20]. ROS are either generated exogenously or produced intracellularly from 
several sources [21]. The family of NADPH oxidases is one of such intracellular source of 
ROS. However, the majority of intracellular ROS is produced by the mitochondria, mainly via 
complex I (NADH dehydrogenase) and complex III (ubiquinone-cytochrome c reductase) of 
the electron transport chain [22]. ROS are furthermore generated by xanthine oxidase, 
cytochrome P450, nitric oxide synthase and myeloperoxidase. Additionally, a number of 
exogenous agents can stimulate ROS production, such as ultraviolet light, ionizing radiation 
and chemotherapeutics. ROS-mediated damage of nucleic acids, proteins, and lipids, and 
has been implicated in carcinogenesis, neurodegeneration, atherosclerosis, diabetes, and 
as previously described, ageing [23]. 
Antioxidant protection 
Regarding the harmful effects of ROS, one important protective mechanism that 
counteracts ROS production exists. This is the antioxidant system that includes the 
enzymatic scavengers (SOD, catalase and glutathione peroxidase) and the non-enzymatic 
antioxidants (such as ɴ-carotene, vitamin C, vitamin E, uric acid, flavonoids and 
glutathione)[24, 25]. The balance between ROS and antioxidants determines the level of 
oxidative stress [26]. Several studies have shown an increased level of ROS and oxidative 
damage in ageing cells and organisms [27]. Apparently, increased ROS levels accelerate 
ageing and age-related diseases. Understandably, the public interest for developing anti-
ageing therapies is tremendous. Based on its role in ageing, the ability to prevent or battle 
oxidative damage is considered to be a key determinant in stimulating longevity. Enforcing 
the antioxidant systems via dietary supplementation would provide a good approach to 
decrease oxidative stress. Although many in vitro experiments and experiments in 
mammalian models support this, antioxidant therapy has had only little or no effect in 
enhancing longevity in man yet [28, 29]. In order to optimize such approaches, a better 
understanding of the pharmacological properties of anti-oxidative agents is required.  
Further research is needed to unravel the process of ageing to come up with anti-ageing 
approaches that are effective in humans. 
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Figure 1| Age composition of the Dutch population in 2000 and the estimated age composition in 
2050. 
Age-related physiological changes 
‘Elderly’ is the term for people having an age of 65 or more [30]. Because the physiological 
reserves of adults decline over the years, the impact of events that have a negative impact 
on the quality of life is higher in elderly. In general, the impact of ageing affects all 
physiological processes [16].  Progressive damage accumulates during life, ultimately 
leading to a decrease in function of organ systems, including the cardiovascular system, 
gastrointestinal system and neuroendocrine system. The decrease in function and the 
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accompanying changes in pharmacokinetics and pharmacodynamics due to ageing increase 
the chance to develop diseases. Some important age-related changes are discussed. 
Cardiovascular system 
Ageing is associated with cardiovascular changes, such as a reduced elasticity of the great 
arteries [31]. These changes lead to a higher systolic arterial pressure, a decreased rate of 
myocardial relaxation and subsequently left ventricular hypertrophy. The left ventricle also 
becomes stiffer, leading to a decreased cardiac output [32]. Ageing is furthermore 
associated with a reduction in heart rate and an increased sinoatrial node conduction time 
[33]. Moreover, elderly people have a different response to postural changes compared to 
young people. The cardiac output is more efficiently maintained by increasing the heart 
rate in the young in contrast to elderly [16]. This may lead to orthostatic hypotension in 
elderly. 
Furthermore, the prevalence of hypertension, which is the most important risk factor for 
vascular disease and death, is higher in older age groups [34]. Especially, the systolic blood 
pressure is elevated at old age. Approximately 50% of the people older than 65 is 
diagnosed with hypertension. 
Gastrointestinal system 
Ageing affects all organs of the gastrointestinal system. The main change is a decrease in 
the secretion of hydrochloric acid and pepsin in the stomach [35]. Moreover, heartburn is 
highly prevalent in the elderly population, since the band of muscle tissue which is essential 
for maintaining a pressure barrier against backflow of contents from the stomach weakens 
[36]. In the small intestine, ageing is accompanied by reduced absorption of  nutrients such 
as sugars, calcium and iron [37]. This may contribute to the relatively high prevalence of 
malnutrition and iron deficiency in elderly. 
Central nervous system 
The central nervous system (CNS) is also influenced by ageing. In particular, the 
hypothalamic-pituitary-adrenal (HPA) axis is changed, which lead to changes in responses 
to psychological or physical stress [16]. The HPA axis is excessively activated, which 
together with hypersecretion of glucocorticoids, can lead to dendritic atrophy in neurons, 
for instance in the hippocampus. This results in learning and memory impairment in elderly. 
More importantly, the Blood-Brain-Barrier (BBB) is deteriorated during ageing [38]. Brain 
endothelial cells and perivascular mural cells form the BBB die, which reduces the barrier 
for entering of neurotoxic compounds, pathogens, red blood cells and leucocytes into the 
brain [39]. Hence, ageing affects the BBB by increasing its permeability. Additionally, drugs 
or food supplements more easily enter the brain. Next to the increased permeability of the 
BBB, the number of cholinergic neurons and receptors in the brains of elderly also 
decreases. This increases the chance of adverse side effects in the brains, such as 
anticholinergic side effects including cognitive impairment [40]. Many drugs display 
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anticholinergic effects by blocking muscarinic receptors in our brain. Consequently, 
cholinergic neurotransmission is blocked.  The anticholinergic side effect of a single 
compound is usually relatively mild. However, when several compounds are taken 
simultaneously, more receptors will be blocked, aggravating the impact. This is known as 
anticholinergic accumulation [41]. Anticholinergic accumulation results in complaints as 
confusion, delirium, dry mouth, headache, pain, anxiety and blurred vision. 
Urinary tract 
Ageing is accompanied by an enlargement of the prostate gland. Some of the prostate 
tissue is replaced by scar tissue. Enlargement of the prostate gland is also known also 
benign prostatic hyperplasia (BPH) [42]. BPH affects approximately 50% of the elderly men.  
BPH interferes with urination, by partly blocking the tube that drains the bladder. Elderly 
men that suffer from BPH therefore often have problems with urinating and ejaculation. 
Also urinary tract infections are common in elderly men. 
Pharmacokinetics and pharmacodynamics 
Ageing is accompanied by changes in body composition, exemplified by the reduction of 
total body water and lean body mass [43]. It is furthermore known to influence the 
pharmacokinetics (absorption, distribution, metabolism and elimination) of drugs [16]. 
Pharmacokinetic studies have shown that ageing is associated with a reduced absorption of 
nutrients such as vitamin B12, iron and calcium [35]. The first-pass metabolism is also 
reduced by ageing, due to a reduction in liver mass and blood flow. Consequently, the 
bioavailability of drugs undergoing first-pass metabolism is significantly increased. For this 
reason, the activity of drugs that actually need to be converted into active metabolites in 
the liver might be reduced. As a result of the changes in total body water, water-soluble 
drugs have a smaller volume of distribution resulting in higher serum levels in older people 
[44]. Since ageing reduces renal function, the clearance of drugs and metabolites can be 
affected. As a consequence, drugs are more likely to accumulate, which gives more adverse 
effects [45].  
Besides pharmacokinetic changes, also pharmacodynamic changes occur during ageing 
[30]. Pharmacodynamics refers to the pharmacological effect of a drug on the body, 
including adverse effects. Changes in pharmacodynamics during ageing will make elderly 
people more sensitive to the effects of drugs compared to younger patients. These add on 
the pharmacokinetic changes during ageing. The pharmacodynamic effects of drugs 
depend on several factors, such as the concentration of a particular drug at its receptor, 
the response it elicits on the receptor, post-receptor events and homeostatic mechanisms 
[38]. All these factors may be affected by ageing. An example of a pharmacodynamic 
change in elderly is the decreased effect of ɴ-adrenergic agonists, which results in a 
decreased effectiveness of beta-blockers on heart rate and stroke volume [46]. Another 
adverse effect of drugs that has a greater chance to occur in elderly is orthostatic 
hypotension. Orthostatic hypotension is a sudden temporary decrease in blood pressure 
after standing up or stretching. The increased risk for orthostatic hypotension in elderly is 
due to decreased arterial compliance and baroreceptor response [47].  Hence, 
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pharmacodynamic changes lead to an increased likelihood of adverse effects of drugs to 
happen among elderly, which might have serious consequences such as falls. 
Medicine use in elderly 
As mentioned earlier, the ageing process is accompanied by structural and functional 
changes affecting all organ systems and resulting in reduced homeostatic capacity. Elderly 
therefore often suffer from multiple diseases. To prevent or treat diseases, elderly people 
often receive a multitude of medicines.  Numerous studies have shown that elderly are the 
largest group of consumers of medicines. Polypharmacy, which is defined as the 
simultaneous use of at least 3 drugs, is also very common among elderly [48]. The use of 
multiple drugs at once not only causes a higher risk of toxic reactions and adverse effects, it 
may also lead to unwanted interactions between these drugs, aggravating side effects 
instead of improving the quality of life of the elderly. Polypharmacy is identified as one of 
the most important risk factors for hospitalization. In 2013, the Dutch National Institute for 
Health and Innovations reported that approximately 45% of the elderly population was 
prescribed 5 or more different medicines [49]. Moreover, 20% of the population over 75 
years was taking at least 10 different prescribed medicines.  
Next to prescription medicines, self-medication, i.e. the use of over-the-counter (OTC) 
drugs, is on the rise. OTC drugs are medicines which can be bought without a prescription. 
A huge number of OTC drug products are currently available on the market. These drugs 
are defined as products that must be safe for consumers [50]. Most individuals assume that 
OTC drugs are safe and free from side effects. However, the use of OTC drugs even further 
increases the possibility for drug-drug interactions. Since 2005, the number of elderly at 
risk for major drug-drug interactions increased to approximately 1 in 6 older adults [51, 52]. 
 (Mal)nutrition in elderly 
Besides medication, nutrition is a major factor important for maintaining a good health, as 
previously highlighted. Food, including food supplements, is nowadays more and more 
used to treat diseases and to improve health.  A main problem in elderly is malnutrition, 
which is defined as ‘a state of nutrition in which a deficiency, or excess, of energy, protein 
and micronutrients causes measurable adverse effects on tissue/body form (body shape, 
size and composition) and function, and clinical outcome’ [13]. In 24% of elderly men and 
47% of elderly women, malnutrition or an inadequate intake of one or more essential 
nutrients has been reported [53]. With the predicted increase in elderly people in the 
upcoming years, the percentage of malnourished people will also increase.  In general, 
three main causes of malnutrition can be pointed out:  
1) A low intake of nutrients, which may be caused by poor dietary habits, isolation, 
depression, dementia, medication or dental or chewing problems.  
2) An increased demand of nutrients due to fever, infection or dementia.  
3) A reduced uptake of nutrients due to an impaired absorption or diarrhea.  
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Low levels of nutrients will result in a decline of functioning of the body. Malnutrition can 
affect every function and organ of the human body, such as bones, brains, cardiovascular 
system, immune function, lung function and muscle functioning. This explains the 
association of poor nutritional status with increased morbidity and mortality [54, 55]. 
An adequate nutrition is necessary for a good health. The nutritional status can be 
influenced by the intake of nutrients. Important aspects are the quantity and the 
accessibility to food, flavor and meal ambience. Additionally, the quality of nutrient intake 
is also important. This may be improved by dietetic advising, delivery of nutrient dense 
foods or nutritional supplementation. Supplementation improves the quantity and 
potentially also the quality of nutrient intake and can prevent or cure malnutrition. 
Supplementation of nutrients is commonly applied in (malnourished) elderly. 
Nutritional supplementation 
Dietary or nutritional supplements are intentional to provide nutrients that are not 
consumed in sufficient quantities. According to the United States Food and Drug 
Administration (FDA), a dietary supplement is defined as a product, which is not a 
pharmaceutical drug, a food additive, such as spices or preservatives, or conventional food, 
and which fulfills the following criteria [56]: 
- It is intended to supplement a person’s diet and not to replace a meal. 
- It contains vitamins, minerals, fatty acids, fibers, herbs, amino acids or any substance that 
contributes to other food eaten. The product may also contain any metabolite, ingredient, 
extract or combination of these ingredients. 
- It is labeled as a food supplement. 
There are several types of dietary supplements: vitamins, minerals, herbals, amino acids, 
proteins, essential fatty acids and bodybuilding supplements, of which the vitamin and 
mineral supplements are used the most. The National Institute for Public Health and the 
Environment (RIVM) made an inventory on the vitamin and mineral supplements available 
on the Dutch market [57]. The inventory included supplements that were specifically 
promoted for the elderly population as well as vitamin or mineral supplements often taken 
by elderly.  The vitamin and mineral content of these supplements were compared to the 
Recommend Dietary Allowance (RDA) of elderly people aged 51 to 70 years, as established 
by the Health Council of the Netherlands. Furthermore, the recommended daily dosages, 
as recommended by the manufacturer of the supplements, were calculated as a 
percentage of the RDA. Finally, the composition of the supplements was compared to the 
Tolerable Upper Intake Level (UL), which was set by the European Food Safety Authority 
(EFSA). Some supplements were available that exceed the RDA and sometimes even exceed 
the UL. 
Vitamins 
Vitamins are organic compounds that organisms require in a relatively low amount as 
essential nutrients [58]. Vitamins cannot be synthesized by man and must therefore be 
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obtained from the diet. Vitamin supplementation is important in the treatment of 
deficiencies, but evidence is lacking for beneficial effects when used by those who are 
otherwise healthy [59]. The most used vitamin supplements are vitamin A, the B-vitamins, 
vitamin C, vitamin D and vitamin E. 
Vitamin A supplements were found to have a very narrow therapeutic range, namely 
between a RDA of 1000 µg and a UL of 3000 µg. Only a few vitamin A supplements are 
available on the market, of which the highest dose was 1557 µg/day. In contrast, ɴ-
carotene, which is the precursor of vitamin A, can be found in supplements with doses up 
to 15 mg/day. 
The B-vitamins are often present in multi-vitamin supplements. In several (single) 
supplements, high dose levels of B-vitamins were found. The highest dose for the different 
B vitamins were found to be much higher than the corresponding RDA, e.g. 55 times for 
vitamin B1,  67  times  for  vitamin  B2, 38 times for vitamin B3,  50  times  for  vitamin  B5, 56 
times for vitamin B6, 16 times for vitamin B11 (folic acid) and even 357 times for vitamin B12. 
More importantly, the UL for the B vitamins was only exceeded for vitamin B6 (with 400%) 
and folic acid (with 500%).  Most of the vitamin B6 supplements range from 25-150 mg/day. 
The UL for  vitamin B6 was recently lowered by the EFSA from 100 mg/day to 25 mg/day.  
Most of the folic acid supplements were found to have a dose between 800 and 1000 
µg/day. However, one supplement with a dose of 5000 µg/day was found, which is five 
times higher than the UL of 1000 µg/day. For vitamin B12 no UL was set by the EFSA. 
Vitamin C was found in high doses in several supplements. The highest dose was found to 
be 1500 mg/day. No UL is established for vitamin C by the EFSA, since there were 
insufficient data available. However, even at concentrations of 1500 mg/day, no adverse 
effects have been reported for humans. 
An UL of 50 µg/day was proposed by EFSA for vitamin D. Most of the vitamin D 
supplements had doses between 20-25 µg/day. The highest dose was found to be 1000 
µg/day. 
Several vitamin E supplements have high doses, varying from 268 to 671 mg/day. This is 
about 25-63 times the RDA for elderly people aged 50-71 years. The UL of vitamin E was set 
at 300 mg/day.  The highest dose found for vitamin E was 224% of its UL. 
Minerals 
Minerals comprise chemical elements required by humans, other than carbon, hydrogen, 
nitrogen and oxygen. Iron, zinc and selenium are the most common mineral supplements. 
Iron was found in relatively high doses with the highest dose being 50 and 100 mg/day.  
Most of the supplements contained 14-30 mg iron/day. No UL was set by the EFSA because 
of insufficient data, but supplemental intake of (non-heme) iron at 30 mg/day or more was 
associated with high saturation of the iron storage, which is a risk factor for several chronic 
diseases. 
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The UL of zinc is set at 25 mg/day. This dose is exceeded by a number of supplements. The 
highest dose was found to be 400 mg/day, which is 16 times higher than the UL. 
Selenium has a narrow range between the RDA (150 µg/day) and the UL (300 µg/day).Only 
one supplement was found to exceed the UL, having a dose of 400 µg/day. 
Herbals 
Herbal supplements contain plant-derived ingredients or components, which were used as 
medicine through human history before the development of synthetic drugs. Herbal 
supplements are still used in traditional medicinal systems. The World Health Organization 
(WHO) estimated that approximately 80% of the Asian and African population presently 
uses herbal products for primary health care [60]. In contrast to pharmaceuticals, which are 
often too expensive for these populations, herbal products are grown from seeds or 
gathered from nature for little cost.  
The use of herbal products, which should be developed and tested according to the strict 
guidelines that are used in the Western science, is not strictly based on scientific evidence. 
Therefore herbal supplements are categorized in the Western society as a form of 
alternative medicine. Remarkably, according to the WHO 25% of the Western medicines 
contain compounds also found in herbs, such as opium, aspirin and quinine. Moreover, 
there is a revival of the use of herbal dietary supplements and they are increasingly used in 
the Western world. The use of these products is more prevalent in people suffering from 
chronic diseases, such as cancer, diabetes and asthma. Females and elderly tend to use 
herbal products relatively frequently. 
Herbs can be processed in several ways. Traditionally, the herbs were mixed with boiling 
water and the resulting ‘tea’ was drunk. Nowadays, more and more herbals are produced 
in tablets or capsules. The most well-known herbal supplements in the Netherlands are 
Ginkgo Biloba and St. John’s wort. Herbal supplements are most commonly used as self-
medication to promote heath. These supplements are widely available at many pharmacies, 
health food stores, and doctors' offices. However, there currently is a lack of conclusive 
scientific evidence for the beneficial health effects of herbal supplements. This does not 
necessarily mean that these supplements are unsafe, but that precise scientific 
investigation of these supplements has not been performed. Most herbal preparations 
have prominent effects on biochemical pathways. However, any substance in a large 
enough concentration will have a biochemical effect. Carefulness is necessary in testing 
these agents since essential details regarding extract type, concentration, and formulation 
are frequently not adhered to, thereby impeding safe and accurate application of the 
scientific method. Moreover, herbal supplements are often used in combination with 
prescribed medication, which may lead to unwanted interactions, affecting the effects of 
these drugs leading to potentially adverse health effects. In order to profit from herbal 
supplement use, more research is needed to make an accurate benefit-risk assessment. 
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Amino acids 
Amino acids are biologically important organic compounds containing an amine, carboxylic 
acid group and a side group that is specific for a particular amino acid. Three subclasses of 
amino acids are known: essential amino acids, non-essential amino acids and conditional 
amino acids. Essential amino acids cannot be produced by the human body and must be 
obtained via food. In contrast, non-essential amino acids can be produced by the human 
body. Conditional amino acids are only essential during illness or stress. Commonly used 
amino acid supplements are L-arginine and glutamine, both conditional amino acids.  
Essential fatty acids 
Essential fatty acids are fatty acids that humans cannot synthesize by themselves, but 
which are essential for a good health. Essential fatty acids must therefore also be obtained 
via food. Most used fatty acid supplements are omega-3 fish oil supplements 
Bodybuilding supplements 
These supplements are commonly used by athletics and bodybuilders. Bodybuilding 
supplements are often used to replace meals in order to enhance weight gain, improve 
performance or to promote weight loss. Most well-known body building supplements are 
creatine, branched-chain amino acids (BCAA) and glutamine. Bodybuilding supplement are 
often used in high doses with a high frequency. This could lead to adverse health effects. 
Accurate benefit-risk assessment is necessary to optimally benefit from bodybuilding 
supplements. 
Regulation of food supplements 
Current legislation on food supplements in the Netherlands is based on European 
legislation. The European directive 2002/46/EG on food supplements has recently been 
amended by Directive 1170/2009. This directive is included in the Dutch regulation on food 
supplements. These regulations mainly concern food supplements containing vitamins and 
minerals. 
Food supplements containing vitamins and minerals can be put into the market without 
any permission, under the condition that the supplements only contain the vitamins and 
minerals that are present on appendices of the Food and Drug Act. Quantities of these 
vitamins and minerals not only have to be complementary to the normal diet, but they also 
have to be safe. The European Commission sets minimum and safe maximum levels. 
Maximum levels have to be set based on ULs.  
In Europe, EFSA advices the European Commission on the different aspects of food safety. 
Specifically, EFSA gives advice on the ULs and Dietary Reference Values for vitamins and 
minerals.  
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With respect to herbal supplements, there is no European regulation. In the Netherlands, 
herbal supplements can be put into market without any permission, as long as they do not 
contain harmful compounds. In general, the Netherlands Food and Consumer Product 
Safety Authority (NVWA) investigates and monitors the safety of food and consumer 
products, such as food supplements. 
 
 
Figure 2 | Percentage dietary supplement users in the Dutch population aged 7 to 69 years (DNFCS 
2007-2010), weighted for socio-demographic factors, season and day of the week (n=3,819).  
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Use of food supplements 
Over the past years, the use of food supplements is increasing.  As part of the Dutch dietary 
monitoring system, the RIVM collected data on the food consumption of children and 
adults in the Netherlands between 2007 and 2010 [61]. 27-56% of the Dutch population 
reported using one or more dietary supplements (figure 2). Supplement use was the 
highest during the winter compared to the rest of the year. The most frequently used 
supplements in all age groups were (multi)vitamins and minerals. Other often used food 
supplements were fish oil and the different vitamins. An inventory of the most used food 
supplements among the population is shown in figures 3 and 4.  
The European Prospective Investigation into Cancer and Nutrition (EPIC) study studied the 
use of dietary supplements in different countries in Europe [62]. The use of dietary 
supplements varied in frequency and type across countries. The mean frequency of 
supplement use was higher in the older age groups compared to the younger groups. It was 
furthermore shown that the use of supplements was the highest in those reporting 
moderate or poor health. These two findings could be linked to each other, since ageing is 
associated with a reduced health status. 
Also in the USA, the use of food supplements is increasing [63]. Half of all adults (53%) 
reported to use at least one food supplement, primarily in the form of multivitamins and 
minerals. A major part reported to use supplements on a daily basis. Moreover, 10% of the 
Americans were using more than 5 supplements daily. The use of supplements increased 
with advancing age. Approximately 70% of the adults over the age of 71 years reported to 
use dietary supplements. Remarkably, recent studies show that Americans are increasingly 
replacing prescription medication with dietary supplements.  
Despite the increased use of dietary supplements, physicians are generally unaware of the 
use of these supplements. Additionally, patients do not inform their doctor on the use of 
supplements. This leads to incomplete information for a physician. Being unaware of the 
use of any food supplement, physicians may prescribe drugs that might have (adverse) 
interactions with these food supplements. 
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Figure 3 | Intake of the most used dietary supplements during the winter by the Dutch population 
aged from 7 to 69 years. Data are obtained from DNFCS 2007-2010 performed by the RIVM. 
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Figure  4  |  Intake of the most used dietary supplements during the rest of the year by the Dutch 
population aged from 7 to 69 years. Data are obtained from DNFCS 2007-2010 performed by the 
RIVM 
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Perception on food supplements 
From 2007 to 2010, the National Health and Nutrition Examination Survey (NHANES) 
investigated the motivations for the use of dietary supplements in the USA [64]. Most 
common reasons for using these supplements were to improve overall health, to maintain 
health and to compensate for an unhealthy lifestyle. Other reasons were for a good bone 
health, organ-specific health reasons, getting more energy and a better mental health. 
Remarkably, only 22% of the users really used food supplements as a supplement to their 
diet. The enormous increase in food supplement use is based on the widespread believe 
that the products are healthy and that products of natural origin are safe [65]. Consumers 
assume that the quality of prescription and over-the-counter supplements is high. 
Generally, the consistency, purity and potency of these products are accepted without 
questioning. In 2007, a study among Americans of 60 years and older showed that 
approximately 66% of the responders mistakenly believed that herbal and dietary 
supplements are per se safe and pose no risk to the general public. Moreover, 70% falsely 
believed that these products were tested by the FDA and 60% incorrectly believed that 
these products were regulated by the FDA [65]. Additionally, 22% of the responders stated 
that they believed it is not important to disclose the use of any supplement to their 
physicians. 
Also in the Netherlands, the frequent use of food supplements is based on the presumption 
that they provide health benefits. In a survey, 61% of the responders assumed that the 
efficacy of these food supplements was proven sufficiently, and 48% regarded vitamin and 
mineral supplements as an easy tool to stay healthy [66]. 
Adverse effects of supplements 
Although the general perception is that food supplements support (general) health, they 
may also induce harm. In conjunction with the increased use of food supplements, the 
number of adverse events, drug interactions and deaths involving these supplements is on 
the rise. Mostly, over-consumption, particularly of minerals and vitamins which accumulate 
in the body, is causing damage. Dietary supplements were implicated in approximately 
23.000 emergency department visits and 2000 hospitalizations annually in the USA from 
2004 to 2013 [67]. More than 12% of these cases concerned older adults. Importantly, this 
reported number of emergency department visits related to food supplements induced 
adverse events is probably an underestimation. Supplement use by patients is often not 
reported and physicians do not associate adverse events with supplement use, in contrast 
to drugs.  Next to over-consumption, interactions between supplements and drugs can also 
cause adverse events. Drug-food interactions give variability to effects and adverse effects 
of food supplements and drugs. For instance, a high intake of vitamin K is known to 
counteract the effect of the drug warfarin [68]. Furthermore, grape juice has been shown 
to inhibit the metabolism of cyclosporine and non-selective monoamine oxidase inhibitors 
[69].  
Physicians often lack knowledge about interactions of food supplements with other food 
supplements and medications. In the Netherlands, such data have not been recorded yet. 
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Nowadays, The Netherlands Pharmacovigilance Centre Lareb collects and analyses reports 
of adverse reactions of food supplements, medicines and vaccines. The adverse reactions 
can be reported to Lareb by healthcare professionals, patients and also manufacturers. 
Among these adverse reactions, also potential interactions between food supplements and 
drugs are reported.  All the reported complaints are collected into a database, which is 
used to write reports on adverse effects of drugs and food supplements. Lareb also sends 
these reports to the European Medicines Agency and the World Health Organization, 
helping monitoring the global food supplement and drug safety. Moreover, healthcare 
professionals are also informed. 
 Types of interactions 
Two types of interactions between drugs and dietary supplements exist. Pharmacodynamic 
interactions occur when the activity of a drug is either augmented or inhibited by the 
intrinsic action of a food supplement. Pharmacokinetic interactions occur when the 
absorption, distribution, metabolism, or excretion of a drug is influenced by another food 
supplement. This leads to a change in pharmacologic activity of a drug. The most frequent 
pharmacokinetic interactions involve enzymes of the cytochrome P450 and P-
glycoproteins. Due to the potentially harmful effects of these drug interactions, it is 
important to inform consumers, physicians and pharmacists of the possible risks involved. 
Due to the age-related changes in pharmacokinetics and pharmacodynamics, especially 
elderly are a vulnerable group for interactions between food supplements and drugs.  
 Evidenced supplement-drug interactions 
Numerous interactions between food supplements and drugs are reported. The most well-
known example is the interaction between grapefruit juice and the enzyme CYP3A4, which 
is responsible for the metabolism of various drugs. Grapefruit juice inhibits this enzyme, 
resulting in changes in doses of drugs that are metabolized by this enzyme [70]. We have 
reviewed the literature to determine potential interactions between food supplements and 
drugs. Most cases of supplement-drug interactions were found for herbal supplements 
such as St. John’s wort, Ginkgo biloba, garlic, and Ginseng. Some evidenced examples are 
being discussed below. 
St John’s wort 
St. John’s wort is a food supplement that is effective for depression [71]. When used in 
isolation, St. John’s wort is relatively safe [72]. However, St. John’s wort is able to effectively 
induce CYP enzymes and P-glycoproteins in the intestines. Therefore, numerous 
pharmacokinetic interactions with drugs may occur [73-76] . Many interactions of St John’s 
wort with several drug types have been shown. The interaction between the 
immunosuppressant cyclosporine is the best documented [77-84]. This interaction leads to 
decreased plasma concentrations of cyclosporine in heart, renal and liver transplant 
patients when taking St John’s wort.  
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Numerous studies have shown that st. John’s wort furthermore interacts with hormonal 
contraception [85-87]; cardiovascular drugs, including antiarrhythmic, antihypertensive, 
cardiotonic and anticoagulant drugs [88-94]; anti-cancer drugs [95-98]; drugs acting on 
central nervous system;[99-101]; respiratory drugs, hypoglycemic drugs, antimicrobials and 
drugs acting on the gastrointestinal drugs. These interactions include both pharmacokinetic 
and pharmacodynamic interactions. The pharmacokinetic interactions arise when St John’s 
wort is combined with drugs that are metabolized by CYP3A4, CYP2E1 and CYP2C19 [102]. 
The pharmacodynamic interactions involve drugs that enhance serotonin signaling in the 
brain. 
Ginkgo Biloba 
Also for Ginkgo biloba several interactions have been identified. Ginkgo is mainly used for 
memory deficits and peripheral vascular disease. Ginkgo exerts its effects via antiplatelet 
activity, which is thought to be involved in causing bleeding after operations. The 
antiplatelet activity of Ginkgo increases the chance of interactions with drugs that affect 
platelet function and coagulation, such as warfarin and NSAIDs.  Adverse events of ginkgo 
use have been reported with the concomitant use of aspirin, warfarin and ibuprofen, which 
led to spontaneous hyphemia, intracerebral hemorrhage and comatose state with 
intracerebral bleeding respectively [103-105]. Ginkgo is furthermore thought to affect 
CYP2C19 and CYP3A4 activity. It is therefore advised not to take ginkgo together with drugs 
that are substrates of these enzymes. One case is published on the interaction between the 
antidepressant trazodone  and ginkgo, which led to a state of coma in an 80-year old 
woman [106].  
Garlic 
Garlic supplements are used for the treatment of hypercholesterolaemia and 
arteriosclerosis. Some case reports suggested that garlic supplements influence platelet 
function and blood coagulation [107]. Garlic supplements were furthermore reported to 
interact with warfarin and fluindione [108], although some trials did not find the interaction 
with warfarin.  Other interactions are found in patients receiving the antiretroviral drugs 
saquinavir and ritonavir, the antidiabetic chlorpropamide and the analgesic paracetamol 
[109-111]. Moreover, garlic oil has been shown to inhibit CYP2E1 activity, which might lead 
to interactions with drugs that are metabolized by this P450 enzyme.  
Ginseng 
Ginseng supplements are used for a wide variety of indications, such as erectile 
dysfunction, cancer, and cognitive decline [112]. In elderly, the inhibition of CYP2D6 by 
ginseng has been reported [100]. Ginseng supplements have furthermore been shown to 
inhibit platelet aggregation [112]. Moreover, after taking ginseng together with the 
antidepressant phenelzine, one patient experienced insomnia, headaches and 
tremulousness [113]. Hence, also for ginseng supplements clinical evidence exists for 
potential adverse interactions with drugs.  
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Lareb: reported interactions between food supplements and drugs 
In the Netherlands, Lareb reported at least 55 reports on interactions between food 
supplements and drugs [114].Thirteen of these reports involved St John’s wort. 
Furthermore, interactions with Ginkgo biloba were also reported. Inhibition of CYP3A4 by 
Ginkgo explains the interaction with the anti-viral agent efavirenz [115]. Next to 
interactions with herbal supplements, also several interactions were reported by Lareb 
concerning non-herbal supplements, such as glucosamine.  Glucosamine was reported to 
have adverse interactions with vitamin K antagonists, antidiabetic and antiepileptic drugs 
[114].Also folic acid, vitamin B6 and multivitamin supplements induced adverse drug 
reactions to vitamin K antagonists. Moreover, multivitamin supplements also interacted 
with the anti-epileptic and anti-depressant drug levetiracetam. These are all examples of 
reported pharmacokinetic and pharmacodynamic interactions between food supplements 
and drugs. Again, the interactions that are currently reported to Lareb are expected to be 
an underreporting, since the use of food supplements is often unknown to a patient’s 
health care professional. The perception of food supplements is that they are natural and 
safe. People therefore do not link any adverse events to the use of food supplements. 
However, adverse events due to interactions might have serious consequences. It is 
therefore important that healthcare professionals are aware of the use of food 
supplements and that consumers are informed about potential adverse effects of food 
supplements. 
Benefit-risk assessment 
The number as well as the use of over-the-counter and dietary supplements is greatly 
increasing, making it urgent to evaluate their health effect by making an accurate benefit-
risk assessment [116]. It is common knowledge that a too low intake of (micro)nutrients 
has adverse health effects. It is not generally realized that (micro)nutrients will also have 
adverse health effects when the intake is too high. Therefore, strategies aimed at dietary 
supplementation should be carefully evaluated. The need for regulation of specific 
nutrients depends on the severity of their adverse health effects. In order to reduce the risk 
of excessive intake, ULs are set. The UL is defined as the maximum level of daily intake of a 
nutrient taken chronically, which is unlikely to pose a risk for adverse effects to the general 
population. This is not a recommended level of intake. ULs  are derived for all groups of the 
general healthy population, including sensitive individuals. Ideally, a benefit-risk assessment 
should be performed for each individual. However, this is impossible.  The UL is often set in 
such a way that even the most sensitive subjects are protected. An important factor that 
also needs to be considered is that the optimal intake of different population subgroups 
often differs. Therefore, groups that are at risk for a certain supplement as well as groups 
that would benefit of a certain supplement should be identified. 
Aims and outline of the thesis 
The use of self-medication, which includes food supplements and over-the-counter drugs, 
is still on the rise. Moreover, the variety in food supplements available on the market is also 
increasing. The general perception of food supplements is that they are safe and healthy. 
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However, safety issues of food supplements are actually not well addressed yet. In this 
thesis we will further discuss the (health) effects of food supplements and unravel potential 
adverse effects of food supplements either combined with other food supplements or 
drugs or alone in specific population groups. Since elderly are a frail group of people 
vulnerable to the side effects of drugs and food supplements and the largest consumer 
group, we mainly focused on this population group.  The research question that arose was 
whether food products, such as supplements, which are aimed to intervene with the 
process of ageing, could be damaging for this vulnerable population group?  
In order to answer this research question, the following aims were set: 
- Identify frequently used food supplements that may possibly have damaging 
effects. 
- Identify potential interactions between food supplements and drugs that may 
have hazardous effects (in elderly). 
Outline of the thesis 
In  chapter two we have evaluated the question if antioxidants should be considered as 
healthy or toxic by examining the presumed health effects of two individual antioxidants 
with opposite images i.e. the ‘toxic’ ɴ-carotene and the ‘healthy’ vitamin E, we focused on 
one aspect, namely their role in inducing benzo(a)pyrene diolepoxide (BPDE)-DNA adducts. 
In chapter three the pharmacodynamic interaction of quercetin with tamsulosin was 
investigated. The food supplement quercetin is used as self-medication for prostate 
disorders and is known to induce vasorelaxation. The drug tamsulosin is used in the 
treatment of benign prostatic hyperplasia. A major side effect of tamsulosin is orthostatic 
hypotension, mediated by vasorelaxation resulting from ɲ1-adrenoceptor blockade. The 
vasorelaxation effects of tamsulosin and quercetin, combined and alone, were investigated 
in mesenteric arteries. 
Many compounds display anticholinergic effects which might give rise to cognitive 
impairment and even delirium. These side effects are caused by their ability to bind to 
muscarinic receptors in our brain. Especially with combination of compounds, these effects 
are observed. This phenomenon, known as anticholinergic accumulation, is especially 
observed in elderly. In chapter four a number of food supplements have been screened for 
their ability to bind to muscarinic receptors.  
In chapter five the effect of the combination of three different iron supplements with 
magnesium peroxide on reactive oxygen species formation was determined. Iron 
supplements and magnesium peroxide both produce adverse effects via the formation of 
ROS.  
In chapter six the toxic effects of the different vitamers of vitamin B6 are investigated. Since 
2014, more than 50 cases of sensory neuronal pain due to vitamin B6 supplementation 
were reported to Lareb. However, the mechanism of this toxicity and the contribution of 
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the various B6 vitamers to this toxicity are largely unknown. The neurotoxicity of the 
different forms of vitamin B6 is tested on two different cell lines. 
In chapter seven the results of the present thesis are discussed and placed in a broader 
scientific perspective. This is followed by a brief summary of the findings of this thesis in 
chapter eight.  
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Abstract 
Antioxidants are vital for aerobic life, and for decades the expectations of antioxidants as 
health promoting agents were very high. However, relatively recent meta-analyses of 
clinical studies show that supplementation of antioxidants does not result in the presumed 
health benefit, but is associated with increased mortality. The dilemma that still needs to 
be solved is: what are antioxidants in the end, healthy or toxic? We have evaluated this 
dilemma by examining the presumed health effects of two individual antioxidants with 
opposite images i.e. the “poisonous” ɴ-carotene and the “wholesome” vitamin E and 
focused on one aspect, namely their role in inducing BPDE-DNA adducts. It appears that 
both antioxidants promote DNA adduct formation indirectly by inhibition of the protective 
enzyme glutathione-S-transferase ʋ (GST ʋ). Despite their opposite image, both 
antioxidants display a similar type of toxicity. It is concluded that, in the appreciation of 
antioxidants, first their benefits should be identified and substantiated by elucidating their 
molecular mechanism. Subsequently, the risks should be identified including the molecular 
mechanism. The optimal benefit-risk ratio has to be determined for each antioxidant and 
each individual separately, also considering the dose. 
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Main Text 
From a toxicological point of view, molecular oxygen and other reactive oxygen species 
(ROS) are among the most reactive compounds we encounter in daily life [1, 2]. Moreover, 
their level of exposure is relatively high and the duration of exposure is lifelong. This 
cumulates in the permanent threat of oxidative stress; a toxicological process implicated in 
the pathogenesis of virtually any disease [3, 4]. Antioxidants, which protect against ROS, are 
therefore vital for aerobic life. For that reason, nutrients rich in antioxidants or antioxidants 
administered as supplement are applied on a large scale in an attempt to alleviate ROS 
induced damage [5]. The concept of oxidative stress emerged in the second half of the 
previous century. Consequently, at that time the expectations for the health benefits of 
antioxidants were very high and the use of all kinds of antioxidants in relative high 
quantities were recommended based on the ideas that all antioxidants are equal, and that 
the higher the intake, the higher the health benefits of antioxidants would be. 
However, relatively recent meta-analyses of clinical studies insinuate that that the high 
expectations could not be met. It seems as if supplementation of antioxidants does not 
result in the presumed health benefit, but paradoxically a high intake of antioxidants is 
associated with increased mortality [6-9]. More than 68 randomized control trials were 
analyzed for the effects of ɴ-carotene, vitamin A and vitamin E on mortality. All these 
compounds, given in a relatively high dose as a single compound or in different 
combinations, had no beneficial effects. The supplements even increased all-cause 
mortality. In this respect, it should be noted that vitamin A is considered not be an 
antioxidant, indicating that any compound (not only antioxidants) will be toxic when the 
dose is too high.  In fact, this is the fundamental rule in toxicology coined five centuries ago 
by Paracelsus. As a consequence of the reports on the adverse effects of antioxidants given 
in a relatively high dose, the appreciation of antioxidants rigorously changed from healthy 
to toxic [10-12]. To date, the discussion on the health benefits of antioxidants continues. 
The dilemma remains: what are antioxidants in the end, toxic or healthy? We evaluated this 
dilemma by examining the presumed health effects of two individual natural antioxidants in 
which the opposite images are materialized i.e. the “poisonous” ɴ-carotene and the 
“healthy” vitamin E [13-17]. The interaction of ɴ-carotene and vitamin E with physiological 
systems should be evaluated at a molecular level, because at this level the biological effect 
of a compound arises. ɴ-carotene and vitamin E display a wide variety of effects from free 
radical scavenging to modulation of signal transduction [18-22]. In the present evaluation, 
we focused on one aspect, namely their role in inducing DNA damage by focusing on the 
interaction of ɴ-carotene and vitamin E with glutathione-S-transferase ʋ (GST ʋ). However, 
our perception of antioxidants should not be limited to their risks; actually their benefits 
should be put in first place. A risk-benefit analysis is made and is based on the interaction of 
the antioxidants on the molecular level. It will be discussed if we should adjust our 
perception of both compounds. The benefits of antioxidants on a molecular level are 
neutralizing ROS and prevent oxidative damage. The health benefits are supported by a 
large body of epidemiological evidence. For instance, a low plasma level of ɴ-carotene is 
associated with increased mortality [23-25]. Additionally, vitamin E is associated with a 
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reduced risk of coronary heart disease and colon cancer [13, 14, 26, 27]. Our knowledge on 
how these compounds act has drastically increased (box 1). In the 1970’s, it was believed 
that antioxidants only needed to scavenge free radicals which would totally absorb their 
reactivity. In the current concept on the molecular mechanism of action, scavenging is the 
first step in a series of at least three steps. The second step is that the radical is 
safeguarded in the antioxidant radical. Finally the radical has to be transferred safely into 
the antioxidant network. Although initially all antioxidants were considered to be equal, we 
now realize that each antioxidant has its own biochemical profile. Vitamin E for instance 
protects membranes from lipid peroxidation by scavenging lipid peroxyl radicals, while ɴ-
carotene is one of the most potent scavengers of singlet oxygen [28, 29]. The molecular 
mechanism of action of the major antioxidants is already partially unraveled. Nevertheless, 
several important aspects such as the interaction with the endogenous antioxidant 
network, needs to be fully elucidated in order to completely exploit the health benefits of 
these antioxidants. 
 
Box  1 Antioxidant protection.|For a long time, it was thought that antioxidants only needed to 
scavenge radicals to offer protection. Currently, our knowledge on how antioxidants functions has 
progressed. The mechanism of action of antioxidants consists of multiple steps, as illustrated with the 
protection of lipoproteins against lipid peroxidation by vitamin E. During the process of lipid 
peroxidation lipid peroxyl radicals (LOOභ) are formed. In the protection, the first step is the 
scavenging of LOOභ by the lipophilic antioxidant vitamin E·. This is a chemical reaction in which the 
reactive radical (LOOභ) is transformed into a non-radical (LOOH) that is relatively unreactive. The 
second step is that the radical is safeguarded in the antioxidant radical. The vitamin E radical is 
relatively unreactive due to delocalization of the radical over the antioxidant molecule. In the final 
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step, the radical is transferred safely into the antioxidant network. In sequential reactions, the radical 
is transferred from one antioxidant to another antioxidant. In the example, the radical located on 
vitamin E in the lipoprotein is taken over by vitamin C in the plasma [62]; the vitamin C radical might 
react with NADH to regenerate vitamin C, a reaction catalyzed by the ascorbate free radical 
reductase. In the end, the reactivity of the radical is totally absorbed in the 3 steps. 
ɴ-carotene  
ɴ-carotene belongs to the group of naturally occurring carotenoids and has a lipophilic 
character containing pro-vitamin activity. ɴ-carotene is naturally occurring in dietary fruits 
and vegetables, but is also present as food supplements. The chemical, biological and 
physical properties of ɴ-carotene are well-described [30]. Besides the proposed beneficial 
effects of ɴ-carotene, several clinical trials do not support these effects and reported toxic 
effects of ɴ-carotene supplementation. Regarding these risks, the ATBC study revealed in 
1994 that ɴ-carotene supplementation was associated with an increased incidence of lung 
cancer in smokers [31]. In the years that followed, other epidemiological studies 
corroborated this alarming effect [32-35]. The blame was put on ɴ-carotene.  However, the 
molecular mechanism for inducing lung cancer could not be evidently tied to ɴ-carotene.  
Especially in the combination with smoking, ɴ-carotene supplementation is extra dangerous 
[36, 37]. The polycyclic aromatic hydrocarbon benzyo[a]pyrene (BaP), present in tobacco 
smoke, has a well-known carcinogenic track record and the molecular evidence is beyond 
reasonable doubt [38]. BaP is activated into its highly mutagenic metabolite 
benzo(a)pyrene diol epoxide (BPDE). The electrophile BPDE attacks the nucleophilic regions 
of DNA, yielding BPDE-DNA adducts [39, 40]. The carcinogenic potential of BPDE is 
corroborated in the present study by the presence of 153 ± 23 BPDE-DNA adducts/107 
nucleotides (figure 1A) in lung epithelial cells (BEAS-2B) after exposure to BPDE. These DNA 
adducts cause chromosomal instability and eventually initiate tumor formation [41].  
Protection against BPDE is provided by GSTs. This family of enzymes catalyzes the 
conjugation of BPDE to glutathione (GSH), which neutralizes the carcinogenic potential of 
BPDE [42]. These GSTs are divided into five major isoforms (ɲ, µ, ʋ, ɽ, and ʍ), of which the ʋ 
isoform is found to be the most abundant isoform in erythrocytes, lung and the human skin 
[43-46]. In our experiments, GST ʋ effectively decreased the number of BPDE-DNA adducts 
in the lung epithelial cells to 75 ± 10 BPDE-DNA adducts/107 nucleotides (P< 0.01) (figure 
1B). The evidence on the protective role of GST ʋ is circumstantiated by the elevated risk 
for lung cancer in humans with impaired GST ʋ activity [45, 47, 48]. 
We also observed that ɴ-carotene attenuated the enzyme activity of GST ʋ. Five µM and 10 
µM ɴ-carotene inhibited the GST-ʋ activity with 35% and 43% respectively (figure 1C). 
Consequently, ɴ-carotene weakens the defense against BPDE. Indeed, in lung epithelial 
cells exposed to BPDE, ɴ-carotene inhibits the protective effect of GST ʋ, by increasing the 
number of BPDE-DNA adducts to 125 ± 10 /107 nucleotides (P< 0.05) (figure 1B).  This 
means that ɴ-carotene indirectly increases the formation of BPDE-DNA adducts, since the 
conjugation of BPDE to GSH will not take place. This finding implies that inhibition of the 
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protective activity of GST ʋ by ɴ-carotene is involved in the tumor promoting effect in 
smokers (figure 3) [31].  
 
Figure 1| The effects of ɴ-carotene (10 µM) on BPDE-DNA adduct formation (A), on GST ʋ induced 
detoxification of BPDE (B) and the inhibitory effect ɴ-carotene on the activity of GST ʋ. The inhibitory 
effect of ɴ-carotene on GST ʋ induced BPDE detoxification. BPDE-DNA adduct formation was 
measured by 32P-postlabeling assay. BEAS2B-cells were treated for 1 hour with 0.1 µM BPDE in the 
absence or in the presence of ɴ-carotene, the combination of GST ʋ (50 mU/mL) and GSH (1 mM) or 
the combination of GST ʋ (50 mU/mL), GSH (1 mM) and ɴ-carotene (10 µM). After treatment, 
medium was removed and cells were collected and stored at -20 °C. DNA adduct levels were 
determined according to the nuclease P1 enrichment technique as described by Reddy and 
Randerath with minor modifications [59, 60]. GST ʋ activity measurements were performed as 
described by Mannervik and Guthenberg with slight modifications [61]. In short, the reaction of 1 mM 
CDNB with 1 mM GSH in 100 mM potassium phosphate buffer (pH 6.5; 37°C) was 
spectrophotometrically monitored by measuring the increase in absorbance at 340 nm. The effect of 
ɴ-carotene (final concentrations: 5 µM and 10 µM) on GST enzyme activity (0.05 U/ml in buffer) was 
determined. The control activity (of 127±3 nmol/min/ml) was set to 100%. Data are shown as means 
± SEM (n=6). One way analysis of variance (ANOVA) with Bonferroni post hoc correction was used to 
examine differences in enzyme activities of GST ʋ. In order to determine differences in BPDE-DNA 
adduct formation, Student’s t–test was used. Differences were considered to be statistically 
significant when P <0.05. *P < 0.05, **P < 0.005, ***P<0.001. 
The blame the ATBC study put on ɴ-carotene supplementation fitted in the disappointment 
on the unrealistically high expectations of the health effect of antioxidant supplementation 
of that time [3]. However, by classifying it as toxic does injustice to ɴ-carotene, and we do 
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not recognize its beneficial health effects. Nevertheless, we do have to be fully aware of the 
hazard of ɴ-carotene in a specific group at risk, namely smokers. 
Vitamin E  
Vitamin E is the blanket term that covers all biological active tocopherols and tocotrienols 
and their derivatives. The chemical, biological and physical properties of vitamin E are well-
described [27] Vitamin E is abundant in our diet and present in numerous food 
supplements. Also the dermal exposure has to be considered due to the inclusion of vast 
quantities of vitamin E in cosmetic products such as shampoos and skin creams. Numerous 
beneficial health effects have been proposed for vitamin E, which are attributed to its 
antioxidants activity. Despite its reputation of being healthy, vitamin E has a dark side that 
is astonishingly similar to that of ɴ-carotene. Mitchel et al. [49] found that vitamin E had 
tumor promoting activity of in the skin of mice exposed to 7,12-Dimethylbenz(a)anthracene 
(DMBA), a reference compound for inducing cancer that displays a molecular mechanism 
similar to that of  BPDE. 
Figure 2| The effects vitamin E (30 µM) on BPDE-DNA adduct formation (A), on GST ʋ induced 
detoxification of BPDE (B) and the inhibitory effect of vitamin E on the activity of GST ʋ. BPDE-DNA 
adduct formation was measured by 32P-postlabeling assay. HaCaT cells were treated for 1 hour with 
0.1 µM BPDE dissolved in DMSO in the absence or in the presence of vitamin E, the combination of 
GST ʋ (50 mU/mL) and GSH (1 mM) or the combination of GST ʋ (50 mU/mL), GSH (1 mM) and 
vitamin E. After treatment, medium was removed and cells were collected and stored at -20 °C. DNA 
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adduct levels were determined according to the nuclease P1 enrichment technique as described by 
Reddy and Randerath with minor modifications [59, 60]. The GST ʋ activity was determined by 
recording the conjugation of 1 mM 1-chloro-2,4-dinitrobenzene (CDNB) by 1 mM GSH. The reaction 
of 1 mM CDNB with 1 mM GSH in 100 mM potassium phosphate buffer (pH 6.5; 37°C) was 
spectrophotometrically monitored by measuring the increase in absorbance at 340 nm. The effect of 
vitamin E (final concentrations: 1.25 µM, 5 µM and 10 µM) on GST enzyme activity (0.05 U/ml in 
buffer) was determined. The control activity (of 127±3 nmol/min/ml) was set to 100%. Data are 
shown as means ± SEM (n=6). One way analysis of variance (ANOVA) with Bonferroni post hoc 
correction was used to examine differences in enzyme activities of GST ʋ. In order to determine 
differences in BPDE-DNA adduct formation, Student’s t–test was used. Differences were considered 
to be statistically significant when P <0.05. *P < 0.05, ***P<0.001. 
 
In accordance to these findings, we observed that BPDE-DNA adducts were formed in skin 
keratinocytes (HaCaT cells) after exposure to BPDE (221 ± 28 BPDE-DNA adducts/107 
nucleotides) (figure 2A). The effective protection of GST ʋ is corroborated in these cells, 
evidenced by the effective decrease in the number of BPDE-DNA adducts, which were 
found to be 78 ± 4 BPDE-DNA adducts/107 nucleotides (P< 0.01) (figure 2B). Similar to 
inhibition of GST ʋ by ɴ-carotene, we found that vitamin E also inhibited this enzyme [50]. 
The enzyme activity of GST ʋ is even more potently inhibited by vitamin E in a 
concentration dependent manner (figure 2C). In a concentration of 1.25 µM, 5 µM or 10 
µM vitamin E significantly decreased the enzyme activity of GST ʋ with 57%, 73% and 74% 
respectively (p<0.001). Conversely, in rats a diet deficient in vitamin E was found to 
increase GST activity [51]. As a consequence of GST ʋ inhibition, vitamin E also significantly 
attenuated detoxification of BPDE by GST ʋ (149 ± 22 BPDE-DNA adducts/107 nucleotides; 
P< 0.05). The resulting net effect is an increase in BPDE-DNA adducts (figure 2B). This 
finding implies that inhibition of the protective activity of GST ʋ might explain the tumor 
promoting effect of vitamin E in mice (figure 3) [49].  
Coal tar contains polycyclic aromatic compounds (PAH) including BP (the precursor of BPDE) 
and dermal exposure is associated with inducing skin cancer [52]. After being banned, coal 
tar is currently making a surprising comeback as ingredient in medicated shampoos, soap 
and ointment for the treatment of numerous skin diseases as eczematous dermatitis and 
psoriasis [53, 54]. Coal tar ointments induce PAH-DNA adducts in skin [55]  and in analogy 
with ɴ-carotene in smokers, vitamin E may have an additional toxic effect on people using 
coal tar creams. By classifying it as wholesome we have a one-sided view on the health 
effect of vitamin E, and we do not recognize its toxic effect. Indeed, we do have to be fully 
aware of the hazard of vitamin E in a specific group at risk, namely people using coal tar 
creams. 
Conclusion and perspectives 
Apparently, the appreciation of an antioxidant is a reflection of the prevailing perception of 
the risks and benefits at a certain point in time, and this is subject to change (box 2). We 
earlier found that smokers and patients treated with coal tar ointments that are genetically 
deficient in GST detoxifications had higher DNA adducts in blood cells and skin [56, 57]. 
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Figure 3| Increase (%) in risk for lung cancer in smokers induced by ɴ-carotene (left y-axis) and in 
skin tumor formation in mice treated with DMBA induced by vitamin E (right y-axis). ɴ-carotene has a 
relative risk of lung cancer in smokers of 1.36, giving an increase of 36%. Vitamin E increased the 
number of skin tumors in mice from 1 tumor/25 animals in the control group to 154 tumors/26 
animals in DMBA treated mice, giving an increase of 15400 %. The ɴ-carotene data were obtained 
from The Alpha-Tocopherol, ɴ-Carotene Cancer Prevention Study Group, in which male smokers were 
daily supplemented with ɴ-carotene (20 mg). Lung cancer incidence was determined during a follow-
up of 5-8 years [32]. Vitamin E data were obtained from Mitchel et al [50]. In this study, DMBA with 
and without vitamin E were topically applied to the dorsal skin of female SENCAR mice from which 
the hair was shaved. 98 days and 153 days after DMBA initiation, skin tumor formation was 
determined. 
So modulation of GSTs by antioxidants as ɴ-carotene and vitamin E would certainly impose 
a risk in these groups of exposed persons. To come to an accurate risk-benefit analysis the 
following issues should be kept in mind: 
1. Antioxidants are consumed to improve health and not because they are not toxic. In our 
appreciation on antioxidants priority is given to the risks and this needs to be corrected. 
The priority should be to identify groups that are likely to benefit. A challenge is that clear 
pharmacological endpoints still need to be defined that also includes the impact on redox 
signaling.  
2. The molecular mechanism of the benefit is the actual fundament. Since each antioxidant 
has its own unique biochemical profile, antioxidants should not be treated as group. Based 
on the molecular pathways involved in pathology, the specific protection can be 
determined and the antioxidant which fits the profile best can be selected. 
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3. Next to groups that benefit, also groups that are at risk should be identified. Benefits are 
well-defined and therefore relatively easy evaluated. In contrast, risks can in principle be 
anything. Therefore, finding a group at risk is often a matter of chance. For example, it 
could not have been foreseen that smokers are at risk for ɴ-carotene supplementation. 
Probably, there are additional, not yet identified, risks in smokers or other specific groups. 
4. Risks should be substantiated by elucidating the molecular mechanism. This does not 
have to be related to the molecular mechanism for the benefit. The toxicity of the 
antioxidants in the present study does not arise from their antioxidant effect or their 
reactive products, but from the interaction with a protein. ɴ-carotene inhibited BPDE 
detoxification by GST ʋ. This molecular mechanism puts the toxicity of ɴ-carotene in the 
right perspective. BPDE is the actual culprit, whereas ɴ-carotene is more of an accomplice 
to BPDE, since it inhibits the detoxifying enzyme GST. By putting the toxicity in the right 
perspective, an overreaction (such as a general ban on ɴ-carotene) can be prevented. On 
the other hand, the molecular mechanism can be used to predict other risks, such as shown 
in the present study, the toxicity of vitamin E in people using coal tar. 
Although the accurate appreciation of antioxidants seems straight forward to do, in 
practice this appears to be quite awkward. This can be exemplified by the case of ɴ-
carotene in smokers. Since smoking causes oxidative stress, it is logical to supplement 
smokers with antioxidants. ɴ-carotene was selected because relatively low levels of this 
antioxidant were found in smokers. Unpredictably, ɴ-carotene appeared to be toxic in this 
group and therefore ɴ-carotene proved to be the wrong choice. 
 
 
Box 2 The health effect of antioxidants.| In the perception of the health effect of an antioxidant, it 
is often considered that an antioxidant either only provides benefits or that it only poses risks. These 
opposing, one side views are the main obstacles in the accurate perception of the health effect of 
antioxidants. A more balanced view is mandatory as any bioactive, antioxidants included, have 
benefits as well as risks. In fact, the distinction between the two is not as clear-cut as generally 
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assumed; as coined by Adrien Albert, the benefit is a form of selective toxicity. Critical in the risk-
benefit analysis is that each individual balance is biased. In people that are expected to profit, the arm 
of the benefit is relatively long. Contrariwise, in vulnerable people, the arm of the risk is relatively 
long. The latter is seen for the risk of ɴ-carotene in smokers. Apparently, it has to be determined for 
each individual separately whether the benefit outweighs the risk. The molecular mechanism is the 
pulling force that determines the weight of the benefit as well as the risk 
Undoubtedly, oxidative stress has a substantial contribution to smoke toxicity. Therefore, 
smokers are expected to benefit from antioxidant supplementation. Fully elucidating the 
molecular mechanism is needed to identify the antioxidant that fits smokers. 
In conclusion, as seen in the case of ɴ-carotene and vitamin E, there is a thin line between 
toxic and healthy.  Supplementation of antioxidants does not necessarily have to be 
beneficial and a natural origin is no guaranty for safety. The optimal benefit-risk ratio has to 
be determined for each antioxidant and each individual separately, also considering the 
dose. The molecular mechanism is the fundament to put the benefits as well as the risks in 
an accurate perspective. 
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Abstract 
The food supplement quercetin is used as self-medication for prostate disorders and is 
known to induce vasorelaxation. The drug tamsulosin is used in the treatment of benign 
prostatic hyperplasia. A major side effect of tamsulosin is orthostatic hypotension, 
mediated by vasorelaxation resulting from ɲ1-adrenoceptor blockade. The overlapping 
profile prompted us to investigate the pharmacodynamic interaction of quercetin with 
tamsulosin. Since quercetin is extensively metabolized in the intestines and the liver, the 
metabolites quercetin-3-glucuronide and 4’O-methyl-quercetin were also examined. 
Vasorelaxation induced by the compounds was tested in rat mesenteric arteries (average 
diameter: 360 ± 8 ʅm) constricted by the ɲ1-adrenoceptor agonist phenylephrine. 
Tamsulosin (0.1 nM) decreased phenylephrine sensitivity 17-fold (n=10). Quercetin (5, 10 
and 20 µM) also caused a decrease (2-, 4- and 6-fold respectively) of phenylephrine 
sensitivity, while 10 µM of quercetin-3-glucuronide and 4’O-methyl-quercetin decreased 
this sensitivity (1.5- and 2-fold) only slightly (n=6). The combination of tamsulosin with 
quercetin or quercetin metabolites proved to be far more potent than the compounds in 
isolation. The combination of quercetin, quercetin-3-glucuronide or 4’O-methyl-quercetin 
with tamsulosin decreased the phenylephrine sensitivity approximately 200-, 35- and 150-
fold (n=6). The strong pharmacodynamic interaction between the food supplement 
quercetin and tamsulosin underlines the potential of the impact of supplement-drug 
interactions that warrant more research. 
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Introduction 
Dietary supplements are used for all sorts of indications and have been linked to a wide 
variety of health benefits. Among these supplements, quercetin belongs to the best studied 
dietary flavonoids, a class of polyphenolic compounds that are abundantly present in 
vegetables and fruit [1-3]. It displays a multitude of activities, such as antioxidant, anti-
inflammatory and anti-atherogenic activities [3-7]. In addition, quercetin has been found to 
induce vasorelaxation of resistance arteries, which has been shown to potentially reduce 
blood pressure [2, 8-10]. The exact mechanism by which quercetin causes vasorelaxation is 
not fully elucidated. Quercetin is known to act as a signaling molecule by forming reactive 
intermediates [11-13]. These reactive intermediates may activate particular signaling 
cascades. One example of such intermediate is H2O2, which is an important regulator of 
signal transduction, by which it induces endothelium-dependent vasorelaxation [9]. The 
formation of H2O2 has been implicated in the vasorelaxant effect of quercetin.  
Among the indications of quercetin is prostate pain and swelling, chronic pelvic pain 
syndrome and chronic prostatitis [14, 15]. In contrast to the growing interest in the 
biological effects and the side effects of quercetin supplementation, the interaction of 
quercetin with drugs has gained remarkably little attention. Similar to drug-drug 
interactions, drug-nutrition interactions may be predicted from the overlap in their 
pharmacodynamic profiles. This strategy revealed the potentially hazardous interaction of 
quercetin with the drug tamsulosin on vasorelaxation with orthostatic hypotension as 
primary threat.  
Tamsulosin belongs to the ɲ1-adrenoceptor antagonists that are used to treat urine 
retention caused by benign prostatic hyperplasia (BPH) [16]. BPH has a prevalence of over 
70% in men above the age of 60 [17, 18]. Blocking ɲ1-adrenoceptors limits constriction of 
smooth muscles in the urinary tract and the prostate, facilitating urinary flow [19].  
Three subtypes of the ɲ1-adrenoceptor exist: ɲ1A,ɲ1B and ɲ1D. These adrenoceptors have a 
contractile role in the vasculature [20]. Tamsulosin is an insurmountable antagonist for all 
three ɲ1-adrenoceptor subtypes, meaning that it depresses maximal effects of ɲ1-agonists 
[21]. The selectivity of tamsulosin is generally considered to be ɲ1Aхɲ1Dхɲ1B [22]. Blocking 
ɲ1-adrenoceptors in the vasculature causes vasorelaxation, potentially reducing the 
vasoconstrictor response of our body to maintain normal blood pressure after standing up. 
This might ultimately lead to an orthostatic drop in blood pressure [23, 24]. A major side 
effect of tamsulosin therefore is orthostatic hypotension, i.e. a sudden fall in blood 
pressure when standing up [18]. Especially in elderly, orthostatic hypotension is critical, 
since a sudden drop in blood pressure increases the risk of falling and fainting. Fall-induced 
injuries are the fifth leading cause of death worldwide in the elderly population [25-27].  
The common pharmacodynamic profile, the use of both compounds in a group of frail 
patients and the major clinical impact prompted us to assess the potential interaction 
between the supplement quercetin and the drug tamsulosin on vasorelaxation. The 
supplement-drug interaction was assessed in rat mesenteric arteries constricted by the ɲ1-
adrenoceptor agonist phenylephrine. Nourian et al (2008) have shown a strong correlation 
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between the in vivo orthostatic hypotensive effects of antipsychotic drugs in an animal 
model of orthostatic hypotension, with the in vitro effects of these drugs on ɲ1-
adrenoceptors of mesenteric arteries in rats [28]. This corroborated the experimental 
strategy that ɲ1-adrenoceptors of mesenteric resistance arteries are responsible for the 
orthostatic hypotensive effects. Since quercetin is extensively metabolized in the intestine 
and the liver, the biological effects of quercetin are mainly mediated by its metabolites, the 
effects of the metabolites quercetin-3-glucuronide and 4’O-methyl-quercetin were also 
determined [2]. Here we show that quercetin and its metabolites 4’O-methyl-quercetin and 
quercetin-3-glucronide strongly augment the vasorelaxing effects of tamsulosin.  
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Materials and Methods 
Animal treatments 
16 weeks old male Wistar Kyoto (WKY) rats (Charles River, Maastricht, the Netherlands), 
weighing 200-300 gr, were housed in cages together and maintained at room temperature 
in a room with a 12-h light-dark cycle. Rats had free access to drinking water and standard 
chow. No adverse events were present in the study. All experiments were performed in 
accordance with the institutional guidelines and were approved by the Ethics Committee 
on Experimental Animal Welfare of the Maastricht University. A total of 30 animals was 
used in this study. 
Chemicals 
Phenylephrine (Sigma Aldrich) was dissolved in Krebs Ringer bicarbonate buffer (KRB) 
containing (in mM): NaCl 118.5, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25.0 and 
glucose, 5.5. Quercetin (Sigma Aldrich), 4’O-methyl-quercetin (Extrasynthese, France), 
glucuronidated quercetin (Sigma Aldrich) and tamsulosin (Sigma Aldrich) were all dissolved 
in dimethyl sulfoxide (DMSO). Ferrous ammonium sulfate (Sigma Aldrich) and potassium 
thiocyanate (Sigma Aldrich) were both dissolved in miliQ. 
Vasorelaxation of mesenteric arteries 
WKY rats were killed by CO2-inhalation. The mesentery was excised and immediately 
submersed in KRB at room temperature. Second-order branches of the superior mesenteric 
artery were dissected and isolated, by removing fat and connective tissue around the 
artery. Then, the artery was cut into 2 mm long segments and these were mounted in wire 
myographs (DMT, Aarhus, Denmark), in which 5 ml KRB was maintained at 37°C and 
aerated with 95% O2 and  5%  CO2. One holder of the myograph organ bath served as 
anchor, while a second holder was connected to an isometric force transducer, which was 
coupled to a signal amplifier. The myograph organ bath is connected to a computer to 
record isometric tension. Vascular functions were assessed as following: the arterial 
segments were stretched to the diameter at which contractile response to 10 µM 
phenylephrine was observed to be the largest. This was done by increasing the arterial 
diameter in steps of 50 µm, which loaded the resting tension, and subsequently measuring 
the magnitude of the contractile response to 10 µM of phenylephrine. In this study, the 
optimal internal diameter of the arterial averaged 360 ± 8 ʅm and contractile responses to 
10 ʅM phenylephrine averaged 3.4 ± 0.1. N m-1.  
After the optimal arterial diameter was determined, endothelial function was tested by 
adding 10 µM acetylcholine, which induced a complete endothelium-dependent relaxation 
of the arteries. Only arteries with intact endothelium have been used for our experiments. 
The resting tension of the arteries averaged 0.71 ± 0.08 N m-1. Then the arterial mesentery 
segments were washed again and equilibrated for 30 min, after which a first constructing 
cumulative concentration-response curve (CCRC) of phenylephrine (10-7 to 10-3 M in 
logarithmic half-units) was constructed. The contractile response to phenylephrine is 
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regarded as the control CCRC. After wash-out with KRB, the vessel segments were 
equilibrated again for 15 min, after which 0.1 nM tamsulosin was added. Nine minutes 
later, a second CCRC of phenylephrine was constructed to determine the effect of 
tamsulosin on phenylephrine-induced contraction. After wash-out, vessels were incubated 
for 9 min with 0.1 nM tamsulosin in combination with 5, 10, or 20 µM quercetin. Hereafter, 
a third CCRC of phenylephrine was constructed to determine the effect of combination of 
quercetin and tamsulosin on phenylephrine-induced contraction.  
In order to determine the effect of quercetin metabolites on tamsulosin function, vessels 
were incubated with 10 µM of either 4’O-methyl-quercetin or quercetin-3-glucuronide in 
combination with 0.1 nM tamsulosin for 9 min, after which the vessels were contracted by 
phenylephrine. The effects of quercetin, 4’O-methyl-quercetin and quercetin-3-glucuronide 
alone on phenylephrine-induced contractions were also determined. A possible reaction 
between quercetin and tamsulosin was checked spectrophotometrically. No reaction was 
found. Furthermore, as a control experiment, the effect of the vehicle (DMSO) was 
determined in the same concentration (max. 0.2%) as used in the experiments. DMSO was 
found to have no significant effect on phenylephrine-induced contractions. After each 
wash-out and equilibration period, the arterial tension returned back to baseline 
independent of treatment. Finally, time-control experiments were performed by repeating 
a dose-response curve with phenylephrine at the end of the experiment. The sensitivity of 
the arteries to phenylephrine had not been changed during time and exposures. 
Ferrous thiocyanate assay 
To determine H2O2  levels, the ferrous thiocyanate assay was performed as described by 
Hildebrandt et al [29]. In this assay, ferrous ion is oxidized to ferric ion by H2O2. 
Subsequently, thiocyanate will couple the ferric ion under strongly acidic conditions to form 
a red colored ferric iron–thiocyanate complex. This complex can be quantified 
spectrophotometrically [29]. A calibration curve with H2O2 curve was produced. In the 
cuvettes  350 µl of standards were mixed with 350 µl of concentrated HCl, 200 µl of 
potassium thiocyanate (final concentration 200 mM) and 100 µl of ammonium iron sulfate 
(final concentration 5 mM) respectively. After 10 min at room temperature, absorption was 
measured at 483 nm. A blank was prepared using H2O. KRB and the flavonoids did not 
interfere with the assay. H2O2 levels induced by quercetin or quercetin metabolites were 
determined every minute during the 9 min incubations in KRB buffer. 
Data analysis 
Data are shown as mean ± S.E.M. Contractile responses are expressed as percentage of the 
maximal contractile response to phenylephrine (PheMAX) before administration of any other 
compound. Individual CCRC were Įtted to a non-linear regression curve and EC50 was 
calculated using GraphPad Prism 5.02 (GraphPad Software Inc., La Jolla, CA, USA). In order 
to correct for any variability among the conditions, average EC50 values for each condition 
are summarized in table 1. Decreases in sensitivity to phenylephrine are calculated by 
dividing the EC50 of  the particular  condition by the EC50 of the control condition one-way 
ANOVA tests were used to compare EC50 values between the different conditions. Data 
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were analyzed using two-way ANOVA (comparison of CCRC). Bonferroni’s post hoc t-tests 
were used to compare multiple groups. 
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Results 
Effect of tamsulosin on phenylephrine-induced vasoconstriction 
Phenylephrine dose-dependently constricted isolated mesenteric arteries (figure 1). 
Tamsulosin decreased the maximal response with approximately 30%. More importantly, 
tamsulosin (0.1 nM) produced a non-competitive rightward displacement of the 
concentration-response curve to phenylephrine (figure 1 and table 1), since it significantly 
decreased (17-fold) the sensitivity towards phenylephrine (P<0.001).  
 
 
Figure 1| The effect of 0.1 nM tamsulosin on phenylephrine-induced vasoconstriction. 
Phenylephrine-induced vasoconstriction is shown for control. Findings are expressed as % PheMAX and 
are shown as means ± S.E.M. (n=10). ***P < 0.001. 
Effect of quercetin on phenylephrine-induced vasoconstriction and tamsulosin-induced 
vasorelaxation 
Quercetin (5, 10 and 20 µM) also shifted the concentration-response curve to 
phenylephrine rightward in a concentration dependent manner (with a 2-, 5-, and 6-fold 
decrease in phenylephrine sensitivity, respectively). Additionally, quercetin decreased the 
maximal response (Emax: 85%, 75% and  68% respectively) (figure 2 and table 1). Although 
higher concentrations were used, these effects were less than that of tamsulosin. The 
combination of tamsulosin and quercetin (5, 10, and 20 µM) was found to produce an even 
greater rightward shift of the CCRC to phenylephrine by decreasing the sensitivity to 
phenylephrine 173-, 207- and 112-fold (figure 2), without further affecting Emax. These 
reductions in sensitivity were greater than those observed for tamsulosin and quercetin 
alone. Hence, quercetin strongly increased the potency of tamsulosin (P<0.001). 
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Effects of quercetin metabolites on phenylephrine-induced vasoconstriction and tamsulosin-
induced vasorelaxation 
4’O-methyl-quercetin (10 µM) and quercetin-3-glucuronide (10 µM) decreased the arterial 
sensitivity to phenylephrine slightly by 2- and 1.5-fold respectively (P<0.005) (figure 3 and 
table 1). In combination with tamsulosin 4’O-methyl-quercetin and quercetin-3-glucuronide 
shifted the CCRC to phenylephrine markedly to the right. The sensitivity to phenylephrine 
was decreased 146- and 39-fold (figure 3), respectively, without further affecting Emax. As 
shown in table 1, these reductions in sensitivity were greater than obtained with 
tamsulosin and the quercetin metabolites alone (P<0.001). Thus, similary as quercetin also 
the metabolites 4’O-methyl-quercetin and quercetin-3-glucuronide strongly increased the 
tamsulosin-induced effects.  
H2O2 formation by quercetin and metabolites 
Quercetin produces H2O2 in a concentration-dependent manner (figure 4A). After 9 min of 
incubation in the organ bath, approximately 7.8 µM H2O2 was formed by quercetin (10 
µM).  In contrast, 4’O-methyl-quercetin (10 µM) and quercetin-3-glucuronide (10 µM) only 
produced minor amounts of H2O2 namely 1.1 µM H2O2 and 2.2 µM H2O2 respectively, which 
were substantially lower than the H2O2 levels induced by 10 µM quercetin (figure 4B). 
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Figure 2| The decrease in the sensitivity of the arteries towards phenylephrine and the increase in 
tamsulosin effects induced by different concentrations of quercetin (5, 10 and 20 µM; A,B and C).  
Findings are expressed as % PheMAX and are shown as means ± S.E.M. (n=6). ***P<0.001 (compared 
to tamsulosin). Q: quercetin. 
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Figure 3| The decrease in the sensitivity of the arteries towards phenylephrine and the increase in 
tamsulosin effects induced by 10 µM 4’O-methyl-quercetin (A) or 10 µM quercetin-3-glucuronide (B).  
Findings are expressed as % PheMAX and are shown as means ± S.E.M. (n=6). **P<0.005, ***P<0.001 
(compared to tamsulosin).Q3G: quercetin-3-glucuronide, 4’O-met-Q: 4’O-methyl-quercetin. 
 
Figure 4| H2O2 levels after addition of different concentrations quercetin (A) or 10 µM 4’O-methyl-
quercetin and quercetin-3-glucuronide (B) during 9 min of incubation. Findings are shown as means ± 
S.E.M. (n=4). **P<0.005, ***P<0.001. Q: quercetin; Q3G; quercetin-3-glucuronide; 4’O-met-Q: 4’O-
methyl-quercetin. 
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Discussion 
Our study reports on the pharmacodynamic supplement-drug interaction between 
tamsulosin and quercetin. The major finding is that the supplement quercetin strongly 
potentiates ɲ1-adrenoceptor antagonizing of the drug tamsulosin.  
Mesenteric arteries are involved in regulation of local blood flow and systemic blood 
pressure [30]. Arterial smooth muscles of mesenteric arteries are densely occupied with ɲ1-
adrenoceptors. The flavonoid quercetin has previously been shown to induce 
vasorelaxation by reducing the sensitivity of arteries to both the ɲ1-adrenoceptor agonists 
phenylephrine and noradrenaline in arteries with and without endothelium [2, 9, 29, 31-
33]. Vasorelaxation induced by the ɲ1-adrenoceptor blocker tamsulosin, as well of 
quercetin and its metabolites and combinations were determined on mesenteric arteries, 
to evaluate the interaction of the supplement quercetin with the drug tamsulosin.  
In vivo, quercetin was found to decrease mean arterial pressure and blood pressure in rats 
and humans [34]. In rats, plasma concentrations of quercetin were found to range from 15 
µM to 60 µM after feeding them a meal containing quercetin [35]. In humans, plasma 
concentrations of quercetin range from 0.1 to 1 µM [36]. However, chronic 
supplementation with quercetin elevates plasma concentrations up to 3 µM [37]. In 
addition, it should be taken into account that quercetin is extensively metabolized and 
these metabolites are held responsible for at least part of the effects of quercetin. Based 
on previous studies on the vasorelaxing effect of quercetin, three different concentrations 
of quercetin (5, 10 and 20 µM) were used in this study and compared to the effects of the 
metabolites quercetin-3-glucuronide and 4’O-methyl-quercetin. Our study shows that 
quercetin and the two quercetin metabolites 4’O-methyl-quercetin and quercetin-3-
glucuronide can induce vasorelaxation by reducing the sensitivity to phenylephrine.  
The drug tamsulosin (0.1 nM) was able to strongly antagonize the vasoconstrictor effect of 
phenylephrine. This corresponds to previous research in which the vasorelaxing effects of 
several concentrations (ranging from 0.1 nM to 30 nM) of tamsulosin on phenylephrine and 
(nor)adrenaline constricted arteries were determined [21]. Although tamsulosin is 
administered to block ɲ1A-adrenoceptors in the prostate, it will also block ɲ1A- and ɲ1D-
adrenoceptors in the vasculature  [21]. As a consequence of this lack of selectivity, the 
vasoconstrictor tone to ɲ1-adrenoceptor agonists as phenylephrine, adrenaline and 
noradrenaline is blocked. This results in orthostatic hypotension, a common side effect of 
tamsulosin. 
Orthostatic hypotension is caused by a drastic fall in blood pressure due to gravitational 
displacement of blood when standing up. Normally, the sympathetic system increases 
sympathetic outflow, heart rate, vascular resistance, constriction of the veins and cardiac 
output by activating ɲ1A-adrenoceptors in the vasculature in order to redistribute the blood 
and to normalize blood pressure. Blocking the ɲ1-adrenoceptors in the arteries and veins 
will antagonize such a physiological vaso- and venoconstrictor reflex, which forms the 
molecular basis for orthostatic hypotension. Tamsulosin treatment is normally started with 
0.3 or 0.6 mg capsules. Harada et al (2000) showed showed that 0.6 mg tamsulosin, giving a 
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steady state plasma concentrations of 0.3 nM, induced orthostatic hypotension in healthy 
men [38, 39]. The results found in the present study confirm the vasorelaxing ability of 
tamsulosin by blocking ɲ1-adrenoceptors, which form the pharmacological fundament of 
orthostatic hypotension. Similar to tamsulosin, other ɲ1-adrenoceptor antagonists as 
phenoxybenzamine, phentolamine and prazosin have been reported to induce orthostatic 
hypotensive effects by blocking these receptors [40-42]  
Strikingly, the combination of quercetin, 4’O-methyl-quercetin and quercetin-3-glucuronide 
with tamsulosin further diminished the sensitivity to phenylephrine. The decline in 
sensitivity by the combination of agents was much more pronounced than that of either 
tamsulosin or quercetin and its metabolites in isolation. This demonstrates the potential 
supplement-drug interaction of quercetin and tamsulosin.  
Although reports on vasorelaxing properties of quercetin are univocal, there is no 
consensus on the molecular mechanism. Several mechanisms have been implicated, such 
as an increase in intracellular Ca2+, a decreased smooth muscle calcium-sensitivity or 
increased nitric oxide (NO) bioavailability [9, 33]. H2O2 is also suggested to play a role in 
quercetin-induced vasorelaxation as endothelium-derived hyperpolarizing factor [43, 44]. 
Quercetin is known to induce the formation of H2O2 [11, 12]. H2O2 is an important regulator 
of signal transduction. Once H2O2 is produced, it activates eNOS via AKT and ERK1/2 to 
produce NO, which causes vasorelaxation [9, 45]. 
To further unravel the mechanism, H2O2 production was assessed. Quercetin was found to 
produce significant amounts of H2O2 in a concentration-dependent manner, which might 
be involved in quercetin-induced vasorelaxation. In addition, 4’O-methyl-quercetin and 
quercetin-3-glucuronide hardly produced H2O2. Quercetin dependent production of H2O2 
did not correlate with the potentiation of the tamsulosin effects. Moreover, the tamsulosin 
effects are also strongly augmented by the quercetin metabolites that hardly give rise to 
H2O2 production. These results suggest that H2O2 is not essential for increasing the 
vasorelaxation effects of tamsulosin. 
The orthostatic hypotensive effect of tamsulosin is known to be aggravated by the 
concomitant use of sildenafil, a drug belonging to the phosphodiesterase inhibitors, which 
is used to treat erectile dysfunction [23]. This drug-drug interaction is well studied and 
documented. In the combined interaction, the side effect of tamsulosin is amplified by 
sildenafil. Besides drug-drug interactions, bioactive constituents from nutrition are also 
known to impact the response of drugs [46]. Most reported interactions are of 
pharmacokinetic nature, affecting the metabolism of drugs [47]. The best known is grape 
fruits that inhibit cytochrome P-450 3A4, a metabolic enzyme involved in the metabolism of 
numerous drugs [48, 49]. As a consequence, levels of drugs such as nifedipine, nitrendipine 
and felodipine will rise to potential toxic levels.   Besides pharmacokinetic interactions, 
bioactives might also modify drug effects, potentially causing adverse health effects [47]. 
Such pharmacodynamics interactions are scarcely investigated. Our study draws attention 
to a pharmacodynamic interaction between the drug tamsulosin and the supplement 
quercetin. Tamsulosin effects are strongly amplified by quercetin. The simultaneous use of 
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these compounds may increase the potential for orthostatic hypotension and hence the 
risk of falling, which has serious consequences for the elderly, a group of frail patients [26]. 
The phamacodynamic interaction described in the present study, the frequent use of 
quercetin, and the potentially major clinical impact of this and probably other combinations 
[50, 51], draws attention to supplement-drug interactions that warrant more research. 
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Abstract 
Many compounds display anticholinergic effects which might give rise to cognitive 
impairment and even delirium. These side effects are caused by their ability to bind to 
muscarinic receptors in our brain. Especially with combination of compounds, these serious 
effects are seen. This phenomenon, known as anticholinergic accumulation, is especially 
seen in elderly. A classification of drugs for anticholinergic side effects has been made 
based on clinical observations, the ACB score. Here, we aimed to substantiate this 
classification by comparing the affinity of numerous drugs for the muscarinic receptors to 
the ACB score. Additionally, a number of supplements are screened. The affinity of the 
compounds was determined by their ability to displace the radioligand [3H]pirenzepine of 
the muscarinic receptor induced by these compounds. Our results show that the affinity of 
a compound for the muscarinic receptors correlated with its ACB score. Also food 
supplements appeared to bind to these muscarinic receptors. Moreover, several drug-drug, 
supplement-supplement and supplement-drug combinations had an affinity for that is 
higher than the affinity of single compounds. This explains the phenomenon of 
anticholinergic accumulation. In conclusion, care should be taken to drug-drug and 
supplement-drug combinations with respect to anticholinergic accumulation.  
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Introduction 
Many compounds display anticholinergic side effects caused by their ability to block 
muscarinic receptors in our brain [1, 2]. Binding to this receptor may give rise to cognitive 
impairment and even delirium [3]. The anticholinergic side effect of a single compound is 
often relatively mild. However, when several compounds are taken simultaneously, more of 
the receptors will be blocked, aggravating the impact [4, 5]. This is known as anticholinergic 
accumulation. Anticholinergic accumulation especially occurs in elderly as a result of 
polypharmacy, changes in brain neurochemistry as well as kinetics, risk factors that are all 
age-associated [6, 7].  
Anticholinergic accumulation in elderly has important implications for health-care 
utilization and costs [8]. Delirium results in increased nursing time per patient, higher 
hospital costs (total nursing costs of approximately $69 498 per patient per year), and an 
increased duration of hospital stay (of 20.7 days compared to 8.9 days for controls) [9-11]. 
The resulting economic burden is substantial (which ranges from $38 billion to $152 billion 
each year in the USA) as well as the negative impact on the quality of life [8, 12]. 
In 2008 the Anticholinergic Cognitive Burden (ACB) scale was developed, which classifies 
drugs based on their anticholinergic effect [13, 14]. Drugs with possible anticholinergic 
effects have an ACB score of 1, drugs with established clinically relevant cognitive effects 
have an ACB score of 2 and drugs with severe clinically relevant cognitive effects have an 
ACB score of 3. The ACB list is based on clinical studies determining the anticholinergic side 
effects of drugs. Remarkably, in contrast to drugs, the effect of food supplements on 
anticholinergic accumulation has not gained any attention. 
In the present study, we investigate the correlation of the affinity of drugs for the 
muscarinic receptor to the ACB score of that drug. Additionally, a number of supplements 
are screened for binding to muscarinic receptors. Since especially combinations of drugs 
give rise to anticholinergic accumulation with clinical relevant problems, several 
combinations of compounds are tested.    
It was concluded that the affinity for the muscarinic receptors correlates with the clinical 
anticholinergic effects of the compounds tested. Not only drugs but also food supplements 
bind to muscarinic receptors.  
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Materials and Methods 
Chemicals 
[3H]pirenzepine (84 Ci/mmol)([3H]PZ) and Whatman filters were obtained from 
PerkinElmer. Amantadine, Atropine, Choline, Chondroitin, Cimetidine, Desipramine, 
Glucosamine, Hyoscyamine, Orphenadrine, Pirenzepine dichloride, Quercetine, 
Scopolamine, Theophylline, Ascorbic acid (Vitamin C), Adenosine (Vitamin B4), Pyridoxine 
(Vitamin B6), Cobolamine (Vitamin B12), Warfarin and Zinc were all obtained from Sigma 
Aldrich and dissolved in assay buffer (50 mM Na/K phosphate buffer; pH 7.4). 
Tissue preparation  
Male Wistar Kyoto (WKY) rats (200-250 g, Charles River, Maastricht, the Netherlands), were 
sacrificed by CO2-inhalation. Brains were rapidly removed and put in assay buffer. All 
experiments were approved by the University Animal Ethical Committee and conducted in 
accordance to the ethical guidelines (EEC Council directives 86 / 609) for using 
experimental animals ( ''European Convention for the Protection of Vertebrate Animals 
Used for Experimental and other Scientific Purposes'' (1986)  and the ''Guiding Principles in 
the Use of Animals in Toxicology'', adopted by the Society of Toxicology (1989)).  Brains 
were homogenized in assay buffer using a potter tube. Brain homogenates were first 
centrifuged at slow speed in order to remove unwanted pieces of tissue, which was 
followed by centrifuging at 20 000 x g for 15 minutes. The precipitated material was 
resuspended in assay buffer and diluted in order to reach the final concentration given 
below. 
Binding assays 
For [3H]PZ binding assays, 1 mg of protein was used. Analysis of [3H]PZ binding (final 
radioactive concentration: 100 µCi/mL) was determined as described by Michel et al (1993) 
[15]. For saturation binding experiments, tissues were incubated in assay buffer containing 
the radioligand and drugs or food supplements as indicated. The final assay volumes were 
0.25 ml. Binding reactions were initiated by addition of tissues to the mixture, after which 
tubes were placed in the water bath for 60 minutes at 37°C. After 1 hour binding reactions 
were terminated by adding 5 mL of ice-cold assay buffer to the reaction mixtures. This was 
followed by filtering the tissues over Whatman filters. Filters were washed 5 times with 5 
ml of assay buffer, after which they were dried by suction. Finally, filters were placed into 
counting vials and 16 mL of scintillation cocktail was added to dissolve the filters. Then, 
filters were counted at the beta-counter. The amount of radioligand bound was less than 
10% of total added ligand in all the experiments. 
For saturation binding experiments, tissues were incubated for 60 minutes in a 
concentration-range of [3H]PZ (0-100 nM). Non-specific binding was determined in parallel 
incubations using 1 µM atropine. In the displacement experiments, tissues were incubated 
at 37°C for 60 minutes in the presence of 30 nM of [3H]PZ and either 100 nM of drugs listed 
with an ACB score of 3, 1 µM of drugs listed with an ACB score of 2 and 100 µM of the 
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drugs  listed with an ACB score of 1. Also, numerous food supplements (100 µM) were 
screened for binding to muscarinic receptors. Moreover, drug-drug, supplement-
supplement and drug-supplement combinations were also screened for binding to 
muscarinic receptors. Incubations were terminated as described above. 
Calculation of the affinity of the compound for the muscarinic receptor 
The affinity of the compounds for the muscarinic receptor was expressed as the pKD values 
(=  -log  KD ;  KD = dissociation constant of the compound). pKD values were calculated 
according to the modified Cheng-Prusoff equation that gives an accurate  KD value  for  
displacements between 20 and 80% of the labeled ligand (0.2 < B/Bmax <0.8): 
              pKD = - log (  [A]*Kp*B
Bmax*[P]-[P]*B*KP-KP*B )                               (1) 
B = [3H]PZ bound to receptor 
Bmax = Concentration of receptors 
[P]= concentration of [3H]PZ 
KP = dissociation constant of [
3H]PZ for the receptor 
[A]=concentration of test compound in mM 
KD= Dissociation constant of [A] for the receptor 
pKD = - log KD 
Apparent pKD values were calculated when food supplements were combined or when two 
drugs were combined. 
Statistics 
Results are shown as mean ± S.E.M. Saturation data were Įtted to a non-linear regression 
curve. The kinetic parameters KD and Bmax of [
3H]PZ were calculated using GraphPad Prism 
5.02 (GraphPad Software Inc., La Jolla, CA, USA). Data were analyzed using a two-tailed 
Student’s t-test to compare the (apparent) pKD values. P values of < 0.05 were considered 
statistically significant. 
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Results 
In figure 1 binding of [3H]PZ to the muscarinic receptors in rat brains is depicted. Non-
specific binding was determined by incubating rat brain with a fixed concentration of 
atropine (1 µM) and various concentrations of [3H]PZ (1 – 100 nM)  (figure 1). The pKD value 
(8.7) of atropine was determined after incubation of a fixed concentration of [3H]PZ (30 
nM) and a variable concentration of atropine (0.1 nM – 1 µM) (figure 1 insert). [3H]PZ binds 
to the receptor with an affinitiy (pKD) of 7.9 and the concentration of muscarinic receptors 
(Bmax) was 18.0 ± 1.3 fmol/mg protein (figure 1).  
 
Figure 1| Binding of [3H]PZ to the muscarinic receptors in rat brains (figure) and the affinity of 
atropine for these receptors (insert). Analysis of total [3H]PZ binding (final radioactive concentration: 
100 µCi/mL) was determined as described by Michel et al (1993). Tissues were incubated for 60 
minutes in a concentration-range of [3H]PZ (0-100 nM). Non-specific binding was determined in 
parallel incubations using 1 µM atropine. Specific binding was calculated using Prism 5.02. The affinity 
of atropine was determined after incubation of a fixed concentration of [3H]PZ (30 nM) and different 
concentrations of atropine (0.1 nM – 1 µM) (figure 1 insert). Data are shown as means ± SEM (n=4). 
In order to determine whether the ACB score of a drug could be correlated to its ability to 
bind  to  muscarinic  receptors,  the  affinity  for  the  receptor  of  a  selection  of  drugs  with  
different ACB scores was quantified. The drugs with an ACB score of 1, chloretalidone, 
cimetidine, furosemide, haloperidol, metoprolol, risperidone, theophylline and warfarin, 
had a relatively low affinity for the receptors; pKD-values (mM) ranged from 1.4 to 1.6 
(figure 2). Amantadine, carbamazepine and oxcarbazepine, the drugs with an ACB score of 
2, had an intermediate affinity for the receptors; pKD-values ranged from 3.7 to 3.8. Finally, 
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atropine, desipramine, hyoscyamine, olanzapine, scopolamine and orphenadrine, the drugs 
with an ACB score of 3, had a high affinity for the muscarinic receptors; pKD-values ranged 
from 4.3 to5.3 (figure 2). Combination of warfarin (pKD: 1.7), cimetidine (pKD: 1.6) and 
theophylline (pKD: 1.7) resulted in an apparent pKD value of the combination of 2.6 (P<0.05; 
figure 2). 
 
 
Figure 2| The affinity of numerous drugs listed on the ACB list for the muscarinic receptors (A) and 
the effect of combination of warfarin, cimetidine and theophylline on the apparent pKD (B). The 
affinities were calculated using a modified Cheng-Prusoff equation that gives an accurate KD value for 
displacements between 20 and 80% of the labeled ligand. In the displacement experiments, tissues 
were incubated at 37°C for 60 minutes in the presence of 30 nM of [3H]PZ and either 100 nM of drugs 
listed with an ACB score of 3 (red bars), 1 µM of drugs listed with an ACB score of 2 (orange bars) and 
100 µM of the drugs listed with an ACB score of 1 (yellow bars). Data are shown as means ± SEM 
(n=4). Differences were considered to be statistically significant when P <0.05. *P < 0.05. 
Numerous supplements were also screened for binding to the muscarinic receptors. Zinc 
and choline did not displace [3H]PZ effectively. pKD values of zinc and choline were less than 
0.5 indicating that both supplements did not strongly bind to the receptor. Glucosamine, 
quercetin and the vitamins B4, B6, B12 and C bound more potently with pKD values of 1.4 to 
1.7 (figure 3).  
These pKD were comparable to those of the drugs with an ACB score of 1. Chondroitin had 
the highest affinity; its pKD value was 1.7.  
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Figure 3| The affinitiy of numerous food supplements for the muscarinic receptors (A) and the 
apparent affinity of a combination of several of these supplements (B). The affinities were calculated 
using a modified Cheng-Prusoff equation that gives an accurate KD value for displacements between 
20 and 80% of the labeled ligand, after performing displacement experiments. Tissues were 
incubated at 37°C for 60 minutes in the presence of 30 nM of [3H]PZ and 100 nM of the food 
supplement. Data are shown as means ± SEM (n=4). 
Similar to the combination of drugs, a combination of food supplements can have a higher 
affinity for the receptor than that of the single compounds. This is evidenced by the 
combination of glucosamine (pKD: 1.3), vitamin B6 (pKD: 1.5), vitamin B12 (pKD: 1.5) and 
vitamin C (pKD: 1.4) (all with an affinity which would give an ACB score of 1) had an 
apparent pKD value of 2.1. Based on this pKD value, the combination has an ACB score of 2 
(figure 3).  
In addition, the combination of supplements with drugs can also result in a higher affinity 
for the receptor than the single compounds.  This is seen with the combination of vitamin 
B6, vitamin B12 and glucosamine (pKD: 1.6) with either cimetidine (pKD: 1.6), risperidone 
(pKD: 1.8) and haloperidol (pKD: 1.7) (all drugs with an ACB score of 1) all had an apparent 
pKD of 2.1 (P < 0.05). Based on this pKD value, combinations of the supplements with the 
drugs have an ACB score of 2. 
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Figure 4| The effect of supplement-drug combination on the apparent affinity for muscarinic 
receptors.  Tissues were incubated with either three food supplements (vitamin B6,  vitamin B12 and 
glucosamine) or cimetidine, risperidone or haloperidol with and without a combination of food 
supplements (vitamin B6, vitamin B12 and glucosamine). The apparent affinity was calculated using a 
modified Cheng-Prusoff equation. Data are shown as means ± SEM (n=4). Differences were 
considered to be statistically significant when P <0.05. *P < 0.05. 
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Discussion  
The ACB score has been proposed as a convenient way to predict the anticholinergic side 
effects of drugs and combinations of drugs. The ACB score was based on the anticholinergic 
effect of compounds determined in clinical studies. The aim of the present study is to 
correlate the ACB score of compounds to their binding to muscarinic receptors, so that the 
anticholinergic effect of a drug can be screened in a relatively simple way by determining 
the affinity for the muscarinic receptor in a binding study. The ACB score of several 
compounds correlate well with the affinity, confirming the usefulness of the screening 
assay. It should be noted that it is a screening assay and positive results of new compounds 
need to be confirmed in a clinical setting.  
Anticholinergicity refers to blockade of cholinergic neurotransmission, and especially 
blockade of muscarinic receptors in the brain is of relevance, since they play an important 
role in numerous processes, including cognition, attention, sleep, metabolism, motivation 
and movement. Five muscarinic receptor subtypes exist: M1,  M2, M3, M4 and M5, of which 
the  M1,  M4 and  M5 receptor subtypes are present in the brains [16]. Blocking of the M1 
receptor on these cholinergic neurons plays an important role in the development of both 
acute and chronic cognitive impairment. PZ (pKD of 7.9) has a very high affinity for M1 
receptors and therefore PZ was used as radioligand in our study. The affinity of PZ found in 
our study corresponds to that reported previously (pKD: 7.8) [17].  
Over 600 medicinal products with a broad therapeutic range as well as an adverse effect 
profile are recognized to have anticholinergic activity [5]. These include psychoactive drugs, 
such as hypnotic, antipsychotic, antiparkinsonian  and antidepressant drugs, and non-
psychoactive drugs, such as cardiac, corticosteroids  and antibiotic drugs [7, 18]. These 
drugs can give cognitive impairment, especially when they are combined [19]. Thus, 
anticholinergic accumulation results in confusion, delirium, dry mouth, headache, pain, 
anxiety and blurred vision [20]. Drugs have been extensively investigated for their 
anticholinergic properties.  In 2008, an ACB list has been developed. This list contains 
numerous drugs that are classified by the clinical impact of their anticholinergic effects on 
cognition. Drugs with an ACB score of 1 are classified as drugs with possible anticholinergic 
effects. Drugs with an ACB score of either 2 or 3 are classified as drugs with established 
clinically relevant cognitive effects and the effect of drugs with an ACB score of 3 can be 
quite severe. 
In the present study, a correlation between muscarinic receptor affinity and clinically 
established symptoms of anticholinergic toxicity was found. The drugs cimetidine, 
theophylline, warfarin and furosemide (with an ACB score of 1) all had the lowest affinity 
for the muscarinic receptors in the brain with a pKD value below 2. Additionally, the drugs 
with established clinically anticholinergic effects (ACB score of 2) display higher affinities for 
muscarinic receptors (pKD 2-3), while the drugs with the highest anticholinergic effects (ACB 
score of 3) had the highest affinity for these receptors (pKD >4). Hence, in the present study 
we have validated the anticholinergic effects of drugs using a binding study. Also, the 
anticholinergic effect of a drug can be screened in a relatively simple way by determining 
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the affinity for the muscarinic receptor in a binding study, which is much more convenient 
than the epidemiological approach.  
In general, anticholinergic accumulation is especially observed in people when multiple 
drugs are used. Polypharmacy with anticholinergic compounds is common in nursing home 
residents and indeed increases the risk for anticholinergic toxicity tremendously [2, 5]. 
Moreover, elderly are a group at risk for the anticholinergic effects of drugs. This can be 
explained by age-related changes in pharmacokinetics and pharmacodynamics (Moore et 
al., 1999). These changes include a relatively low number of cholinergic neurons and 
receptors in brain, a relatively low hepatic and renal clearance of drugs, the relatively high 
blood brain barrier permeability and the frequent use of multiple drugs (Molchan et al., 
1992; Zlokovic, 2008). As a consequence, elderly are more prone to develop cognitive 
impairment (Tan et al., 2015; Tune et al., 1991). 
That even the use of the combination of 3 drugs may lead to anticholinergic accumulation 
is corroborated in the present study. The combination of cimetidine, warfarin and 
theophylline, all drugs with an ACB score of 1, increased the apparent pKD by  one.  The  
resulting pKD value was comparable to that of drugs having an ACB score of 2. Hence, this 
combination is an example of anticholinergic accumulation and the higher risk of adverse 
cognitive effects. 
In contrast to drugs, the binding of food supplements to the muscarinic receptor binding 
has not been investigated yet. This is remarkable since the frequency of using dietary 
supplements increases with age. Over 50% of the elderly consumes at least one 
supplement a day. We screened the food supplements used most frequently by elderly. 
Among these supplements are glucosamine, vitamin B6, vitamin B12, vitamin C, chondroitin, 
zinc, choline, quercetin and vitamin B4. Most of these compounds have the ability to 
penetrate the blood brain barrier (BBB) [21-23]. In elderly, even higher levels of these 
supplements in the brains might be found, since the permeability of the BBB increases with 
age [24]. The pKD value of these supplements for the muscarinic receptors was relatively 
low, which are comparable to that of the drugs with an ACB score of 1. This indicates that 
food supplements may produce relatively mild adverse cognitive effects.  
Combinations of food supplements are more relevant in this respect. The present study 
indicates that especially the use of a combination of food supplements most frequently 
used e.g. in a multivitamin supplement, increases the risk of anticholinergic accumulation. 
The simultaneous use of food supplements and drugs is also often observed in elderly. 
Importantly, drug-drug, supplement-supplement and supplement-drug combinations had 
an affinity for the muscarinic receptor that is higher than that of the compounds in 
isolation. This indicates that these combinations may increase anticholinergic burden, the 
phenomenon known as anticholinergic accumulation. In estimating the ACB burden of a 
combination of drugs, it is assumed that this is equal to the sum of the ACB score of the 
separate drugs. It is indeed expected that the anticholinergic effect will increase when 
using multiple drugs; however, determining the ACB score of the combination by summing 
up the ACB scores of all the separate drugs probably gives an overestimation. Based on the 
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affinity to bind to the receptors, the combination of three drugs with an ACB score of 1 
does not give a total ACB score of 3, but a score of 2. 
Anticholinergic accumulation may be detrimental for elderly. Even anticholinergic effects, 
that might be considered as relatively mild, such as a dry mouth, reduces the ability to 
communicate, predisposing to malnutrition, and increasing the risk of respiratory infection. 
Additionally, mydriasis might impair near vision, which could increase the risk of accidents, 
including falls that might be fatal in these elderly.  
When making a risk-benefit analysis of the drugs on the ACB list and the food supplements, 
it is noteworthy that the benefits of the single drugs or supplements outweigh their risks. 
The present study provides a convenient method to screen the risks. In elderly, 
supplementation can also have benefits and in practice a clear risk-benefit analysis has to 
be made. It highlights that especially the combination of drugs and food supplements may 
give rise to the risks, which are increased anticholinergic effects. 
In conclusion, the affinity for muscarinic receptors obtained in a simple receptor binding 
experiment of compounds correlates with the ACB score which is a clinical measure of 
anticholinergic effects. This confirms the validity of the screening assay. However, it should 
be noted that it is a screening assay and positive results of new compounds need to be 
confirmed in a clinical study. Our results draw attention to drug-drug and supplement-drug 
combinations that may lead to anticholinergic accumulation. Attention should be given to 
the use of food supplements when prescribing drugs, to prevent drug- or supplement-
induced problems in elderly. More research on the anticholinergic effects of drugs and food 
supplements is warranted, especially in groups at risk, such as elderly.     
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Abstract 
The use of self-medication, which includes dietary supplements and over-the-counter 
drugs, is still on the rise, while safety issues are not well addressed yet. This especially holds 
for combinations. For example, iron supplements and magnesium peroxide both produce 
adverse effects via the formation of reactive oxygen species (ROS). This prompted us to 
investigate the effect of the combination of three different iron supplements with 
magnesium peroxide on ROS formation. 
Hydroxyl radical formation by the three iron supplements either combined with magnesium 
peroxide or alone, was determined by performing a deoxyribose assay. Free iron content of 
iron supplements was determined using FerroZine assay. To determine hydrogen peroxide 
formation by magnesium peroxide, a ferrous thiocyanate assay was performed. Finally, 
electron spin resonance spectroscopy (ESR) was performed to confirm the formation of 
hydroxyl radicals.  
Our results show that magnesium peroxide induces the formation of hydrogen peroxide. All 
three iron supplements induced the formation of the extremely reactive hydroxyl radical, 
although the amount of radicals formed by the different supplements differed. It was 
shown that combining iron supplements with magnesium peroxide increases radical 
formation. The formation of hydroxyl radicals after the combination was confirmed with 
ESR. 
All three iron supplements contained labile iron and induced the formation of hydroxyl 
radicals.  Additionally, magnesium peroxide in water yields hydrogen peroxide, which is 
converted into hydroxyl radicals by iron. Hence, iron supplements and magnesium peroxide 
is a hazardous combination and exemplifies that more attention should be given to 
combinations of products used in self-medication. 
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Introduction 
The use of self-medication, which includes dietary supplements and over-the-counter drugs 
(OTC’s), is still on the rise. Improving or maximizing health or compensating for an 
unhealthy lifestyle are top reasons for using supplements. In addition, the desire for self-
care further increases the use of self-medication. Besides the beneficial health effects, the 
use of self-medication also has risks. For drugs, both benefits and risks are meticulously 
monitored and examined. Although risks of self-medication are increasingly realized, this is 
not well addressed yet [1]. Therefore, more attention should be given to the safety issues 
of dietary supplements and OTC’s.  
Relative to the safety issues of the use of a single supplement or OTC, the use of 
combinations is expected to be more hazardous. This prompted us to investigate the 
combination of a potential hazardous combination, i.e. the combination of iron 
supplements and magnesium peroxide.  
Iron deficiency is the single most prevalent nutritional deficiency worldwide with elderly as 
a group with the highest prevalence [2]. Subsequently, iron supplements are in the top of 
the dietary supplements used in the older population [3]. 
Iron deficiency will result in anaemia, characterized by a relatively low number of red blood 
cells and a low haemoglobin level [3]. Symptoms of anaemia are fatigue, decreased physical 
endurance, decreased immune system activity and increased sensitivity to cold [3]. The 
human adult body normally contains approximately 45 milligram of iron per kilogram body 
weight. The only source of iron is nutrition. In order to maintain adequate iron levels, a 
daily dietary intake of 15 milligrams for adult women and 10 milligrams for adult men is 
required [4].   In order to restore or maintain iron levels, iron supplements are often taken 
[5]. Numerous iron supplements are available, each containing relatively high doses of iron 
ranging from 14 mg to 695 mg. 
Besides its beneficial effects, iron can also be toxic. When iron supplements are taken 
orally, free iron is known damage intestinal cells by generating free radicals via Fenton 
chemistry [3, 6]. In the Fenton reaction, homolytic cleavage of hydrogen peroxide by 
ferrous iron generates the very reactive hydroxyl radical (equation 1) [7]. 
  ܨ݁ଶା + ܪଶܱଶ ՜ ܨ݁ଷା + ܱܪି + ܪܱ•   (1) 
The produced hydroxyl radical is able to cause protein modification, lipid peroxidation, or 
damage to RNA and DNA, especially in the intestines [8, 9]. Hence, iron is able to exert toxic 
effects. 
Magnesium peroxide is an antacid that is available as an OTC. It neutralises gastric acid, 
thereby relieving symptoms of for instance gastro-oesophageal reflux disease or gastric 
ulcers, which may be caused by iron supplements [10]. A major side effect of magnesium 
peroxide is that it causes diarrhoea [11], which is suggested to be caused by radical 
formation in the intestines. After ingestion of magnesium peroxide, hydrogen peroxide is 
Chapter 5 
90 
formed. Since it may reduce the absorption of iron, it is advised not to combine magnesium 
peroxide with iron supplements. However, there is no literature about the toxic effects of 
combining both. 
Due to the formed hydrogen peroxide, the combination of iron supplements and 
magnesium peroxide is expected to raise the production of reactive oxygen species (ROS), 
especially hydroxyl radicals. Remarkably, this combination has not been identified as 
potentially toxic. In the present study, the radical formation by the combination of three 
different iron supplements with magnesium peroxide was determined [12] .  
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Materials and Methods 
Chemicals 
L-ascorbic acid, 2-deoxy-D-ribose, ferrous ammonium sulphate, magnesium hydroxide 
(MgOH), magnesium peroxide (MgO2), potassium thiocyanate (KSCN), 2-thiobarbituric acid 
(TBA), trichloroacetic acid (TCA), ferrous chloride (FeCl2•4H2O), ferric chloride (FeCl3•6H2O), 
hydrogen peroxide (H2O2), KH2PO4 and  K2HPO4•3H2O were obtained from Sigma-Aldrich. 
EDTA titriplex III was obtained from Merck. The three different iron supplements contained 
iron lactate, iron sulfate (Fero Gradumet) and iron gluconate (Losferron) and were obtained 
from Kruidvat, Teofarma and Will-Pharma respectively. 
Deoxyribose assay 
Hydroxyl radical formation induced by the different iron supplements and FeCl3 as positive 
control was determined by performing the deoxyribose assay [13]. Iron mixtures of FeCl3 or 
each of three iron supplements with variable final concentrations, ranging from 0 to 20 ʅM, 
were made using deoxygenated water as solvent. Additionally, deoxyribose (2.8 mM), 
ascorbic acid (0.1 mM), H2O2 (2.8 mM), KH2PO4/KOH buffer (pH 7.4; 10 mM), together with 
the FeCl3 mixtures, were added in test tubes. Stock solutions of these compounds were 
freshly made every day. The reaction mixtures were incubated for 1 hour at 37 °C in a 
water bath. During this incubation Fe3+ was reduced to Fe2+ by ascorbic acid. Together with 
H2O2, the Fe
2+ generated hydroxyl radicals, which in turn attacked deoxyribose to form 
fragments.  In order to stop the reaction, 2 ml stop solution (0.5% (w/v) TBA, 1.4% (v/v) TCA 
in MQ) was added to each tube after 1 hour. Then, these mixtures were heated for 20 
minutes at 100 °C. By adding the stop solution, fragments that were formed yielded a pink 
chromogen (MDA-TBA). Finally, the test tubes were cooled on ice and the absorbance of 
the reaction mixtures was measured at a wavelength of 532 nm using a spectrophotometer 
(Varian-Cary PCB50). The concentrations of generated hydroxyl radicals were calculated via 
Lambert-Beer’s law, using the molar extinction coefficient of malondialdehyde (MDA) as 
0.156 ʅM-1cm-1 [14].  
In order to test the hydroxyl radical formation by FeCl3 and  three  different  iron  
supplements in combination with different concentrations of MgO2, the same protocol was 
performed using a fixed concentration (10 ʅM) of either FeCl3 or the iron supplements. A 
1.78 mM MgO2 stock solution was made using a sodium phosphate buffer (pH 3.8) as 
solvent. This stock solution was diluted to variable final concentrations of MgO2 (0-1.78 
mM) using the KH2PO4/KOH buffer. In these experiments, MgO2 was used instead of H2O2. 
The reactions mixtures ultimately contained 2.8 mM 2-deoxy-D-ribose, 0.1 mM ascorbic 
acid, 10 ʅM iron, and the variable concentrations of MgO2. 
FerroZine assay 
The labile iron content of FeCl3 and the three different iron supplements was determined 
by performing the FerroZine assay.  Different concentrations of iron samples (0-20 µM) 
were made using deoxygenated water as solvent.  The iron samples were incubated at 37°C 
for a few minutes. Reagent (consisting of ascorbic acid (0.1 mM), FerroZine (1 mM) and 
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KH2PO4/KOH buffer) was made and also incubated for a few minutes at 37°C.  Next, 100 µL 
of iron samples was added to reagent. In the presence of ascorbic acid, Fe3+ was reduced 
into Fe2+.  When Fe2+ was bound to ferozine, a colored complex was formed. The formation 
of this complex could spectrophotometrically be followed by measuring the absorbance at 
562 nm and 37°C for 1 hour. Concentrations of the formed complexes were calculated 
using Lambert-Beer’s law, using the molar absorbance coefficient of the purple complex 
(=27.9 mM-1cm-1). 
Ferrous thiocyanate assay 
Ferrous thiocyanate assay was performed to determine H2O2 levels formed after solving 
MgO2 in the buffer. MgO2 was used in the same concentrations as in the deoxyribose. 
MgO2 stock solution was dissolved and further diluted in 20 mM potassium phosphate 
buffer (pH 3.8).  A calibration curve of H2O2 (final concentrations ranged from 0 to 100 ʅM) 
was prepared using Milli-Q as solvent. HCl (350 mM), KSCN (200 mM) and ferrous 
ammonium sulphate (100 mM) were prepared in cuvettes (1 mL) containing the sample. In 
a final volume of 1 ml, the cuvettes contain: variable concentrations of H2O2, 350 mM HCl, 
200 mM KSCN and 100 mM ferrous ammonium sulphate. After 10 minutes at room 
temperature, the absorbance was measured at a wavelength of 483 nm and the 
concentration of H2O2 was calculated using the calibration curve. 
Electron spin resonance spectroscopy 
Electron spin resonance (ESR) spectroscopy was performed to determine hydroxyl radical 
formation after incubating MgO2 with FeCl3 and ascorbic acid. A sample containing 10 ʅM 
FeCl3, 100 ʅM ascorbic acid and 0.89 mM MgO2 was prepared. Added to this sample was 
5,5-dimethyl-1-pyrroline N-oxide (DMPO), serving as a spin-trap agent. After adding all the 
compounds, a 100 µl glass capillary was filled with the solution and sealed. ESR signals were 
then recorded at room temperature by X-band ESR on a Bruker EMX 1273 (Bruker BioSpin, 
Wormer, the Netherlands).  
Statistical analysis 
All results were shown as mean ± SEM (n=3-6). Data were analysed compared to FeCl3 
using an unpaired t-test (95% confidence interval). Results were considered statistically 
significant when P < 0.05.  
  
  Iron supplements and magnesium peroxide  
93 
Results 
Radical formation by the different iron supplements  
The ability of iron supplements to generate hydroxyl radicals was determined using the 
deoxyribose assay. Hydroxyl radical formation was measured after incubation with various 
concentrations of iron supplements (iron lactate, iron sulfate and iron gluconate) and FeCl3 
(figure 1A).  
 
Figure 1| Hydroxyl radical formation generated by iron supplements and FeCl3 at various 
concentrations (A). Hydroxyl radical formation generated by iron supplements and FeCl3 at 1 ʅM (B). 
Data are shown as mean ± SEM (n=3) and considered statistically significant compared to FeCl3. 
*P<0.05 
FeCl3, which was used as a positive control, promoted hydroxyl radical formation. All three 
supplements also induced the formation of hydroxyl radicals, but remarkably to a different 
extent. The iron gluconate supplement induced the most hydroxyl radicals (up to 3.4 ʅM), 
while iron sulfate and iron lactate induced a comparable amount of hydroxyl radicals as 
FeCl3 (figure 1A). The hydroxyl radical formation of the different iron supplements at a 
concentration of 1 µM is shown in figure 1B. At this concentration, all supplements 
significantly generated more hydroxyl radicals than FeCl3. 
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Table 1| The formation of hydroxyl radicals by FeCl3 (10 µM), either combined with MgO2 (1.78 mM) 
or MgOH (1.78 mM). Data are shown as mean ± SEM (n=6) and considered statistically when p<0.05. 
***P<0.005 
 Hydroxyl radical formation (µM) 
FeCl3 1.88 ± 0.39 
FeCl3 + MgO2 4.46 ± 0.67*** 
FeCl3 + MgOH 1.80 ±  0.19 
 
Labile iron content of the different iron supplements  
In order to determine the labile iron content of the different supplements, the FerroZine 
assay was performed with various concentrations of the iron supplements (0-1-2-5-10-20 
µM).The iron gluconate supplement had the highest amount of labile iron of all iron 
supplements (4.15 ʅM), whereas the iron lactate supplement had the lowest amount of 
labile iron (0.94 ʅM).Iron sulfate had an intermediate amount of labile iron. The labile iron 
content of the iron lactate supplement and the iron sulfate supplement differ significantly 
from FeCl3 (p = 0.0022 and p = 0.0490) (figure 2).  
 
Figure 2| Labile iron content of FeCl3 and different iron supplements at a fixed concentration of 
10ʅM Fe2+. Data are shown as mean ± SEM (n=3) and considered statistically significant compared to 
FeCl3. *P<0.05 
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Hydrogen peroxide formation by MgO2 
Hydrogen peroxide formation formed by MgO2 was determined by performing a ferrous 
thiocyanate assay [15]. MgO2 induced the formation of H2O2 in a concentration-dependent 
way (figure 3). An initial concentration of MgO2 of 1.5 mM yielded approximately 200 µM of 
H2O2. The antacid function of MgO2,
 which is illustrated by the increase in pH of the acidic 
buffer, is furthermore shown in table 2. 
 
Figure 3| The formation of  H2O2 from MgO2, which was determined using the Ferrous thiocyanate 
assay. Data are shown as means ± SEM (n=3). 
Radical formation by iron supplements with MgO2  
The effects of FeCl3 and the iron supplements in combination with MgO2 on hydroxyl 
radical formation, determined with deoxyribose assay, are shown in figure 4A. 
All three supplements again induced radical formation without MgO2. Addition of MgO2 to 
iron (10 ʅM) increased the formation of hydroxyl radicals. When MgO2 was combined with 
an iron supplement, this promoted hydroxyl radical formation. The combination of MgO2 
with the supplements (Iron lactate 7.4 ʅM, iron sulfate 8.8 ʅM, iron gluconate 13.2 ʅM) 
was higher than that with MgO2 with FeCl3 (4.5 ʅM) (figure 4A). Addition of MgOH, an 
antacid comparable to MgO2, to FeCl3 did not increase hydroxyl radical formation (table 1). 
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Figure 4| Hydroxyl radical formation by different concentrations MgO2 in combination with a fixed 
concentration of FeCl3 or iron supplements (10 ʅM) (A). ESR spectrum of DMPO-OH• adduct. ESR 
spectroscopy in combination with the use of the spin trapping agent DMPO was used to detect a 
triplet signal that is characteristic for the DMPO-OH radical adduct in the incubation system 
containing Fe and MgO2 (B). Data shown are means ± SEM (n=6). 
Hydroxyl radical formation by MgO2 and Fe 
To corroborate that OH• was formed, ESR spectroscopy was used. With the use of the spin 
trapping agent DMPO, a triplet signal was obtained that is characteristic for the DMPO-OH 
radical adduct in the incubation system containing Fe and MgO2 (figure 4B). When MgO2 
was replaced by MgOH, no radical spectrum was detected (data not shown). 
 
Table 2| The antacid function of magnesium peroxide and magnesium hydroxide which is shown by 
the effect of both compounds on the pH of an acidic buffer. 
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Discussion 
The present study further examines the potential hazard of the use of self-medication, i.e. 
food supplements and OTC’s, and highlights that especially combination increased the risks. 
This was exemplified by the combination of iron supplements and magnesium peroxide.  
The rational for choosing the combination of iron supplements and magnesium peroxide, 
apart from the possible interaction, was the frequent use of these products in elderly, a 
frail group of people vulnerable to the side effects. Elderly often suffer from iron 
insufficiency, which often leads to iron deficiency anaemia. In order to maintain iron levels, 
iron supplements are often used. Numerous iron supplements are present, each containing 
relatively high dose of iron. Only a small part of the iron is absorbed in the intestine and no 
active excretion mechanism exists.  Therefore, elderly people have a relatively high risk of 
iron overload when taking iron supplements, which might lead to accumulation of iron in 
the intestines. This may lead to side effects, which include nausea, stomach ache, diarrhoea 
and obstipation. In these side effects, hydroxyl radicals play a key role [16]. Our results 
confirm that all three iron supplements indeed stimulate the generation of hydroxyl 
radicals. The supplements that were used in the present study all contained Fe2+. However, 
both Fe3+ and Fe2+ containing iron supplements exist. Supplements containing Fe3+ are also 
expected to induce radical formation, since Fe3+ has to be reduced to Fe2+ in  order  to  be 
absorbed. Additionally, we also included FeCl3 in our experiments, which contains Fe
3+, and 
FeCl3 also showed a pronounced effect on radical formation. 
Iron promotes hydroxyl radical formation, especially in the presence of hydrogen peroxide. 
High levels of free radical production will cause oxidative damage of the intestines [6, 8]. 
Our results are in line with a previous study, that shows that iron supplements increase 
inflammation, which  is linked to exacerbations in inflammatory bowel disease [17]. 
Hydroxyl radical formation showed an inverse correlation with the labile iron content of 
each supplement. This indicates that complexation increases the ability of iron to generate 
hydroxyl radicals. 
Symptomatic gastroesophageal reflux is also a common complaint, associated to the use of 
iron supplements. Moreover, the incidence of heartburn is also high among  elderly people 
[18]. Therefore, the combination of iron supplements with an antacid is of clinical 
relevance. The antacid magnesium peroxide is available as OTC. People are advised to take 
380 mg of magnesium peroxide four times per day. This comes down to a dose of 1.52 
grams per day. The primary activity of magnesium peroxide is to neutralize gastric acid by 
increasing the pH. Since the intake of magnesium peroxide may reduce the absorption of 
iron, it is advised not to combine magnesium peroxide and iron supplements. However, 
information on the toxic effects of the combination is lacking.  
Our results confirmed the antacid activity of both magnesium peroxide and magnesium 
hydroxide (table 2). A major side effect of magnesium peroxide is irritation of the 
intestines, leading to diarrhoea [11]. From a chemical point of view, a synergistic toxic 
effect of the combination of MgO2 with iron supplements is plausible. This synergistic 
toxicity of the combination is based on the promotion of Fe-mediated free radical 
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formation by MgO2. The following reactions are likely to occur in the presence of 
magnesium peroxide and iron: 
ܯܱ݃ଶ + 2ܪଶܱ ՜ Mg2+ + 2OH- + H2O2 (3) 
ܨ݁ଶା + ܪଶܱଶ ՜ ܨ݁ଷା + ܱܪି + ܪܱ• (4) 
In examining whether these reactions indeed occur, a step-by-step approach was used. As a 
first step, it was examined whether magnesium peroxide generates hydrogen peroxide 
(equation 3). Our results confirm that magnesium peroxide indeed gives the formation of 
hydrogen peroxide. The more magnesium peroxide, the more hydrogen peroxide is 
formed. Hence, after intake of magnesium peroxide, hydrogen peroxide will be formed 
(equation 3). As second step it was tested whether the combination of magnesium 
peroxide and the different iron supplements formed hydroxyl radicals (equation 4). The 
iron supplements (at a concentration of 10 µM), on their own induce the formation of 
hydroxyl radicals (figure 1). Probably, ferrous iron reacts with dioxygen to form hydroxyl 
radicals [19]. Magnesium peroxide increased the hydroxyl radical production by the iron 
supplements. This is explained by the reaction between the generated hydrogen peroxide 
with ferrous iron leading to hydroxyl radical formation (equation 4). In contrast to 
magnesium peroxide, magnesium hydroxide did not induce the formation of hydroxyl 
radicals in combination with iron (table 1). As a last step it was confirmed that indeed 
hydroxyl radicals were generated using, ESR. Our results show that the combination of iron 
supplements and magnesium peroxide gives an ESR spectrum specific for the hydroxyl 
radical, as shown in figure 4. Replacing MgO2 by magnesium hydroxide did not induce the 
formation of hydroxyl radicals. The step-by-step approach demonstrates that the 
combination of magnesium peroxide and iron supplements leads to the formation of 
hydroxyl radicals that are capable of damaging cells, proteins, enzymes and inducing 
gastrointestinal side effects. 
In conclusion, our results provide the fundament for the interaction between magnesium 
peroxide and iron supplements. Iron induced intestinal damage caused by the highly 
reactive hydroxyl radical, which is enhanced by magnesium peroxide. This is an example of 
an interaction between a food supplement and an OTC. This indicates that especially 
combining products used in self-medication can be hazardous. Elderly are a group at risk 
since they are relatively frail and often combine self-medication [20]. 
A parallel can be drawn with prescription drugs. Much attention is given to the side effect 
of a drug used in isolation. In practice, however, the hazard mostly arises from the 
combination of drugs because side effects accumulate, especially in groups at risk such as 
elderly [21]. The present study highlights that also for food supplements and OTC’s more 
attention should be given to combinations the interactions between food supplements and 
OTCs, which can have hazardous effects.  
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Abstract 
Vitamin B6 is a water-soluble vitamin that functions as a coenzyme in many reactions 
involved in amino acid, carbohydrates and lipid metabolism. Since 2014, more than 50 
cases of sensory neuronal pain due to vitamin B6 supplementation were reported to Lareb. 
Up to now, the mechanism of this toxicity is enigmatic and the contribution of the various 
B6 vitamers to this toxicity is largely unknown. In the present study, the neurotoxicity of the 
different forms of vitamin B6 is tested on SHSY5Y and CaCo-2 cells. Cells were exposed to 
pyridoxine, pyridoxamine, pyridoxal , pyridoxal-5’-phosphate or pyridoxamine-5’-phosphate 
for 24 h, after which cell viability was measured using the MTT assay. The gene expression 
of Bax and caspase-8 was also measured after the 24 hours exposure. The effect of the 
vitamers on two pyridoxal-5-phosphate dependent enzymes was also tested. Pyridoxine 
induced cell death in a concentration-dependent way in SHSY5Y cells. The other vitamers 
did not affect cell viability.  Pyridoxine furthermore significantly increased the expression of 
Bax and caspase-8. Moreover, both pyridoxal-5-phosphate dependent enzymes were 
inhibited by pyridoxine. In conclusion, the present study indicates that the neuropathy 
observed after taking a relatively high dose of vitamin B6 supplements is due to pyridoxine. 
The inactive form pyridoxine competitively inhibits the active pyridoxal-5’-phosphate. 
Consequently, symptoms of vitamin B6 supplementation are similar to those of vitamin B6 
deficiency. 
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Introduction 
Vitamin B6 is a water-soluble vitamin found in e.g. meat, poultry, fish, legumes, bananas, 
nuts and cereals [1]. Vitamin B6 functions as a coenzyme in many reactions that are 
involved in amino acid, carbohydrates and lipid metabolism [2]. Additionally, vitamin B6 also 
plays a role in neuronal signaling through the synthesis of neurotransmitters [3]. The major 
forms of vitamin B6 are: pyridoxine (PN), pyridoxal (PL), pyridoxamine (PM) and their 
phosphorylated derivatives pyridoxine 5’-phosphate (PNP), pyridoxal-5’-phosphate (PLP) 
and pyridoxamine-5’-phosphate (PMP) [1]. 
Vitamin B6 is mainly present in our diet as PN, PL and PM. After passive absorption in the 
intestine, the major part of the vitamin is converted in the liver to PLP [4,5]. After hydrolysis 
to PL by alkaline phosphatases, it becomes available for every cell in our body. Within the 
cells, PL is phosphorylated by pyridoxal kinase to PLP [6]. Most of the PL in excess of tissue 
requirements is oxidized by the liver to 4-pyridoxic acid (4-PA), which is the major 
degradation product of vitamin B6 in the urine. The metabolic routes of vitamin B6 are 
shown in figure 1. 
Vitamin B6 deficiency may arise from a too low intake, malabsorption, or due to drugs that 
inhibit enzymes involved in PLP metabolism. Low levels of vitamin B6 are found in elderly, 
individuals with traumatic femoral fractures, and in alcoholics [7]. Deficiency has been 
related to increased risk of cardiovascular diseases and neuronal symptoms [8]. In these 
cases, vitamin B6 supplements are advised [9-11]. In the US, about 28%–36% of the general 
population uses supplements containing vitamin B6 [12,13] . These supplements are most 
often taken by children up to 6 years and by adults over 51 years of age. Most vitamin B6 
supplements contain PN ranging from 25 – 100 mg/tablet. 
Recently, the European Food Safety Authority (EFSA) has established an upper limit (UL) of 
25 mg/day. This UL was based on neurological complaints observed after taking 50 mg of 
PN per day. This is 4 times lower than the previous UL of 100 mg/day of USDA and other 
authorities. However, since vitamin B6 is considered to be relatively safe, doses of over 
2000-fold the recommended dietary allowance of 1.4–2.1 mg/day (depending on sex and 
age) are used in some circumstances [14].  
Already in 1987, a case of sensory neuropathy induced by a high dose of vitamin B6 has 
been reported [15]. In the years that followed, more cases on vitamin B6 toxicity were 
found. Recently, The Netherlands Pharmacovigilance Centre Lareb, which collects and 
analyses reports of adverse reactions of medicines and vaccines, published a report 
concerning the side effects of vitamin B6 supplements. Since 2014, more than 50 cases of 
sensory neuronal pain due to vitamin B6 were reported to Lareb [16]. The dose of vitamin 
B6 differed from 1.5 - 100 mg. In these cases, high plasma levels of PLP between 183 nmol/l 
and 4338 nmol/l were found. Plasma levels of PN were not determined. Up to now, the 
mechanism of this toxicity is enigmatic and the contribution of the various B6 vitamers to 
this toxicity is largely unknown. Our hypothesis is that PN is the vitamer mainly responsible 
for the vitamin B6 induced toxicity. PN, which is not the active form, is ultimately converted 
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into PLP, which is the active form. High levels of PN are thought to inhibit PLP-dependent 
enzymes by competing with the bioactive vitamer, PLP. 
 
Figure 1| Vitamin B6 metabolism. 
In the present study, the neurotoxicity of the different forms of vitamin B6 is tested on 
neuroblastoma cells (SHSY5Y). In line with our hypothesis, PN showed the highest toxicity. 
The paradox that the vitamin B6 PN vitamer in high concentrations inhibits vitamin B6 
dependent processes was confirmed using vitamin B6 dependent enzymes tyrosine 
decarboxylase and alanine transaminase.  
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Materials and Methods 
Chemicals 
L-alanine, ɲ-ketoglutarate, alanine transaminase, lactate dehydrogenase (LDH),NADH,  PN, 
PL, PM dihydrochloride, PLP hydrate, PMP, Toluene, tyrosine decarboxylase apoenzyme 
(1.1 U/mg) from Streptococcus faecalis, L-tyrosine and picrylsulfonic acid were all obtained 
from Sigma (St. Louis, USA).  
Tyrosine decarboxylase enzyme activity 
Tyrosine decarboxylase activity was measured according to the tyrosine decarboxylase 
enzyme activity assay. In this assay, tyrosine is converted into tyramine by the enzyme 
tyrosine decarboxylase and the co-enzyme PLP. At first, tyrosine (0-100 µM) was added to a 
tube containing tyrosine decarboxylase (1.1 U/mL) with PLP and acetate buffer (pH 5.5). 
This mixture was incubated for 10 minutes at 37 °C. Then, 1 mL of K2CO3 (1 M) was added 
to the tube, which was followed by the addition of 1 mL of TNBS (10 mM). Finally, 2 mL of 
toluene was added, after which the tube was vortexed for 20 s. After centrifugation for 5 
min at 2000 RPM, the enzyme activity was determined by measuring the absorbance at 340 
nm using a spectrophotometer.  In order to determine the effect of the different forms of 
vitamin B6, the enzyme was first incubated together with the vitamer of vitamin B6 (at 5 
µM) for 2 min. Then, the same protocol was followed as described above. 
Alanine transaminase activity 
Alanine transaminase activity was measured according to the alanine transaminase activity 
assay. In short, alanine transaminase catalyzes the transfer of an aminogroup from alanine 
to ɲ-ketoglutarate using PLP as a coenzyme. Glutamate and pyruvate are the products that 
are formed in this reaction. The formation of pyruvate is then spectrophotometrically 
followed during its conversion to lactate by LDH in the presence of NADH. In this reaction, 
NAD is formed which is monitored at 340 nm. After adding alanine transaminase (1 U/ml)  
to the reaction tube containing alanine (0.5 mM), ɲ-ketoglutarate (15 mM), LDH (1.25 
U/ml), NADH (0.18 mM) and Tris buffer (100 mM; pH 7.5), the reaction was started and 
followed during 5 minutes. The effect of PN on this enzymatic reaction was tested by 
following the same protocol as described above including the addition of 5 µM PN in the 
reaction tube. 
Cell culture  
Human neuroblastoma (SHSY5Y) cells were cultured in 75രcm3 cell culture flasks (Corning® 
Flask, Corning Incorporate, NY, USA) in DMEM:F122 (Invitrogen), supplemented with 10% 
Fetal Bovine Serum (FBS; Invitrogen), 1% l-glutamine and 1% penicillin streptomycin (P/S; 
Invitrogen) at 37°C in a 5% CO2 and 20% O2 atmosphere.  Media was renewed twice weekly 
and cultures were split when 90% confluence was reached. Cells were differentiated by 
exposing them to 3% medium containing 10 µM retinoic acid for 5 days.  After 
differentiation, cells were seeded 1 day prior to treatment and maintained at 37 °C in a 5% 
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CO2 atmosphere. CaCo-2 cells were cultured in 75രcm3 cell culture under standard 
conditions. Dulbecco's modified Eagle medium (DMEM) with the addition of 10% FBS, 1% of 
non-essential amino acids, 1% Na-pyruvate and 1% of penicillin–streptomycin. 
Cell treatment 
For the cell viability assays, both differentiated SHSY5Y and CaCo-2 cells were seeded in 96-
wells plates at a density of 25.000 cells/well. After one day, cells were exposed to PN (0 - 5 
µM), PM (0 – 500 µM), PL (0 – 500 µM), PLP (0 – 500 µM) or PMP (0 – 500 µM) for 24 h in 
normal culture medium. In order to determine if PLP could prevent PN-induced toxicity, all 
cells were exposed to 1 µM of PN and an increasing concentration of PLP (0-100 uM). 
Untreated cells were used as controls in all experiments. For gene expression experiments, 
both SHSY5Y and CaCo-2 cells were seeded in 6-wells plate at a density of 500.000 
cells/well After 24 h, cells were exposed to PN (0 - 1 µM), PM (0 – 50 µM), PL (0 – 50 µM), 
PLP (0 – 50 µM) or PMP (0 – 50 µM) for 24 hours, after which RNA was isolated. 
MTT assay 
After the 24 h incubation, medium was removed and cells were washed with PBS. Then, 
200 µl of MTT solution (0.5 mg/ml) was added and cells were incubated for 1 h at 37 මC. 
After this incubation, the wells were washed with PBS, after which the formazan crystals 
were dissolved in 200 µl DMSO. Cells were incubated for 30 min after which the 
absorbance at 540 nm was measured spectrophotometrically using a microplate reader. 
Relative cell viability is expressed as a percentage relative to untreated cells. 
RNA isolation 
After removing the medium, 500 µl of Qiazol was added to each well. After incubation of 5 
minutes at room temperature, the suspension was transferred into an Eppendorf tube. 
Next, 100 µl of chloroform was added in the tube. The tube was vigorously shaken for 15 
seconds. Then, samples were centrifuged for 10 min at 12,000 RPM (4 °C). From this point, 
samples were held on ice. The aqueous phase was transferred to a new tube without 
disturbing the interphase. To this phase, 250 µl of isopropanol was added and the samples 
were incubated for 10 minutes at room temperature. Next, samples were centrifuged for 
10 minutes at 12,000 RPM at 4 °C, after which the supernatant was poured out.  Pellets 
were washed twice by adding 500 µl of 70% ethanol, mixing the samples and centrifuging 
them for 3 minutes at 12,000 RPM at 4 °C, respectively. After pouring of the supernatant, 
pellets were washed one last time with 500 µl of 100% ethanol. Samples were centrifuged 
for 5 minutes and supernatant was poured out. After air drying the pellets, RNA was 
dissolved in 30 µl RNase free water by passing through pipette tip several times. The quality 
and quantity of RNA was determined using the nanodrop (Thermo Scientific Nanodrop 
1000 spectrophotometer, Isogen Life Science, De Meern, The Netherlands). 
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PCR  
One microgram of RNA was converted into complementary DNA (cDNA) by using iScript 
cDNA synthesis kit (Biorad, Veenendaal, The Netherlands). Sensimix SYBR & Fluorescein kit 
(Bioline, Alphen aan de Rijn, The Netherlands) was used to perform quantitative RT-PCR 
measuring BAX (FW: 5഻-GAGAGGTCTTTTTCCGAGTGG-3’and RV: 5഻-
CCTTGAGCACCAGTTTGCTG-3഻) and caspase-8 (FW: 5഻-CATCCAGTCACTTTGCCAGA-3’ and RV: 
ϱ഻-GCATCTGTTTCCCCATGTTT-3഻).  GAPDH (FW: 5഻-CGCTCTCTGCTCCTCCTGTT-3഻ and RV: 5഻-
CCATGGTGTCTGAGCGATGT-3഻) was applied as housekeeping gene. Finally, the 2оȴȴCT 
method was used to determine relative gene expression. 
 
Statistical analysis 
All results were shown as mean ± SEM. Data were analysed compared to (untreated) 
controls using an unpaired t-test. Results were considered statistically significant when P < 
0.05, in which *P< 0.05, **P < 0.01, ***P<0.001.  
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Results 
 
Figure 2| Cell death of SHSY5Y cells in the presence of the 5 different vitamin B6 vitamers at a 
concentration of 5 µM was measured with the MTT assay. Cells were exposed to these vitamers for 
24 hours. Untreated cells were used as controls and results obtained with the vitamin B6 vitamers 
were compared to controls (which was set at 0%). The effect of PN was also determined in a 
concentration-dependent manner (0-5 µM), which is shown in figure 1 insert. Data are shown as 
means ± SEM (n=4). Differences were considered to be statistically significant when P <0.05. **P < 
0.01; ***P<0.001. 
Cell viability after exposure to the vitamin B6 vitamers 
MTT assays were performed to measure vitamin B6-induced cytotoxicity in SHSY5Y cells 
after 24 h incubation.  Of the vitamers, PN induced a significant amount of cell death at 5 
µM (fig. 2). At this concentration, the other vitamers (PM, PL and their phosphorylated 
forms) did not increase cell death.  PN was found to significantly increase cell death also in 
lower concentrations (fig 2. insert). Already at a concentration of 200 nM, cell death 
increased to 17%. After doubling the concentration to 400 nM, cell death increased to 30%.  
Only at very high concentrations (up to 500 µM), PLP tended to induce cell death (data not 
shown) although this did not reach statistical significance. In CaCo-2-cells, PN in various 
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concentrations did not affect the cell viability after 24 h (supplementary data figure 1). 
 
Figure 3|  Gene expression data of two apoptosis genes (BAX and Caspase-8) after exposure of 
SHSY5Y cells to the 5 different vitamin B6 vitamers. The effect of PN (0 – 1 µM) on the expression of 
BAX and caspase-8 is shown in panels (A) and (B). The effects of the other vitamers at a concentration 
of 10 µM are shown in panels (C) and (D).  Untreated cells were used as controls and results obtained 
with the vitamin B6 vitamers were compared to controls (which was set at 1). Data are shown as 
means ± SEM (n=3). Differences were considered to be statistically significant when P <0.05. *P < 
0.05. 
Expression of apoptosis genes after exposure to different vitamers of vitamin B6 
Gene expression levels of two apoptosis genes (BAX and Caspase-8) were measured in 
SHSY5Y and CaCo-2 cells after incubation with the different vitamers. Untreated cells were 
used as control condition, which was set to 1.  In SHSY5Y cells, PN increased the gene 
expression levels of BAX and caspase-8 in a concentration-dependent way (fig. 3A and B). 
At a concentration of 1 µM, the increase in expression of BAX and caspase-8 was 
significant. The expression of the two genes was not changed by PL, PM, PLP and PMP at a 
concentration  of  10  µM  (fig.  3C  and  D).  Even  at  50  µM  of  PL,  PM,  PLP  and  PMP,  the  
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expression of the apoptosis genes remained unchanged (supplementary data figure 2).
 
Figure 4| Gene expression data of two apoptosis genes (BAX and Caspase-8) after exposure of CaCo-
2 cells to the 5 different vitamin B6 vitamers. The effect of PN (0 – 1 µM) on the expression of BAX 
and caspase-8 is shown in panels (A) and (B). The effects of the other vitamers at a concentration of 
10 µM are shown in panels (C) and (D).  Untreated cells were used as controls and results obtained 
with the vitamin B6 vitamers were compared to controls (which was set at 1). Data are shown as 
means ± SEM (n=3). 
In contrast to SHSY5Y cells, PN did not change the expression of BAX and caspase-8 in CaCo-
2 cells (fig. 4). In these cells, the different vitamers of vitamin B6 (at 10 µM) did not change 
the expression of BAX and caspase-8. Even at 50 µM, the expression of these genes was not 
changed (supplementary data figure 3).  
Protection against PN toxicity by PLP 
In order to determine whether PN toxicity might be caused by competing with the bioactive 
vitamer PLP, SHSY5Y cells were exposed to both PN and PLP for 24 hours and cell viability 
was measured using the MTT assay. PN (1 µM) significantly increased cell death (fig. 5). PLP 
already at a concentration of 0.3 µM protected against cell death induced by 1 µM PN, 
indicating that cell death is dependent on competition of PN with PLP. 
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Figure 5| Cell viability of SHSY5Y cells was measured by using the MTT assay. Cells were exposed to 
these 1 µ of PN in the presence of increasing concentrations of PLP (0-100 µM) for 24 hours. 
Untreated cells were used as controls and results obtained were compared to controls (which was set 
at 0%). Data are shown as means ± SEM (n=4). Differences were considered to be statistically 
significant when P <0.05. *P < 0.05; ***P<0.001. 
PLP-dependent enzyme activities 
The effect of the different vitamers (at 5 µM) on the enzyme activity of tyrosine 
decarboxylase was determined (fig. 6A). At a tyrosine concentration of 10 µM, PMP did not 
show any effect on the enzyme activity. PM only slightly decreased the enzyme activity, 
while PL and PLP even tended to increase the enzyme activity. Interestingly, PN decreased 
the enzyme activity with approximately 65%. A tenfold Increase in the substrate 
concentration of tyrosine reduced the inhibitory effect of PN, suggesting that the inhibition 
by PN is competitive. Besides tyrosine decarboxylase, PN (at 5 µM) also inhibited the 
activity of alanine transaminase by 40% (fig. 6B). 
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Figure 6| The effect of the different vitamin B6 vitamers (5 µM) on the PLP-dependent enzyme 
tyrosine decarboxylase using two different substrate concentrations (10 µM (white bars) and 100 µM 
(red bars)) is shown in (A). The effect of PN (5 µM) at a second PLP-dependent enzyme (alanine 
aminotransferase) is shown in (B). Data are shown as means ± SEM (n=3). Differences were 
considered to be statistically significant when P <0.05. *P < 0.05; **P<0.01. 
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Discussion 
In the last decades, various cases of vitamin B6 induced polyneuropathy have been 
reported [15,17,18]. People chronically taking vitamin B6 supplements reported complaints 
such as pain in the extremities and muscle weakness. These complaints were reversible as 
they faded away after stopping the supplementation. Most often, these complaints were 
seen when taking mega doses (>50 mg/day) of vitamin B6 for a longer period of time. 
However, recently, Lareb reported cases in which lower doses (2mg/day) of vitamin B6 
gave the same complaints [16]. Up to now, the mechanism of vitamin B6 induced 
polyneuropathy is still unknown, making it difficult to give well substantiated advices.   
Six  different  vitamers  of  vitamin  B6 exist, namely PN, PL, PM and their phosphorylated 
derivatives PNP, PLP and PMP. PLP is the biological active form of vitamin B6, being a well-
known coenzyme in a wide variety of enzymatic reactions. Of the vitamers, PN is most 
commonly taken as a food supplement. Since vitamin B6 is considered to be safe, 
supplements with high doses of PN are on the market. Once taken up, PN is converted into 
PLP in several steps, of which phosphorylation by pyridoxal kinase to PLP is the most critical 
one. All the supplements that caused adverse effects contained PN.  Therefore, the focus 
was on PN. We hypothesized that PN is the vitamer responsible for the neurotoxic effects, 
by competing with the active form PLP. 
Our study indeed showed that PN significantly increases cell death in the neuronal cell line 
SHSY5Y after a 24 hours exposure. The concentrations were selected based on plasma 
levels that were found in several studies [19-21].  In contrast, the other vitamers did not 
affect cell viability. Additionally, PLP was able to prevent PN induced cell death, indicating 
that PN toxicity is caused by competition with PLP, which is in line with our hypothesis. The 
toxic effects of PN furthermore seem to be neuronal specific, since PN did not induce cell 
death in the intestinal cell line CaCo-2. Neuronal cell death may result in polyneuropathy, 
as seen in diabetics, explaining the neuropathy observed in vitamin B6 toxicity [22].  
Remarkably, sensory neuropathy is seen in vitamin B6 toxicity as well as vitamin B6 
deficiency. In the present study, the effect of the inactive PN on the active PLP was tested 
with two enzymes involving PLP as a coenzyme, namely tyrosine decarboxylase and alanine 
aminotransferase. Tyrosine decarboxylase catalyzes the decarboxylation of tyrosine to 
produce tyramine. Alanine aminotransferase catalyzes the transfer of the amino group of L-
alanine to ɲ-ketoglutarate. The activity of both enzymes was shown to be competitively 
inhibited by PN. The other vitamers either increased the enzyme activities or did not affect 
the enzyme activities.  It was concluded that PN indeed competes with the active PLP 
resulting in the inhibition of vitamin B6 dependent enzymes.  In vitamin B6 deficiency, 
enzymes depending on PLP (the bioactive vitamer) as a cofactor will be (partially) inhibited. 
Vitamin B6 supplementation mostly concerns PN, which is converted by pyridoxal kinase 
and pyridoxine phosphate oxidase into PLP. At high doses, PN saturates these enzymes. As 
a consequence, the inactive vitamer PN accumulates. Indeed, high levels of PN (up to 18 
µM) have been found in the cerebrospinal fluid (CSF) and (up to 200 nM) in plasma of two 
persons taking PN supplements [19-21]. 200 nM of PN already induced cell death in our 
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study, furthermore underlining the relevance of our findings. At such high concentration, 
PN effectively competes with PLP resulting in the inhibition of PLP dependent enzymes. 
Hence, this explains that these effects will be paradoxically similar to that of a deficiency in 
vitamin B6.  
One of the pathways in which PLP is essential is the kynurenine pathway [1,23,24]. In this 
pathway, the amino acid tryptophan is metabolized to nicotinamide. Intermediate products 
formed are quinolinic acid, kynurenine, 3-hydroxykynurenine (3-HK) and 3-
hydroxyanthranilic acid (3-HAA) [1]. 3-HK is converted into xanthurenic acid and 3-HAA by 
two PLP-dependent enzymes. The kynurenine pathway has been linked to several central 
nervous system diseases, such as Huntington’s disease and Alzheimer’s disease [26,27]. 
Significantly increased 3-HK levels were found in brain tissues of Huntington’s disease 
patients [25].  
 It has previously been shown that exposure of SHSY5Y cells to relatively high levels of 3-HK 
increased cell death [28]. Addition of 3-HK to striatal neuronal cell cultures caused 
increased cell death via apoptosis [29]. In this process, hydrogen peroxide and hydroxyl 
radical formation play an important role, since the antioxidant enzyme catalase reduced 3-
HK induced cell death. In the present study, the expression of Bax and caspase-8 was used 
to monitor apoptosis in the neuronal cell line. Of the vitamers, only PN increased the 
expression of Bax and caspase-8. This suggests that accumulation of 3-HK, caused by 
inhibition of the PLP dependent metabolism of 3-HK by PN, may play a role in the 
polyneuropathy observed during vitamin B6 toxicity. 
In conclusion, the present study strongly indicates that the neuropathy observed after 
taking a relatively high dose of vitamin B6 supplements is due to the vitamer that is used in 
the supplements, namely PN. The inactive form PN competitively inhibits the active PLP. As 
a consequence, the paradox arises that the symptoms of vitamin B6 supplementation are 
similar to those of vitamin B6 deficiency. Vitamin B6 supplements are used by a large 
number of people. The safety of vitamin B6 is debated and recently EFSA has lowered the 
upper limit for vitamin B6. The question is whether lowering the safe dose for vitamin B6 is 
the solution. Remarkably, even at relatively low dose, vitamin B6 supplementation has given 
rise to complaints. Our study indicates that the toxicity of vitamin B6 is not only determined 
by the dose, but by the vitamer in which it is taken. Perhaps it might be better to replace 
PN by PL or PLP as vitamin B6 supplements, which are much less toxic. In this way, the 
vitamin B6 paradox may potentially be prevented. 
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Supplementary data 
 
Figure 1| Cell viability assay in CaCo-2 cells after exposure to different concentrations of PN 
(0-5 µM). 
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Figure 2| The effect of PL, PM, PLP and PM (0-50 µM) on the expression of BAX and 
caspase-8 in SHSY5Y cells. 
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Figure 3|The effect of PL, PM, PLP and PM (0-50 µM) on the expression of BAX and 
caspase-8 in CaCo-2 cells. 
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The average age of the world population is rapidly increasing [1]. One of the consequences 
is an increased need for medical and social health care. The prevalence of diseases in 
elderly is much higher compared to the young population. Additionally, the prevalence of 
malnutrition is high among elderly [2]. Medicines and food products, such as food 
supplements, are frequently used by this population to stay healthy. 
The effect of nutrition in maintaining a good health is recognized and nutrition is also more 
and more used to improve health and treat diseases. Bioactive compounds derived from 
food are being developed to promote health status. These so called nutraceuticals also 
comprise food supplements. The use of food supplements has exploded over the past years 
[3]. Thousands of food supplements are on the market, which all claim to improve health or 
battle diseases. People take food supplements with the idea that they only have benefits, 
while they are largely unaware of their potential risks. Although they can support health, 
food supplements may also induce harm. In conjunction with the increased use of food 
supplements, the number of adverse events, drug interactions and deaths involving these 
supplements has increased. In order to inform and protect consumers, an adequate 
benefit-risk assessment of the use of food supplements is mandatory. Since especially the 
risks are largely unknown, the aim of the present thesis was to investigate potential 
adverse effects of food supplements either combined with other food supplements or 
drugs, or alone in specific groups at risk. In this chapter the most important findings are 
summarized and discussed. Additionally, potential implications and suggestions for future 
research are discussed. 
Main findings 
Antioxidant supplements 
In chapter 2 the changing perception on the health effects of antioxidants is discussed. 
Antioxidants are vital for human beings, since they protect against reactive oxygen species 
(ROS) [4, 5]. In living organisms ROS can damage vital biomolecules such as proteins and 
this is known to play an important role in ageing and age-related diseases. Antioxidants are 
therefore considered as important agents in the protection against oxidative stress and 
ageing. Many food supplements are available that are rich in antioxidants. They are used on 
a large scale with the notion that antioxidants are healthy. Moreover, the use of all kinds of 
antioxidants in high doses has been recommended for supplementation. The perception 
was that all antioxidants are equal and that the higher the intake, the higher the beneficial 
health effects will be [6]. However, according to the theory of Paracelsus, in a high dose 
also antioxidants will be toxic, and indeed a too high intake of antioxidants has 
paradoxically been associated with increased mortality. The question arose if antioxidants 
in the end are healthy or toxic. This question was answered by focusing on two antioxidants 
with an opposite image, i.e. the ‘healthy’ vitamin E and the ‘toxic’ ɴ-carotene. Apparently, 
the appreciation of an antioxidant is a reflection of the prevailing perception of the risks 
and benefits that also changes over time. In 1994 the ATBC study showed that ɴ-carotene 
supplementation was associated with an increased incidence of lung cancer in smokers [7]. 
This was furthermore corroborated by other epidemiological studies. Since then, ɴ-
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carotene was considered as toxic, without paying any attention to its beneficial effect. In 
contrast to the toxic effects of ɴ-carotene, numerous beneficial health effects have been 
proposed for vitamin E, which are mainly ascribed to its antioxidant activity. Based on these 
beneficial effects, vitamin E received a ‘healthy’ image. However, despite these different 
images, both antioxidants were shown in chapter 2 to have a similar toxicity in cells 
exposed to benzo(a)pyrene diolepoxide (BPDE), by inhibiting the protective enzyme GST ʋ. 
An increased number of BPDE-DNA adducts in lung epithelial cells (BEAS-2B) and human 
keratinocytes (HaCaT) were found after treatment with both antioxidants. Based on these 
findings, it could be concluded that both vitamin E and ɴ-carotene could have toxic effects 
when combined with electrophilic compounds such as BPDE, which is for instance found in 
cigarette smoke or coal tar cream. In the perception of the health effect of an antioxidant, 
it is often considered that an antioxidant either only provides benefits or that it only poses 
risks. These opposing, one sided views are the main obstacles in the accurate perception of 
the health effect of antioxidants. A more balanced view is necessary as any bioactive, 
antioxidants included, have benefits as well as risks.  It is therefore important to come to an 
accurate benefit-risk analysis. Ideally, such benefit-risk analysis should be performed for 
each individual. However, since this is impossible to do, the focus should first be on specific 
population groups. Identifying groups that would benefit of a certain antioxidant should 
have the priority when performing a benefit-risk analysis. But also groups at risk should be 
identified. Risk groups are often found by chance, as demonstrated by the ATBC study. The 
mechanism of both the benefits and risks should be elucidated. Apparently, the line 
between healthy and toxic is very thin. It is concluded that supplementation of antioxidants 
does not necessarily have to be beneficial and a natural origin is no guaranty for safety.  
Adverse interactions between food supplements and drugs 
Ageing is a process in which structural and functional changes in organs and organ systems 
occur [8]. This often leads to multiple diseases. In order to treat these diseases, elderly 
people often use multiple drugs. Polypharmacy is very common in the elderly population 
[9]. Next to prescription medicines, the use of self-medication, such as OTC drugs, is also on 
the rise. The use of multiple drugs simultaneously increases the risk of adverse effects and 
unwanted interactions, which can aggravate side effects instead of improving the quality of 
life of the elderly. On top of the medicines, elderly people also take numerous food 
supplements to improve health. Generally, food supplements are perceived as being 
healthy and to support (general) health, while they may also induce harm. In conjunction 
with the increased use of food supplements, the number of adverse events, drug 
interactions and deaths involving food supplements has been on the rise.  Again, the elderly 
population is more vulnerable for adverse events associated with food supplement use. 
This is mainly due to the ageing-related changes, such as organ function decline and 
changes in pharmacokinetics and pharmacodynamics. A very common age-related change 
is the enlargement of the prostate gland, also known as benign prostatic hyperplasia (BPH). 
As men age, they are more likely to develop prostate problems, since it tends to grow 
larger as you age. Alpha-adrenergic receptor–blocking agents such as tamsulosin are used 
to treat BPH. By blocking these receptors, the smooth muscle tension is decreased, 
allowing passage of the urine. Although tamsulosin is administered to block ɲ1A-
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adrenoceptors in the prostate, it will also block ɲ1A- and ɲ1D-adrenoceptors in the 
vasculature. This may lead to unwanted side effects, such as orthostatic hypotension. 
Orthostatic hypotension is caused by a drastic fall in blood pressure due to gravitational 
displacement of blood when standing up. Normally, the sympathetic system is able to 
compensate for this effect by increasing the sympathetic outflow, heart rate, vascular 
resistance, constriction of the veins and cardiac output via activation of ɲ1A-adrenoceptors 
in the vasculature. Consequently, the blood will be redistributed and blood pressure will be 
normalized. Blocking the ɲ1-adrenoceptors in the arteries and veins will antagonize such a 
physiological vaso- and venoconstrictor reflex, which forms the molecular basis for 
orthostatic hypotension. In chapter 3, we have evaluated a pharmacodynamic interaction 
of a food supplement, quercetin, and the drug, tamsulosin on isolated mesenteric arteries. 
The combination of tamsulosin with quercetin or quercetin metabolites proved to be far 
more potent than the compounds in isolation. It was shown that the food supplement 
quercetin strongly potentiates the ɲ1-adrenoceptor antagonizing effects of the drug 
tamsulosin. The strong pharmacodynamic interaction between the food supplement 
quercetin and tamsulosin underlines the impact of supplement-drug interactions that 
warrant more research.   
Another main effect of ageing is the deterioration of the blood-brain-barrier [10]. 
Consequently, the permeability of this barrier increases, making it easier for drugs and food 
supplements to enter the brain.  Additionally, the number of cholinergic receptors 
decreases with ageing. Together, these changes make that anticholinergic accumulation is a 
common feature in elderly.  Anticholinergic effects of drugs arise by blocking cholinergic 
neurotransmission, more specifically blocking the muscarinic receptors in the brains. These 
receptors play an important role in numerous processes, including cognition and 
movement. In 2008 the Anticholinergic Cognitive Burden (ACB) scale was developed, in 
which drugs are categorized based on their anticholinergic effect [11]. In chapter 4 it is 
shown that the affinity of the drugs for the muscarinic receptors correlated well with their 
ACB scores. Food supplements also appeared to bind to these muscarinic receptors. The 
anticholinergic side effect of a single compound, drug or food supplement, is often 
relatively mild. However, when several compounds are taken simultaneously, more of the 
receptors will be blocked, which aggravates the impact. It was shown that the combination 
of several drugs and supplements had an affinity that is higher than the affinity of the 
individual compounds. This explains the process of anticholinergic accumulation. Since 
elderly are the largest group of consumers of medicines and polypharmacy is very common 
among this population, they are susceptible to these effects. Cognitive impairment, which 
is a consequence of anticholinergic accumulation, may be detrimental for elderly. Cognitive 
impairment include brain injuries, neurological disorders and mental diseases. Signs of 
cognitive impairment are associated with an increased mortality risk for elderly, indicating 
the relevance of these findings.  
Chapter 5 describes the hazardous interaction between iron supplements and magnesium 
peroxide. Ageing is accompanied by changes in the gastro-intestinal system, such as 
reduced absorption of nutrients and an increased risk for gastro-esophageal reflux disease. 
Because of the reduced absorption of nutrients, malnutrition is very common among 
  General discussion  
127 
elderly. Iron deficiency is the single most prevalent nutritional deficiency worldwide with 
elderly as a group with the highest prevalence. In order to maintain iron levels, iron 
supplements are often used. Numerous iron supplements are present, each containing 
relatively high doses of iron. The European Food and Safety Authority (EFSA) has not set an 
tolerable upper intake level (UL) for iron supplements because of insufficient data on 
adverse effects. However, already at doses of 30 mg/day, supplemental intake of iron was 
associated with high saturation of the iron storage, which is a risk factor for several chronic 
diseases. The highest dose of iron supplements found was 50 and 100 mg/day. In our study 
it was shown that iron supplements induced the formation of hydroxyl radicals. This was 
augmented by magnesium peroxide, an antacid that is available as OTC drugs. The 
increased formation of hydroxyl radicals might lead to adverse events in the intestines. This 
is an example of an interaction between a food supplement and an OTC, indicating that also 
the use of self-medication can lead to hazardous interactions. 
 
In Chapter 6 the neuropathy observed after taking a relatively high dose of vitamin B6 
supplements is examined. In the Netherlands, the Netherlands Pharmacovigilance Centre 
Lareb collects and analyses reports of adverse reactions of food supplements, medicines 
and vaccines. Lareb receives this information by health care professionals, patients and 
manufacturers which report any adverse effect of these products.  Recently, Lareb 
published a report concerning the side effects of vitamin B6 supplements. Since 2014, more 
than 50 cases of sensory neuronal pain were reported after taking vitamin B6 supplements.  
Vitamin B6 functions as a coenzyme in many reactions that are involved in amino acid, 
carbohydrates and lipid metabolism and neurotransmitter synthesis. Vitamin B6 
supplementation is commonly recommended for the genetic disorders cystathioninuria and 
homocystinuria, as well as for other conditions including premenstrual tension, seizures, 
carpal tunnel syndrome, pregnancy and vitamin B6 deficiency. Moreover, low levels of 
vitamin B6 are most frequently found in elderly and in alcoholics. Vitamin B6 deficiency is  
known to give symptoms as sensory neuropathy. These low levels have been related to 
increased risk of cardiovascular diseases and neuronal symptoms. In such cases, vitamin B6 
supplements are advised [12, 13]. In the last decades, various cases of vitamin B6 induced 
polyneuropathy have been reported after the use of vitamin B6 supplements. People 
chronically taking mega doses (>50 mg/day) of vitamin B6 reported complaints as pain in 
the extremities and muscle weakness [14-16]. However, even at lower doses, vitamin B6 
has been found to lead to the same complaints. This is exemplified by some of the reported 
cases to Lareb, in which doses of 2mg/day gave complaints. These complaints are similar to 
those observed in people with a vitamin B6 deficiency. However, the molecular mechanism 
of vitamin B6 induced toxicity is unknown.  
Vitamin B6 supplements are used by a large number of people. Most of the vitamin B6 
supplements that are available on the market contain pyridoxine. In our body, pyridoxine 
will be converted into the biologically active form pyridoxal-5’-phosphate. Our results 
indicate that vitamin B6 toxicity is caused by competition between the active pyridoxal-5’-
phosphate and the inactive pyridoxine. Pyridoxine induced cell death in human 
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neuroblastoma cells, whereas pyridoxal-5’-phosphate prevented cell death induced by 
pyridoxine. On a molecular level, pyridoxine can inhibit pyridoxal-5’-phosphate dependent 
processes, which is shown by the inhibition of the enzyme activity of two pyridoxal-5’-
phosphate dependent enzymes by pyridoxine. As a consequence, the paradox arises that 
the symptoms of vitamin B6 supplementation are similar to those of vitamin B6 deficiency. 
The recommended daily intake of vitamin B6 is debated and EFSA has recently lowered the 
upper limit for vitamin B6 [17]. The question is whether lowering the safe dose for vitamin 
B6 is the best solution. Since vitamin B6 supplementation even at relatively low doses has 
given rise to complaints. Our study indicates that the toxicity of vitamin B6 is not only 
determined by the dose, but especially by the vitamer used. Replacing pyridoxine by 
pyridoxal or pyridoxal-5’-phosphate in supplements is advised, since these are at least 
equally active and much less toxic. 
Perception on food supplements  
In the present thesis we have identified potential adverse effects of some food 
supplements. Moreover, some potential supplement-drug and supplement-supplement 
interactions have been identified, which may have serious adverse effects. Next to these 
potential interactions, numerous evidenced supplement-drug interactions are known, most 
of them between herbal supplements and drugs [18-20].  These potential adverse effects 
do not fit in the positive view that consumers have of food supplements. The idea is that 
food supplements maintain and improve overall health and might compensate for an 
unhealthy lifestyle. The enormous increase in food supplement use is based on the 
widespread believe that the products are healthy and that products of natural origin are 
safe [21]. Food supplements are therefore not only taken to supplement the diet, as what 
they are actually aimed for. This is shown by the low percentage (22%) of the users that 
really used food supplements as a supplement to their diet. The general assumption is that 
the quality of prescription and over-the-counter supplements is high. Generally, efficacy 
and potency of these products are accepted without questioning. Especially for 
antioxidants the expectations are very high. In contrast to these high expectations, reports 
on the adverse events involving these supplements are increasing. These adverse events 
are often caused by over-consumption (due to too high doses) of food supplements and by 
interactions with other food supplements or drugs. In the literature numerous interactions 
between food supplements, especially herbal supplements, and drugs have been reported. 
These include pharmacokinetic and pharmacodynamic interactions, both leading to adverse 
effects. In the Netherlands, Lareb reported at least 55 reports on interactions between 
food supplements and drugs [20]. These included both herbal and non-herbal supplements. 
All these interactions lead to adverse effects in people. All the reported complaints and 
interactions of food supplements are collected into a database, which is used to write 
reports on adverse effects of drugs and food supplements. Lareb also informs the European 
Medicines Agency and the World Health Organization (WHO) about these reports, thereby 
helping monitoring the global food supplement and drug safety. 
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Risk assessment and risk management 
In the appreciation of food supplements, it is important to evaluate their benefits and risks 
in an accurate benefit-risk assessment. Food supplements are consumed to improve health. 
Often, a positive health effect of a food supplement has not been demonstrated. In order 
to recommend the application of food supplements, it is essential to obtain scientific proof 
for the actual benefits by focusing on the molecular mechanisms of these benefits. Food 
supplements should only be administered to people expected to benefit from them. For 
explicit health claims of food supplements, using a similar procedure to drug registration 
would be helpful, so that not only the activity of such particular food supplement has to be 
proven in a clinical study, but also safety issues, metabolism and biological effects have to 
be shown [22]. Regarding the risks, both the necessity and dose of dietary supplementation 
and the identification of vulnerable groups should be carefully evaluated.  
Vitamins and minerals are essential for maintaining an optimal health. However, the 
estimation of optimal intakes of micronutrients for a given population is difficult. Different 
individuals not only have different needs and intakes of certain nutrients, but they also 
have differences in susceptibility to adverse effects of food supplements. For instance, 
elderly are at higher risk for adverse effects of food supplements, including the interactions 
with drugs. This can mainly be contributed to the physiological changes due to ageing. 
Especially the pharmacokinetic and pharmacodynamic changes make elderly at higher risk 
for adverse effects of food supplements. Pharmacokinetic changes during ageing include 
reduced absorption (of nutrients and drugs), distribution (resulting in higher serum levels of 
nutrients and drugs), metabolism (resulting in lowered metabolism of nutrients and drugs) 
and excretion (resulting in reduced clearance of nutrients and drugs). All these 
pharmacokinetic changes may lead to an accumulation of certain nutrients and/or drugs, 
which might lead to more adverse effects. Pharmacodynamic changes refer to changes in 
concentration of a particular drug at its receptor, the response it elicits on the receptor, 
post receptor events and homeostatic mechanisms. Together with the pharmacokinetic 
changes, these changes will increase the vulnerability of the elderly population for drug-
supplement interactions, ultimately leading to adverse effects. Also the high number of 
medicine use among this population makes elderly a vulnerable group for adverse effects 
of food supplements. Moreover, elderly often use multiple drugs at the same time. This will 
not only lead to a higher risk of adverse effects, it will also increase the possibility of 
unwanted interactions with other drugs or food supplements, leading to adverse effects of 
both the drugs as the food supplements. The use of multiple drugs in combination with 
food supplements may therefore decrease the quality of life of elderly.  
The most important challenge in an appropriate risk assessment is to balance the risk of 
deficiencies with the risk of overconsumption within the same population [23]. Adverse 
effects of (micro)nutrients may arise due to too low or too high intake, which is illustrated 
by some examples in table 1. 
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Table 1|Adverse effects of nutrients arise due to a too low or too high intake 
 Too low intake Too high intake 
Iron Anaemia Gastrointestinal side effects 
Vitamin A Growth abnormalities Liver damage, teratogenic 
Vitamin C Fatigue Gastrointestinal side effects 
Vitamin B6 Anaemia,  
Sensory neuropathy 
Sensory neuropathy 
Calcium Osteoporosis Hypercalcaemia,  
Kidney stones 
 
The increasing use of food supplements will lead to increased intake levels of 
(micro)nutrients for different population groups. In order to protect consumers, it becomes 
more and more important to determine safe levels of intake and to perform accurate risk-
benefit analyses. As mentioned before, adverse health effects of food supplements mainly 
occur by excessive intakes or by interactions with other drugs or food supplements. In 
order to reduce the risk of excessive intake, EFSA has set ULs. Upper safe levels of vitamins 
and minerals, which are established by risk assessment, are based on scientific data and 
take into account the different sensitivity of different consumer groups. EFSA provides the 
EC with scientific opinions about the upper levels of vitamins and minerals. However, the 
available scientific data on the safety in use of vitamins and minerals is limited.   
With regards to the risk assessment, the same concept applies to nutrients and minerals as 
to other food chemicals, as agreed upon by the FAO/WHO [17]. The first step is to identify 
known or potential adverse health effects of a particular nutrient (hazard identification). 
Collecting and evaluating all the information regarding adverse effects of this nutrient. The 
second step is the qualitative and quantitative evaluation of the nature of these adverse 
effects of the nutrient (hazard characterization).This step includes the assessment of dose-
response effects, in which no observed adverse effect levels (NOAEL) and lowest observed 
adverse effect levels (LOAEL) are determined. After these evaluations, ULs can be derived, 
which take into account uncertainties in the data. These ULs can be derived for different 
subpopulations. In the third step the usual total daily intake of a nutrient among the 
general population is evaluated (exposure assessment). The three different steps are finally 
concluded in the risk characterization step. Based on the findings of the first three steps, 
the risk is characterized. The risk will depend on the part of the population exceeding the 
UL and the magnitude and duration of the excessive intake. It should be specified whether 
there are distinct sensitivities to the adverse effects of a nutrient for sub-populations.  
Remarkably, ULs do not function as limits for the doses of food supplements. Often food 
supplements are found to have doses much higher than the ULs. Therefore, it might be 
more important to set maximum safe levels (MLS) of nutrients in food supplements [24]. 
MLS can be set by using a risk management model, taking quantitative and qualitative risk 
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assessments into account. When doing this, nutrients can be categorized into three groups, 
depending on the risks. Group 1 contains nutrients that do not represent any relevant risk 
to human health in the general population. When authoritative risk assessments do not 
show adverse effects of particular nutrients and when no UL can be set, these nutrients are 
placed into group 1. For these nutrients, no further risk management is necessary. 
Examples of nutrients that are categorized into group 1 are vitamin B1, vitamin B2, biotin 
and vitamin B12. EFSA did not find any data on hazards related to high intakes of these 
nutrients in their risk assessment. Therefore, no MLS have to be set for these nutrients. In 
these cases, guidance levels (GL) for supplementation can be set. 
Nutrients in group 2 exhibit a low risk of exceeding the UL and nutrients in group 3 have a 
potential risk at excessive intakes. When characterizing the risks for these nutrients, the 
Population Safety Index (PSI) may be used. By using the PSI, vitamins and minerals can be 
classified into two different categories of risks. When the PSI of a certain nutrient is over 
1.5, the chance of exceeding the upper limit is low (group 2).  
Examples of nutrients present in this group are vitamin C, vitamin D, vitamin E, selenium, 
magnesium and folic acid. 
Table 3|Proposed maximum safe levels (MLS) in food supplements for adults. 
 
 
Group 1 
No evidence of adverse effects 
to humans 
No MLS necessary  
Group 2 
Low risk of exceeding UL 
Nutrient MLS 
 Vitamin C 1700 mg 
 Vitamin D 83 µg 
 Vitamin E 270 mg 
 Magnesium 250 mg 
 Folic acid 600 µg 
Group 3 
Potential adverse effect at 
excessive intake 
Nutrient MLS 
 Vitamin A 1200 µg 
 Beta-carotene 7 mg 
 Calcium 1000 mg 
 Iron 20 mg 
 Zinc 15 mg 
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Nutrients with a PSI of 1.5 or lower have a potential risk of exceeding the UL with 
potentially adverse effects (group 3). Examples of nutrients in this group are vitamin A, 
beta-carotene, calcium, iron, and zinc. For the nutrients of both groups MLS have been 
proposed by the International Alliance of Dietary/Food Supplement Associations (IADSA). 
IADSA is an association that brings together over 50 associations of food supplement 
manufacturers and distributors from across the world. Its aim is to guarantee a greater 
exchange of knowledge about science and regulation of food supplements and ingredients 
among industry, scientists, regulators and consumers. The MLS can be used to minimize the 
chance of developing adverse events due to supplementation. Some examples of MLS for 
nutrients are shown in table 2. 
Education 
As the global use of food supplements as well as the number of food supplements is 
increasing, health issues and safety concerns are increasingly debated. Especially since 
evidence of quality, efficacy and safety is not required when putting food supplements on 
the market. Although food supplements have a promising potential, knowledge about 
adverse effects is often lacking. Adverse health effects of food supplements not only occur 
after excessive intakes, but also by interacting with drugs or other food supplements. 
People do not inform their physician about the use of their food supplements. Physicians 
therefore do not associate adverse events with supplement use. Moreover, there generally 
is a lack of knowledge among physicians about interactions of food supplements with other 
food supplements and medications. Such supplement-drug interactions go unrecognized by 
both consumers and health care professionals. As a consequence, the reported food 
supplement-related adverse events are expected to be a large underestimation. 
Nevertheless, it may have serious adverse effects, lead to ineffective therapy and to an 
increased chance for deficiencies or toxicities. In order to reduce the interactions between 
food supplements with drugs, it is important for consumers to be aware of potential 
supplement-drug interactions. It is essential to provide the general public and healthcare 
professionals, with scientific sound information so they become aware of the risks of using 
food supplements. Especially since there is an uncontrolled supply of food supplements via 
diverse sources. Health care professionals should encourage patients to report the use of 
all (self)-medications and food supplements to their general practitioner, so that they can 
screen a patient’s medical history for potential supplement-drug interactions. A better 
education of the consumers and the healthcare professionals in the field of food 
supplements is vital to prevent serious side effects due to food supplements.  
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Summary 
The aim of the present thesis was to investigate potential adverse effects of food 
supplements either combined with other food supplements or drugs or in isolation. The 
world population is rapidly ageing. This leads to increased needs in medical and social 
health care. Next to medicines, nutrition is becoming more important as a way of 
maintaining and promoting health and treating diseases. Nutraceuticals, which are 
bioactive compounds derived from food, are being developed to improve peoples’ health 
status. These also comprise food supplements. The use of food supplements has exploded 
over the past years. The number of food supplement products that is offered by shops, 
supermarkets and online shops is massive. All these supplements claim to improve health 
or battle diseases. The enormous increase in food supplement use is based on the 
widespread believe that the products are healthy and that products of natural origin are 
safe. Peoples‘ perception on food supplements is that they only have benefits, while they 
are unaware of their potential risks.  Remarkably, adverse effects by food supplements, 
which are for instance caused by interactions with drugs, are scarcely investigated. Our 
research identified potential adverse effects by food supplements and shows that the 
perception that food supplements only have beneficial effects is incorrect. 
Perception on antioxidants 
Especially for antioxidants the expectations are very high. Antioxidants are considered as 
being important agents in the protection against oxidative stress and ageing. Many food 
supplements are available that are rich in antioxidants. They are used on a large scale with 
this idea that antioxidants are healthy. Moreover, the use of all kinds of antioxidants in high 
doses was recommended for supplementation. In chapter 2 the changing perception on the 
health effects of antioxidants is discussed, using two examples, namely vitamin E and ɴ-
carotene. Vitamin E is an antioxidant that has been shown to have numerous beneficial 
health effects. In contrast, ɴ-carotene was generally considered as being toxic, since the 
ATBC study was published in 1994. Remarkably, both antioxidants were shown to have a 
similar toxicity in cells exposed to BPDE by inhibiting the protective enzyme GST ʋ. Based 
on these findings, it could be concluded that both vitamin E and ɴ-carotene have toxic 
effects when combined with electrophilic compounds, which can be found in cigarette 
smoke or coal tar cream. Supplementation of antioxidants does not necessarily have to be 
beneficial and a natural origin is no guaranty for safety. It is therefore important to come to 
an accurate benefit-risk analysis. 
Adverse interactions between food supplements and drugs 
Supplementation of food supplements may lead to adverse health effects. Especially 
elderly, in which a decline in structure and function of organs and organ systems occur, are 
more prone to adverse effects of food supplements. Moreover, the use of multiple drugs is 
also common in elderly, which increases the chance of drug-supplement interactions. The 
main types of interactions between drugs and dietary supplements are pharmacodynamic 
interactions and pharmacokinetic interactions. In chapter 3, we have evaluated a 
pharmacodynamic interaction of a food supplement, quercetin, and a drug, tamsulosin on 
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isolated mesenteric arteries. A very common age-related disease is benign prostatic 
hyperplasia (BPH). As men age, they are more likely to develop prostate problems. Alpha-
adrenergic receptor–blocking agents such as tamsulosin are used to treat BPH. Although 
the tamsulosin effect is aimed at ɲ1A-adrenoceptors in the prostate, it will also block ɲ1A-
and ɲ1D-adrenoceptors in the vasculature. Our results showed that the combination of 
tamsulosin with quercetin or quercetin metabolites was far more potent than the 
compounds in isolation. It was shown that the supplement quercetin strongly potentiates 
the  ɲ1-adrenoceptor antagonizing effects of the drug tamsulosin. The strong 
pharmacodynamic interaction between the food supplement quercetin and tamsulosin 
underlines the impact of supplement-drug interactions that warrant more research.  
Anticholinergic accumulation 
Anticholinergic effects of drugs arise by blocking cholinergic neurotransmission, more 
specifically by blocking the muscarinic receptors in the brains. These receptors play an 
important role in numerous processes, including cognition and movement. In 2008 the 
Anticholinergic Cognitive Burden (ACB) scale was developed, in which drugs are categorized 
based on their anticholinergic effect. In chapter 4 it is shown that the affinity of the drugs 
for the muscarinic receptors correlated well with their ACB scores. We found that food 
supplements also have the ability to bind to these receptors. It was shown that the 
combination of several drugs and supplements had an affinity that is higher than the 
affinity of the individual compounds. This explains the process of anticholinergic 
accumulation. It is concluded that the anticholinergic side effect of a single compound, for 
instance a drug or a food supplement, is often relatively mild. However, when several 
compounds are taken simultaneously, more of the receptors will be blocked, which 
aggravates the effect and hence the potential anticholinergic side effect. 
Iron supplements and magnesium peroxide 
Ageing is also accompanied by changes in the gastro-intestinal system, such as reduced 
absorption of nutrients and an increases risk for gastro-esophageal reflux disease. Because 
of the reduced absorption of nutrients, malnutrition is very common among elderly. 
Moreover, iron deficiency is the single most prevalent nutritional deficiency worldwide with 
elderly as a group with the highest prevalence. In order to maintain iron levels, iron 
supplements are often used. Numerous iron supplements are present, each containing 
relatively high doses of iron. In chapter 5,  we  focused  on the hazardous interaction 
between iron supplements and magnesium peroxide. In our study it was shown that iron 
supplements induced the formation of hydroxyl radicals. This was augmented by 
magnesium peroxide, an antacid that is available as OTC drugs. This is an example of an 
interaction between a food supplement and an OTC, indicating that also the use of self-
medication can lead to hazardous interactions. 
Vitamin B6   
Vitamin B6 is important for many physiological functions, being a coenzyme in reactions 
that are involved in amino acid, carbohydrates and lipid metabolism and neurotransmitter 
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synthesis. Vitamin B6 supplements are one of the most used supplements. Recently, Lareb 
published a report concerning the side effects of vitamin B6 supplements. Since 2014, more 
than 50 cases of sensory neuronal pain were reported after taking vitamin B6 supplements 
in the Netherlands. These complaints are similar to those observed in people with a vitamin 
B6 deficiency. However, the molecular mechanism of vitamin B6 induced  toxicity  is  
unknown. In Chapter 6 the neuropathy observed after taking a relatively high dose of 
vitamin B6 supplements is examined. Our results indicate that vitamin B6 toxicity is caused 
by competition between the active pyridoxal-5’-phosphate and the inactive pyridoxine. 
Pyridoxine induced cell death in human neuroblastoma cells, whereas pyridoxal-5’-
phosphate prevented cell death induced by pyridoxine. On a molecular level, pyridoxine 
can inhibit pyridoxal-5’-phosphate dependent processes, since we found that pyridoxine 
inhibited the enzyme activity of two pyridoxal-5’-phosphate dependent enzymes. As a 
consequence, the paradox arises that the symptoms of vitamin B6 supplementation are 
similar to those of vitamin B6 deficiency. 
Overall conclusion 
Although the expectations of food supplements are very high, the number of adverse 
events involving these supplements is increasing. These adverse events are often caused by 
over-consumption of food supplements and by interactions with other food supplements 
or drugs. It is therefore important to evaluate their benefits and risks in an accurate 
benefit-risk assessment. In the future, more attention should be paid to the adverse effects 
of food supplements, including supplement-drug interactions, which could lead to serious 
adverse events. Additionally, a good education of consumers and healthcare professionals 
in the field of food supplements is essential to provide them with the right information and 
to prevent serious side effects due to food supplements.  
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Samenvatting 
Het doel van dit proefschrift is om mogelijke negatieve effecten van voedingssupplementen 
te identificeren, al dan niet gecombineerd met medicijnen of andere supplementen. De 
wereldbevolking is snel aan het vergrijzen. Dit leidt tot een toename in behoeftes in de 
medische en sociale zorg. Naast medicatie, wordt voeding meer en meer gebruikt als een 
middel voor het behoud en de bevordering van de gezondheid en de behandeling van 
ziekten. Nutraceuticals, welke bioactieve stoffen zijn die uit  voeding worden afgeleid, 
worden ontwikkeld om de gezondheidstoestand van mensen verbeteren. Onder 
nutraceuticals vallen ook de voedingssupplementen. Er heeft een enorme toename 
plaatsgevonden in het gebruik van voedingssupplementen over de afgelopen jaren. Het 
aantal voedingssupplementen, dat wordt aangeboden door winkels, supermarkten en 
online winkels is enorm. Van al deze supplementen wordt beweerd dat ze de verbetering 
van de gezondheid stimuleren of helpen bij ziektebestrijding. De enorme toename in het 
gebruik van voedingssupplementen is gebaseerd op de algemene opinie dat deze 
producten gezond zijn en dat producten van natuurlijke oorsprong per sé veilig zijn. De 
algemene perceptie van mensen over voedingssupplementen is dat ze alleen maar 
voordelen hebben, terwijl zij zich niet bewust zijn van potentiële risico's. Nadelige effecten 
van voedingssupplementen, die bijvoorbeeld worden veroorzaakt door interacties met 
geneesmiddelen, worden nauwelijks onderzocht. Ons onderzoek identificeert potentiële 
nadelige gevolgen van voedingssupplementen en toont aan dat de perceptie dat 
voedingssupplementen alleen gunstige effecten hebben, onjuist is. 
Perceptie van antioxidanten 
Voornamelijk voor antioxidanten zijn de verwachtingen zeer hoog. Antioxidanten worden 
beschouwd als belangrijk middelen in de bescherming tegen oxidatieve stress en 
veroudering. Veel voedingssupplementen zijn beschikbaar die rijk zijn aan antioxidanten. 
Deze worden op grote schaal gebruikt met het idee dat antioxidanten alleen maar gezond 
zijn. Bovendien wordt het gebruik van alle soorten van antioxidanten in hoge dosering 
aanbevolen voor suppletie. In hoofdstuk 2 wordt de veranderende perceptie over de 
gezondheidseffecten van antioxidanten besproken, aan de hand van twee voorbeelden, 
namelijk vitamine E en ɴ-caroteen. Vitamine E is een antioxidant dat is aangetoond vele 
gunstige gezondheidseffecten te hebben. ɴ-caroteen daarentegen wordt over het 
algemeen beschouwd als toxisch, sinds de ATBC studie in 1994 werd gepubliceerd. In onze 
studie werd opmerkelijk gevonden dat beide antioxidanten een soortgelijke toxiciteit 
vertoonden in cellen die blootgesteld werden aan BPDE. Dit wordt verklaard door de 
remming van het beschermende enzym GST ʋ. Op basis van deze bevindingen kan worden 
geconcludeerd dat zowel vitamine E en ɴ-caroteen toxische effecten hebben in combinatie 
met elektrofiele verbindingen, die aanwezig zijn in sigarettenrook of koolteer crème. 
Suppletie van antioxidanten hoeft niet noodzakelijk gunstig te zijn en natuurlijke oorsprong 
is geen garantie voor veiligheid. Het is daarom belangrijk om een nauwkeurige baten-risico-
analyse te maken. 
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Nadelige interacties tussen voedingssupplementen en geneesmiddelen 
Suppletie van voedingssupplementen kan leiden tot nadelige effecten op de gezondheid. 
Voornamelijk ouderen zijn meer vatbaar voor de nadelige effecten van 
voedingssupplementen, aangezien er zich in ouderen een afname van de structuur en 
functie van organen en orgaansystemen voordoen. Bovendien komt het gelijktijdige 
gebruik van meerdere medicijnen ook voor bij ouderen, wat de kans op geneesmiddel-
interacties met supplementen verhoogt. De belangrijkste soorten interacties tussen 
geneesmiddelen en voedingssupplementen zijn farmacodynamische interacties en 
farmacokinetische interacties. In hoofdstuk 3 hebben we een farmacodynamische interactie 
tussen het voedingssupplement, quercetine, en een medicijn, tamsuolosine, op geïsoleerde 
mesenteriale slagaders besproken. Een veel voorkomende leeftijd gerelateerde ziekte is 
benigne prostaathyperplasie (BPH). Naarmate mannen ouder worden, zijn ze meer kans om 
prostaat problemen te ontwikkelen. Alfa-adrenergische receptor blokkerende middelen 
zoals tamsulosine worden gebruikt voor de behandeling van BPH. Hoewel het tamsulosine 
effect gercith is op ɲ1A-adrenoceptoren in de prostaat, zal het ook de ɲ1A-en  ɲ1D-
adrenoceptoren in de vasculatuur blokkeren. Onze resultaten laten zien dat de combinatie 
van tamsulosine met quercetine of quercetine metabolieten veel sterkere effecten hadden 
dan de verbindingen afzonderlijk. Er werd aangetoond dat het supplement quercetine de 
antagoniserende effecten van het geneesmiddel tamsulosine op de ɲ1-adrenoceptor sterk 
versterkt. De sterke farmacodynamische interactie tussen het voedingssupplement 
quercetine en tamsulosine onderstreept de impact van supplement-interacties met andere 
geneesmiddelen die meer onderzoek rechtvaardigen. 
Anticholinergische stapeling 
Anticholinerge effecten van geneesmiddelen ontstaan door het blokkeren van cholinerge 
neurotransmissie, in het bijzonder door blokkeren van de muscarine receptoren in de 
hersenen. Deze receptoren spelen een belangrijke rol bij talrijke processen, waaronder 
cognitie en beweging. In 2008 werd de Anticholinergica Cognitive Burden (ACB) schaal 
ontwikkeld, waarin drugs worden gecategoriseerd op basis van hun anticholinerge werking. 
In hoofdstuk 4 wordt aangetoond dat de affiniteit van de geneesmiddelen voor de 
muscarine receptoren goed correleerden met hun ACB scores. Wij laten zien dat 
voedingssupplementen ook het vermogen hebben om aan deze receptoren te binden. Er 
werd aangetoond dat de combinatie van verschillende geneesmiddelen en supplementen 
een affiniteit had die hoger is dan de affiniteit van de afzonderlijke verbindingen. Dit 
verklaart het proces van anticholinergische stapeling. Geconcludeerd wordt dat de 
anticholinergische bijwerking van een enkele verbinding, bijvoorbeeld een geneesmiddel of 
een voedingssupplement, vaak relatief mild. Echter, wanneer meerdere verbindingen 
tegelijkertijd worden ingenomen, zullen meer van de receptoren worden geblokkeerd, 
waardoor het effect en daarmee de potentiële anticholinergische bijwerking verergerd 
wordt.  
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IJzer supplementen en magnesium peroxide 
Veroudering gaat ook gepaard met veranderingen in het maag-darmkanaal, zoals een 
verminderde opname van voedingsstoffen en een stijging van het risico op gastro-
oesofageale refluxziekte. Vanwege de verminderde opname van voedingsstoffen, komt 
ondervoeding veel voor bij bejaarden. Bovendien is ijzertekort de meest voorkomende 
voedingstekorten wereldwijd, met ouderen als groep met de hoogste prevalentie van dit 
tekort. Om het ijzer niveau op peil te houden, worden ijzersupplementen vaak gebruikt. 
Talrijke hoeveelheden van ijzersupplementen zijn beschikbaar op de markt, elk met relatief 
hoge doseringen ijzer. In hoofdstuk 5 hebben we ons gericht op de potentieel gevaarlijke 
interactie tussen ijzersupplementen en magnesium peroxide. In onze studie is aangetoond 
dat ijzersupplementen de vorming van hydroxyl radicalen induceert. Dit effect werd 
vergroot door magnesium peroxide, een antacidum dat beschikbaar is als zelfzorgmedicijn. 
Dit is een voorbeeld van een interactie tussen een voedingssupplement en een 
zelfzorgmedicijn, wat aangeeft dat ook het gebruik van zelfmedicatie kan leiden tot 
gevaarlijke interacties. 
Vitamine B6 
Vitamine B6 speelt een belangrijke rol in veel fysiologische processen, aangezien het een 
co-enzym is dat in veel reacties betrokken is, zoals in het metabolisme van aminozuren, 
koolhydraten en vetmetabolisme en neurotransmitter synthese. Vitamine B6 
supplementen zijn een van de meest gebruikte supplementen. Onlangs heeft Lareb een 
rapport gepubliceerd over de bijwerkingen van vitamine B6 supplementen. Sinds 2014 
werden meer dan 50 gevallen van sensorische neuronale pijn gemeld na het nemen van 
vitamine B6 supplementen. Deze aandoeningen komen overeen met die waargenomen bij 
mensen met een tekort aan vitamine B6. Het moleculaire mechanisme van vitamine B6 
geïnduceerde toxiciteit is echter niet bekend. In hoofdstuk 6 wordt de vitamine B6-
geinduceerd neuropathie onderzocht. Onze resultaten geven aan dat vitamine B6 toxiciteit 
wordt veroorzaakt door competitie tussen de actieve pyridoxal-5'-fosfaat en inactieve 
pyridoxine. Toevoeging van pyridoxine leidde tot celdood van humane neuroblastoma 
cellen, terwijl pyridoxal-5'-fosfaat deze door pyridoxine geïnduceerde celdood kon 
voorkomen. Op moleculair niveau kan pyridoxine pyridoxal-5'-fosfaat-afhankelijke 
processen remmen, wat bevestigd wordt door onze bevinding dat pyridoxine de 
enzymactiviteit van twee pyridoxal-5'-fosfaat-afhankelijke enzymen remde. Hierdoor 
ontstaat de paradox dat de symptomen veroorzaakt door vitamine B6 supplementen 
vergelijkbaar zijn met die van vitamine B6-deficiëntie. 
Algemene conclusie 
Hoewel de verwachtingen van voedingssupplementen erg hoog zijn, is het aantal 
ongewenste voorvallen waarvan deze supplementen de oorzaak zijn, toegenomen. Deze 
bijwerkingen worden vaak veroorzaakt door overconsumptie van voedingssupplementen 
en door interacties met andere voedingssupplementen of geneesmiddelen. Daarom is het 
belangrijk om de voordelen en risico's in een nauwkeurige baten-risico analyse te 
evalueren. In de toekomst moet er meer onderzoek worden gedaan naar de negatieve 
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effecten van voedingssupplementen, inclusief supplement-medicijn interacties, wat kan 
leiden tot ernstige bijwerkingen. Daarnaast is een goede informatievoorziening aan de 
consumenten en beroepsbeoefenaren in de gezondheidszorg op het gebied van 
voedingssupplementen essentieel om hen te voorzien van de juiste informatie en zo 
ernstige bijwerkingen als gevolg van voedingssupplementen te voorkomen. 
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Valorisatie addendum 
De Nederlandse bevolking vergrijst. Dit leidt tot een toename in behoeftes in de medische 
en sociale zorg. Naast de grote hoeveelheden medicijnen die ouderen slikken, worden 
voedingssupplementen ook steeds meer gebruikt om de gezond te worden en te blijven. 
Dit heeft geleid tot een zeer groot aanbod van vitaminesupplementen en 
kruidenpreparaten die gericht zijn op het verbeteren van de gezondheid. 
Voedingssupplementen zijn oorspronkelijk bedoeld als aanvulling op het dagelijkse dieet 
wanneer er een tekort was. Echter, ze worden nu ook steeds vaker gebruikt om gezond te 
blijven, waarmee het supplement eigenlijk meer een medicijn wordt.  
Van voedingssupplementen wordt vaak gedacht dat ze altijd gezond en veilig zijn, vooral als 
het natuurlijke producten zijn. De consumenten denken dat voedingssupplementen alleen 
maar voordelen hebben, en zijn zich niet bewust van potentiële risico's. Dit strookt niet met 
de praktijk. Ook supplementen hebben bijwerkingen. Het aantal bijwerkingen door 
supplementen neemt ook toe. Vanaf 2004 tot 2013, gingen er in de Verenigde Staten 
jaarlijks 23.000 mensen naar het ziekenhuis door het gebruik van voedingssupplementen. 
Meer dan 2000 mensen werden er jaarlijks opgenomen in het ziekenhuis na het gebruik 
van voedingssupplementen. Vaak ging het om mensen boven de 65 jaar. Meestal kwam het 
omdat er teveel supplementen werden gebruikt. Ook combinatie met medicijnen leidde 
vaak tot opnames in het ziekenhuis. Dergelijke Interacties tussen geneesmiddelen en 
voedingssupplementen kunnen ernstige gevolgen hebben. Tot op heden wordt er 
nauwelijks naar interacties gekeken. Dit komt omdat er onvoldoende naar dergelijke 
interacties wordt gekeken. Mede daarom kan er geen goede afweging gemaakt worden 
tussen het voordeel en het nadeel van het gebruik van voedingssupplementen en is het 
belangrijk om een goede baten-risico beoordeling te maken. 
Het onderzoek beschreven in dit proefschrift is gericht op de bijwerkingen 
voedingssupplementen, waaronder mogelijke interacties met medicijnen. Dit is gedaan in 
opdracht van de Nederlandse Voedsel- en Warenautoriteit (NVWA). De resultaten zijn van 
belang voor zowel consumenten, de gezondheidzorg als overheidsinstellingen die op de 
veiligheid van voedingssupplementen toezien. Het onderzoek toont aan dat het 
combineren van voedingssupplementen met medicijnen bijwerkingen kan geven. Door met 
een moleculaire benadering naar de overlap tussen voedingssupplementen en 
geneesmiddelen te kijken, kunnen interacties worden ontrafeld. Deze interactie tussen een 
geneesmiddel en een supplement werd onder andere onderzocht op de relaxatie van 
geïsoleerde bloedvaten en de binding op receptoren. Hiermee werd het mechanisme van 
de interactie in kaart gebracht. Hierdoor is het mogelijk om ook een onderbouwing van het 
risico van voedingssupplementen te krijgen. Naast de consumenten, is het ook belangrijk 
om werkers in de gezondheidszorg goed te informeren over de bijwerkingen van 
voedingssupplementen.  
Meestal vertellen patiënten hun huisarts niet dat ze voedingssupplementen gebruiken. 
Hierdoor kan een mogelijke interactie tussen voedingssupplementen en het medicijn dat 
de arts voorschrijft niet worden voorkomen. Bovendien weten artsen te weinig over de 
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interacties tussen geneesmiddelen en voedingssupplementen. Door zowel consumenten 
als werkers in de gezondheidszorg (met name artsen) goed voor te lichten over interacties 
tussen geneesmiddelen en voedingssupplementen, kunnen de risico’s op bijwerkingen 
verkleind worden. Er is dus nog veel verbetering mogelijk bij de communicatie van 
mogelijke risico’s naar consumenten en professionals in de gezondheidszorg. 
Het onderzoek is ook relevant voor de voedingsindustrie en de overheid. Veel bijwerkingen 
van voedingssupplementen treden vooral op als gevolg de dosis te hoog is. Het is daarom 
belangrijk om goed toe te zien op de doseringen van voedingssupplementen. Dit wordt in 
het proefschrift geïllustreerd met vitamine B6. De Aanbevolen Dagelijkse Hoeveelheid 
(ADH) van vitamine B6 voor volwassen mannen en vrouwen is 1,5-1,7 mg per dag. De 
veilige bovengrens is gesteld op 25 mg per dag door EFSA. De voedingssupplementen op de 
markt hebben een dosering tot 250 mg. Bij het Lareb zijn de afgelopen jaren steeds meer 
klachten binnen gekomen bij het (langdurig) gebruik van deze supplementen. Na aanleiding 
hiervan en ondersteund door het onderzoek in het huidige proefschrift, heeft het NVWA 
recent besloten om de maximale hoeveelheid van vitamine B6 in voedingssupplementen te 
verlagen tot 21 mg. 
Het proefschrift beschrijft enkele mogelijke nadelige effecten van voedingssupplementen, 
gebaseerd op de moleculaire werking. Het toont dat voedingssupplementen niet per sé 
goed zijn voor de gezondheid. Er is een noodzaak om voor voedingssupplementen een 
goede baten-risico analyse te maken.  Hiervoor is in de toekomst meer onderzoek nodig om 
consumenten zo goed mogelijk te kunnen informeren en beschermen. 
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Dankwoord 
In 2013 begon ik aan mijn promotieonderzoek. Nu, bijna 4 jaar later begin ik met het 
schrijven van het laatste, maar meest gelezen deel van het boekje, het dankwoord. Dit 
proefschrift zou er niet zijn geweest zonder de hulp van een heleboel mensen, die ik dan 
ook graag persoonlijk wil bedanken. 
Allereerst wil ik mijn dank en waardering uitspreken voor het promotieteam: Aalt, Antoon, 
Guido en Eugène. Bedankt voor de kans die jullie mij geboden hebben om dit 
promotietraject te volgen. Vanaf de eerste dag was het fijn om met jullie samen te werken 
en heeft jullie enthousiasme me altijd goed weten te motiveren. Zonder jullie hulp was dit 
boekje er nooit geweest!  
Aalt, als promotor heb ik ontzettend veel van je geleerd. Niet alleen op wetenschappelijk 
gebied, maar ook op persoonlijk gebied. Jouw ontzettende enthousiasme en hoeveelheid 
kennis tijdens de wekelijkse besprekingen hebben me altijd enorm gemotiveerd. 
Problemen en stress bestaan voor jou niet, iets waar ik toch wel jaloers op ben. Als er ook 
maar iets tegenzat of niet ging zoals verwacht, kwam jij altijd heel rustig met een oplossing, 
waarmee je de situatie zo draaide dat er toch nog iets positiefs uitkwam. Naast 
wetenschappelijke onderwerpen tijdens de besprekingen, werd er ook over van alles en 
nog wat gesproken. Zo heb je mij ook nog veel bijgeleerd over literatuur, geschiedenis, 
films en noem maar op. Bedankt! 
Antoon, bedankt voor de kans en het vertrouwen die je mij hebt gegeven tijdens het 
onderzoek. Ondanks je drukke agenda, was je altijd beschikbaar en geïnteresseerd in niet 
alleen het onderzoek, maar ook in mij persoonlijk. Jouw begeleiding, adviezen en 
enthousiasme hebben me enorm geïnspireerd. Ik heb waardering voor de grote 
hoeveelheid kennis die je hebt en de manier waarop je die kennis overdraagt. Ontzettend 
bedankt voor de kans die jullie me geven om mezelf verder te gaan ontwikkelen in het 
onderzoek! 
Guido, jouw deur staat altijd open voor je aio’s. Altijd had je antwoorden op mijn vragen, 
altijd had je weer nieuwe ideeën. Daarnaast had je altijd advies en suggesties bij het 
schrijven van de artikelen, dank daarvoor! Ook de gesprekken over andere dingen naast het 
werk waren vaak erg interessant. 
Eugène, heel erg bedankt voor de hulp tijdens mijn onderzoek. Ook al hebben we niet heel 
vaak samengezeten, je vragen en suggesties hebben mij altijd goed geholpen tijdens het 
onderzoek en het schrijven van de artikelen. 
Ik wil ook graag de leden van de beoordelingscommissie, Prof. dr. T.M. Hackeng, Prof.dr.ir. 
I.C.W. Arts, Prof. dr. P.W. de Leeuw, Dr. H. Deluyker en Prof. dr. R. Witkamp bedanken voor 
het beoordelen van mijn proefschrift. 
Dan zijn er natuurlijk een heleboel (oud) collega’s die ik graag zou willen bedanken. Dit zijn 
er nogal een aantal geweest in de afgelopen vier jaren, dus ik hoop dat ik niemand vergeet. 
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Om te beginnen mijn kamergenoten vanaf het moment dat ik begonnen ben: Roger B. en 
Leonie. Ze zeggen wel eens dat het belangrijk is dat je kamergenoten hebt met wie je goed 
overweg kunt. Dit was bij ons totaal geen probleem. Vanaf de eerste dag dat ik begonnen 
ben, voelde het alsof ik al jaren op de kamer zat. Iedere ochtend begonnen we met een 
‘Feel good’ liedje, die we om en om mochten uitkiezen. Het liedje wat me toch wel het 
meeste bijgebleven is: ‘Romeo – I’m coming home’, welke jullie (en vooral Leonie) uit volle 
borst meezongen. Het samen organiseren van verschillende uitjes, zoals de dagjes uit, de 
darttoernooien, het pooltoernooi, het badmintontoernooi, de Thembi-avonden, een 
middagje Snowworld en de kerstdiners zorgden altijd voor veel gezelligheid en een goede 
sfeer op de afdeling.  Mede dankzij jullie kwam ik altijd met ontzettend veel plezier naar 
mijn werk.  
Leonie, vanaf het beginnen hadden we een goede klik. Jij begon meestal al tussen 7.00 -
8.00, dus als ik ’s ochtends aankwam, was het meteen gezellig beginnen. De fijne 
gesprekken (over van alles en nog wat), lunches, koffie-pauzes, grappige filmpjes etc 
hebben me altijd goed gedaan. Ik wacht trouwens nog steeds op een re-match van de 
volleybal wedstrijd, die Roger en ik onterecht verloren hebben (omdat jullie last-minute de 
regels aanpasten van de wedstrijd) van jullie team (wat overigens een oneerlijke strijd was 
aangezien jullie 30 ervaringsjaren aan volleybalwedstrijden en trainingen hadden en Roger 
en ik welgeteld.. 0).Ook de vrijdagen dat Roger er niet was, waren altijd erg gezellig. Ik wil je 
hiervoor heel graag bedanken en jou en Mark heel veel geluk toewensen voor de 
toekomst! 
Roger, sinds de eerste dag dat we kamergenoten waren, waren we niet alleen collega’s, 
maar ook vrienden. Of zoals de Smos zou zeggen, was het een echte: ‘Friendship’!  Ik ben 
ontzettend vereerd dat je mijn paranimf wilt zijn. De vele momenten van ontspanning, 
zoals de lunches bij Van der Valk en Kwizzenjèr, hebben me altijd goed geholpen om er 
weer met volle energie tegenaan te kunnen gaan. Ook het bespreken en bekijken van alle 
onzin die op het internet stond, was altijd erg grappig. Daarnaast was het altijd fijn om na 
het werk even de werkstress van ons af te slaan op de tennisbaan of een drankje te doen 
bij Thembi. Onze competitiviteit, die niet alleen op de tennisbaan te zien was, was ook 
terug te zien in onze voorbereidingen op de darttoernooien en volleybalwedstrijden, 
waarbij we vaak in de pauzes nog even snel gingen trainen op kantoor. Ook de ‘bier-om-
half vier’, vaker wel iets later dan ‘half vier’ waren erg gezellig. Ja, zoals wel eens gezegd 
wordt: ‘sommigen nemen het er van’ ;-). Ook buiten het werk spraken we regelmatig af 
(met Els en Wendy) voor een etentje, een bioscoopje of een Mossel-avondje bij Ronnie. 
Bedankt voor alle hulp en adviezen die je mij als routinier op het gebied van paranimf hebt 
gegeven. Ik hoop dat we nog veel leuke momenten kunnen beleven! 
Dan mijn tweede paranimf, Kevin. Toen ik in 2012 mijn stage liep op de afdeling 
Farmacologie, liep jij daar al rond als aio. Na de fusie tussen farmacologie en toxicologie, 
verhuisde je naar onze kant van de gang en raakte je meer betrokken bij onze aio-groep. Je 
hebt het zelfs geschopt tot ‘Prins Kevin d’n ierste’ met carnaval, wat een gedenkwaardige 
avond was (vooral voor jou). Vorig jaar was ik vereerd dat ik jou mocht bijstaan als paranimf 
op jouw promotie en nu ben ik heel blij dat jij mijn paranimf wilt zijn. Ook al ben je niet 
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meer werkzaam op de afdeling, ik ben blij dat we nog steeds koffie- en lunchafspraken 
hebben. Bedankt voor alle hulp en adviezen bij de voorbereidingen van mijn promotie! 
Ook belangrijk tijdens het promotietraject zijn de andere aio’s. Toen ik in 2013 begon, 
kwam ik binnen in een warme aio-groep. Hiervoor wil de oud-aio’s Kristien (bedankt voor 
de leuke gesprekken, de adviezen die je me altijd gegeven hebt en het beantwoorden van 
mijn vragen tijdens mijn aio periode), Danielle (bedankt voor je adviezen over het bezoeken 
van congressen), Erik (oftewel Partyboy, bedankt voor de gezellige periode in het lab), Matt 
(oftewel Kuusj, thanks for the entertainment and fun times at the department), Alie 
(bedankt voor de bijgewerkte klapper met ‘things to do’ voor de promotie en bedankt voor 
je adviezen en hulp betreffende BKO), Bregje, Agnieszka, en Max graag ontzettend voor 
bedanken. Jullie zorgden ervoor dat ik goed kon beginnen op de afdeling en met de 
lunches, koffie breaks en andere aio-uitjes was er altijd genoeg afleiding en ontspanning.  
Daarnaast zijn er tijdens mijn aio-periode een hoop nieuwe aio’s begonnen. Rianne en 
Mireille, jullie zijn beide ongeveer gelijktijdig begonnen aan jullie PhD als ik en zitten nu ook 
in de afrondende fase. Bedankt voor de gezellige tijd en heel veel succes met jullie eigen 
boekje en verdediging. Quan, thank you for all the amazing conversations we had. You 
always brought a big smile on my face with your funny jokes and amazing stories. I’m really 
happy to have met you. I’d like to wish you good luck with finishing your own thesis. Lots of 
luck and love also for your wife and your little girl! Carmen, na het vertrek van Roger en 
Leonie kwam jij bij op de kamer zitten. Ook al vertrok je vrij snel hierna naar ‘the States’, 
toch wil ik je bedanken voor de gezellige tijd! Jouw enthousiasme en enorm goede 
werkmentaliteit zijn een voorbeeld voor iedereen! Verder wil ik ook de andere aio’s 
Gesiele, Charlotte, Timme, Sven, Philippe en Ming bedanken voor alle gezelligheid en 
ontspanning op de afdeling en tijdens de verschillende borrels. Jullie ook allemaal heel veel 
succes gewenst met jullie PhD. 
Daarnaast wil ik ook de stagiaires die ik heb mogen begeleiden bedanken: Gerly, Nina, 
Aktar, Diana, Lukas en Ankie. Ik heb jullie allemaal met veel plezier begeleid. Jullie hebben 
mij goed geholpen en een goede bijdrage gehad aan mijn onderzoek!  
Frederik-Jan en Roger G, bedankt voor jullie bijdrage en kritische blik op ons gezamenlijke 
artikel over vitamine E en beta-caroteen! Geja, bedankt voor je bijdrage aan ons vitamine 
B6 stuk. 
Een speciaal bedankje voor Lou: Bedankt voor de DNA adduct metingen die je voor ons 
hebt uitgevoerd. Dit heeft bijgedragen aan een mooie publicatie. Daarnaast wil ik je graag 
bedanken voor de erg leuke gesprekken die we altijd hadden en voor de gezellige 
vrijdagmiddag borrels.  
Verder wil ik alle andere collega’s van de afdeling bedanken voor de samenwerking en voor 
de leuke periode: Antje, Gertjan, Alex, Sébastien, Caroline, Pieter, Jan, Agnes, Matthijs, 
Harry, Ben, Paul, Josephina, Agnieszka S, Khrystyna, Agnieszka B, Edwin, Marie-José, Ger, 
Jacques, Peter, Danielle en Lily.  
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Dan wil ik graag nog Marie-Claire in het speciaal bedanken. In de afgelopen 4 jaar heeft u 
ontzettend veel geregeld. Zonder u zou de afdeling niet draaiende blijven. Naast het 
regelen van afspraken en administratieve zaken, hebben wij ook heel vaak leuke 
gesprekken over allerlei andere zaken gehad. U had altijd goede adviezen voor mij en als ik 
ergens wat stress voor had, nam u die stress snel weg. Een hele grote merci voor alle hulp! 
Verder zijn er nog een paar mensen van buiten de afdeling bedanken die het mogelijk 
maken om op de universiteit goed onderzoek te doen. Allereerst de mensen van het 
magazijn, in het speciaal Eddy de Haan. Bedankt voor de bezorging van alle stoffen en 
materialen die nodig waren voor de uitvoering van het onderzoek. Ook bedankt voor de 
altijd korte maar gezellige praatjes die we maakten. Daarnaast een grote dank voor de 
mannen van de spoelkeuken: Wil, Lei en Alex. Jullie zorgen er altijd voor dat wij als 
onderzoekers heel makkelijk ons werk kunnen doen, zonder om te hoeven kijken naar de 
schoonmaak en de sterilisatie van het glaswerk en andere lab benodigdheden. Als wij in het 
lab iets snel gesteriliseerd nodig hebben, zorgen jullie daarvoor. Chapeau hiervoor! 
Daarnaast wil ik jullie bedanken voor de erg leuke en gezellige vrijdagmiddag borrels, wat 
altijd een heel leuk begin van het weekend was. Bedankt voor de goede zorg! Als laatste 
Geraldine en Elly die er altijd voor zorgden dat we op goed opgeruimde en schoongemaakte 
kantoren en labs konden werken.  
Naast de mensen binnen de universiteit, is het heel erg belangrijk om mensen om me heen 
te hebben buiten mijn werk om afleiding en ontspanning te hebben. Hiervoor wil ik graag 
een heel grote dankjewel zeggen tegen mijn vrienden, waarmee we al jaren een hechte 
groep vormen. Bedankt voor alle dagen (en vooral avonden) van ontspanning die we samen 
hebben meegemaakt (en nog mee zullen maken). Ik kan pagina’s volschrijven om jullie te 
bedanken voor alles wat we samen gedaan hebben ter ontspanning en afleiding, maar daar 
ga ik dit wetenschappelijk boekje niet mee vullen. Nogmaals dank voor alles! 
Uiteraard wil ik ook mijn familie heel erg bedanken. Mam en pap,  Desi en Birgit, Chiron en 
Vera, bedankt dat jullie er altijd zijn. Ik ben dankbaar dat jullie me altijd steunen en 
geïnteresseerd zijn in wat ik nou toch allemaal onderzoek. Daarnaast wil ik graag mijn 
schoonouders, Frans en Regina, bedanken dat ik ook daar altijd terecht kan. 
Mijn allerlaatste dank gaat uit naar mijn lieve vrouw, Wendy. Al bijna 10 jaar zijn wij samen 
en als ik terugkijk op wat wij allemaal bereikt hebben en gedaan hebben, voel ik alleen 
maar liefde, blijdschap en trots. Ik zou een heel boek kunnen schrijven over hoe dankbaar ik 
jou ben. Jij bent voor mij de afgelopen jaren de grootste steun en toeverlaat geweest. Het 
is  niet altijd even makkelijk  voor jou geweest als  ik  weer stress had over van alles en nog 
wat. Ik ben je eeuwig dankbaar voor al je steun, adviezen, goede zorg en dat je er altijd alles 
aan deed om de stress bij mij weg te nemen. Als ik het vertrouwen even helemaal kwijt 
was, was jij daar om ervoor te zorgen dat ik het vertrouwen toch weer terug kreeg. Je wist 
me altijd weer gerust te stellen. Dankzij jou heb ik dit boekje kunnen schrijven. Ik ben 
enorm trots op jou. Ik heb je lief! 
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Misha Francois Vrolijk was born on October 10th, 1989 in Maastricht, the Netherlands. 
After finishing secondary school at ‘Porta Mosana College’ in Maastricht, he enrolled in the 
bachelors program Molecular Life Sciences” at Maastricht University.  Following his 
Bachelor Degree in 2011, he started with his master program Molecular Life Sciences. In 
2013 he completed his Master Degree with an internship at the department of 
Pharmacology, Maastricht University. In 2013 he started his PhD project at the department 
of Toxicology, Maastricht University. During his PhD trajectory, he presented his work as a 
poster at several national and international conferences. The research performed during 
this project, under the supervision of prof. dr. A. Bast, prof. dr. A. Opperhuizen and prof. dr. 
G.R.M.M. Haenen, is described in this thesis. 
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